QT Imaging (QTI) S-1 16 Jan 25 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2024
Cover [Abstract]
Entity Registrant Name	QT Imaging Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Primary SIC Number	6770
Entity Tax Identification Number	85-1728920
Contact Personnel Name	Dr. Raluca Dinu
Entity Address, Address Line One	3 Hamilton Landing
Entity Address, Address Line Two	Suite 160
Entity Address, City or Town	Novato
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94949
City Area Code	650
Local Phone Number	276-7040
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Central Index Key	0001844505
Document Type	S-1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024		Dec. 31, 2023		Dec. 31, 2022
Current assets:
Cash	$ 1,544,169		$ 164,686		$ 455,076
Restricted cash and cash equivalents	20,000		20,000		20,000
Accounts receivable, net	256,886		1,290		0
Inventory	3,181,554		4,418,197		4,778,906
Prepaid expenses and other current assets	775,585		214,979		98,876
Total current assets	5,778,194		4,819,152		5,352,858
Property and equipment, net	122,152		490,920		497,747
Intangible assets, net	0		90,139		276,020
Operating lease right-of-use assets, net	1,020,947		1,267,121		1,572,323
Other assets	39,150		39,150		49,150
Total assets	6,960,443		6,706,482		7,748,098
Current liabilities:
Accounts payable	768,264		1,355,512		407,413
Accrued expenses and other current liabilities	3,364,217		369,651		368,366
Related party notes payable	0		705,000		0
Current maturities of long-term debt	887,321		4,199,362		129,057
Deferred revenue	19,841		347,619		0
Operating lease liabilities, current	394,208		361,305		313,448
Accrued advisory fee	100,000		0
Total current liabilities	5,433,851		7,338,449		1,218,284
Long-term debt	3,468,911		95,982		2,652,611
Related party notes payable	5,408,725		3,143,725		3,343,725
Operating lease liabilities	762,904		1,062,633		1,423,938
Warrant liability	9,783		0
Derivative liability	320,900		0
Earnout liability	700,000		0
Other liabilities	507,029		377,772		617,117
Total liabilities	16,612,103		12,018,561		9,255,675
Contingencies (Note 10)
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding			0		0
Common stock, $0.0001 par value; 500,000,000 and 100,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 21,441,416 and 9,575,925 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	2,144	[1]	958	[1]	27,580
Additional paid-in capital	22,468,801	[1]	12,457,108	[1]	10,136,037
Accumulated deficit	(32,122,605)		(17,770,145)		(11,671,194)
Total stockholders’ deficit	(9,651,660)		(5,312,079)		(1,507,577)
Total liabilities and stockholders’ deficit	$ 6,960,443		6,706,482		7,748,098
Previously Reported
Stockholders’ deficit:
Common stock, $0.0001 par value; 500,000,000 and 100,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 21,441,416 and 9,575,925 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively			27,941
Additional paid-in capital			12,430,125
Total stockholders’ deficit			(5,312,079)		(1,507,577)
GIGCAPITAL5, INC
Current assets:
Cash			2,438		78,196
Prepaid expenses and other current assets			94,008		172,508
Total current assets			96,446		250,704
Cash and marketable securities held in Trust Account			23,302,116		41,561,656
Interest receivable on cash and marketable securities held in the Trust Account			0		133,211
Total assets			23,398,562		41,945,571
Current liabilities:
Accounts payable			767,615		195,064
Accrued expenses and other current liabilities			893,830		103,344
Note payable to related party			1,564,673		603,880
Related party notes payable			1,506,389		257,492
Accrued advisory fee			3,500,000		2,157,037
Payable to related parties			1,610,875		781,561
Other current liabilities			79,162		88,021
Deferred underwriting fee payable - current			2,760,000		0
Total current liabilities			12,682,544		4,186,399
Warrant liability			7,950		31,800
Deferred underwriting fee payable			0		9,200,000
Total liabilities			12,690,494		13,418,199
Common stock subject to possible redemption, 2,114,978 shares, at a redemption value of $10.98 per share, and 4,014,050 shares, at a redemption value of $10.37 per share, as of December 31, 2023 and 2022, respectively			23,222,954		41,606,846
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding			0		0
Common stock, $0.0001 par value; 500,000,000 and 100,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; 21,441,416 and 9,575,925 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively			655		655
Additional paid-in capital			4,589,179		0
Accumulated deficit			(17,104,720)		(13,080,129)
Total stockholders’ deficit			(12,514,886)		(13,079,474)
Total liabilities and stockholders’ deficit			$ 23,398,562		$ 41,945,571
[1] Amounts as of December 31, 2023 differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par or stated value per share (in dollars per share)		$ 0.0001	$ 0.001
Preferred stock, shares authorized (in shares)		10,000,000	10,000,000
Preferred stock, shares issued (in shares)		0	0
Preferred stock, shares outstanding (in shares)		0	0
Common stock, par or stated value per share (in dollars per share)		$ 0.0001	$ 0.001
Common stock, shares authorized (in shares)		100,000,000	100,000,000
Common stock, shares, issued (in shares)		9,575,925	27,580,040
Common stock, shares, outstanding (in shares)		9,575,925	27,580,040
Previously Reported
Common stock, shares, issued (in shares)		27,941,290
Common stock, shares, outstanding (in shares)		27,941,290
GIGCAPITAL5, INC
Redeemable common stock, shares (in shares)	0	2,114,978	4,014,050
Redeemable common stock, price per share	$ 0	$ 10.98	$ 10.37
Preferred stock, par or stated value per share (in dollars per share)		$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)		1,000,000	1,000,000
Preferred stock, shares issued (in shares)		0	0
Preferred stock, shares outstanding (in shares)		0	0
Common stock, par or stated value per share (in dollars per share)		$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)		100,000,000	100,000,000
Common stock, shares, issued (in shares)		6,545,000	6,545,000
Common stock, shares, outstanding (in shares)		6,545,000	6,545,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2024		Sep. 30, 2023		Sep. 30, 2024		Sep. 30, 2023		Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 955,970		$ 24,657		$ 4,032,168		$ 35,404		$ 40,355	$ 708,244
Cost of revenue	350,667		23,799		1,792,234		73,497		134,988	556,925
Gross profit (loss)	605,303		858		2,239,934		(38,093)		(94,633)	151,319
Operating expenses:
Research and development	925,214		311,829		2,492,842		1,083,373		1,485,636	2,386,086
Selling, general and administrative	2,007,277		932,124		9,873,029		3,072,720		3,427,690	3,551,527
Total operating expenses	2,932,491		1,243,953		12,365,871		4,156,093		4,913,326	5,937,613
Loss from operations	(2,327,188)		(1,243,095)		(10,125,937)		(4,194,186)		(5,007,959)	(5,786,294)
Other income (expense), net	16,995		0		(191,330)		0
Other income									(544,566)	0
Change in fair value of warrant liability	8,805		0		199,624		0		0	(108,100)
Change in fair value of derivative liability	87,200		0		4,800,000		0
Change in fair value of earnout liability	50,000		0		(700,000)		0
Interest expense, net	(1,455,306)		(132,844)		(3,149,315)		(394,714)		(544,826)	(468,174)
Loss before income tax expense	(3,619,494)		(1,375,939)		(9,166,958)		(4,588,900)		(6,097,351)	(6,254,468)
Income tax expense									1,600	1,600
Net loss	(3,619,494)		(1,375,939)		(9,166,958)		(4,588,900)		$ (6,098,951)	$ (6,256,068)
Supplemental Income Statement Elements [Abstract]
Net loss and comprehensive loss attributable to common stockholders	$ (3,619,494)		$ (1,375,939)		$ (14,352,460)		$ (4,588,900)
Net loss per share, basic (in dollars per share)	$ (0.17)	[1]	$ (0.14)	[1]	$ (0.77)	[1]	$ (0.48)	[1]	$ (0.22)	$ (0.23)
Net loss per share, diluted (in dollars per share)	$ (0.17)	[1]	$ (0.14)	[1]	$ (0.77)	[1]	$ (0.48)	[1]	$ (0.22)	$ (0.23)
Weighted-average number of common shares used in computing net loss per common share, basic (in shares)	21,441,416	[1]	9,541,643	[1]	18,712,468	[1]	9,533,185	[1]	27,815,913	27,364,975
Weighted-average number of common shares used in computing net loss per common share, diluted (in shares)	21,441,416	[1]	9,541,643	[1]	18,712,468	[1]	9,533,185	[1]	27,815,913	27,364,975
GIGCAPITAL5, INC
Revenue									$ 0	$ 0
General and administrative expenses									4,927,599	4,279,100
Operating expenses:
Loss from operations									(4,927,599)	(4,279,100)
Other income									14,953	384,108
Interest expense, net									(219,686)	(23,098)
Interest income on cash and marketable securities held in Trust Account									1,526,860	1,630,398
Loss before income tax expense									(3,605,472)	(2,287,692)
Income tax expense									419,119	486,615
Net loss									(4,024,591)	(2,774,307)
Supplemental Income Statement Elements [Abstract]
Net income attributable to common stock subject to possible redemption									1,107,741	1,143,783
Net loss and comprehensive loss attributable to common stockholders									$ (5,132,332)	$ (3,918,090)
Net loss per share, basic (in dollars per share)									$ (0.78)	$ (0.60)
Net loss per share, diluted (in dollars per share)									$ (0.78)	$ (0.60)
Weighted-average number of common shares used in computing net loss per common share, basic (in shares)									6,540,000	6,540,000
Weighted-average number of common shares used in computing net loss per common share, diluted (in shares)									6,540,000	6,540,000
Common Stock Subject to Possible Redemption
Supplemental Income Statement Elements [Abstract]
Net loss per share, basic (in dollars per share)									$ 0.37	$ 0.06
Weighted-average number of common shares used in computing net loss per common share, basic (in shares)									3,020,634	17,954,419
Common Stock Subject to Possible Redemption | GIGCAPITAL5, INC
Supplemental Income Statement Elements [Abstract]
Net income attributable to common stock subject to possible redemption									$ 1,107,741	$ 1,143,783
Net loss per share, basic (in dollars per share)									$ 0.37	$ 0.06
Net loss per share, diluted (in dollars per share)									$ 0.37	$ 0.06
Weighted-average number of common shares used in computing net loss per common share, basic (in shares)									3,020,634	17,954,419
Weighted-average number of common shares used in computing net loss per common share, diluted (in shares)									3,020,634	17,954,419
[1] Amounts for the three and nine months ended September 30, 2023 and before that date differ from those in prior year condensed consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)		Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Revision of Prior Period, Adjustment	Revision of Prior Period, Adjustment Common Stock	Revision of Prior Period, Adjustment Additional Paid-in Capital	Adjusted, Beginning of Period	[1]	Adjusted, Beginning of Period Common Stock	[1]	Adjusted, Beginning of Period Additional Paid-in Capital	[1]	Adjusted, Beginning of Period Accumulated Deficit	[1]	Previously Reported	Previously Reported Common Stock	Previously Reported Additional Paid-in Capital	Previously Reported Accumulated Deficit	Convertible Notes Payable	Convertible Notes Payable Common Stock	Convertible Notes Payable Additional Paid-in Capital	Bridge Loan	Bridge Loan Common Stock	Bridge Loan Additional Paid-in Capital	GIGCAPITAL5, INC	GIGCAPITAL5, INC Common Stock	GIGCAPITAL5, INC Additional Paid-in Capital	GIGCAPITAL5, INC Accumulated Deficit	Private Placement	Private Placement Common Stock	Private Placement Additional Paid-in Capital	Potential shares from Pre-Paid Advance	Potential shares from Pre-Paid Advance Common Stock	Potential shares from Pre-Paid Advance Additional Paid-in Capital	Potential shares from Cable Car Loan	Potential shares from Cable Car Loan Common Stock	Potential shares from Cable Car Loan Additional Paid-in Capital	Non-Redemption Extension Agreement	Non-Redemption Extension Agreement Common Stock	Non-Redemption Extension Agreement Additional Paid-in Capital	Early Investor Consideration	Early Investor Consideration Common Stock	Early Investor Consideration Additional Paid-in Capital	Settle Transaction Expenses	Settle Transaction Expenses Common Stock	Settle Transaction Expenses Additional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2021			27,351,290																									6,545,000
Beginning balance at Dec. 31, 2021		$ 2,938,270	$ 27,351	$ 8,326,045	$ (5,415,126)																						$ (8,918,238)	$ 655	$ 0	$ (8,918,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)																																228,750
Issuance of common stock																															$ 906,300	$ 229	$ 906,071
Stock-based compensation		790,755		790,755
Fair value of warrants		113,166		113,166
Debt discount on note payable to related party																											54,034		54,034
Shares subject to redemption																											(1,440,963)		(1,440,963)
Reclass of negative additional paid-in capital to accumulated deficit																													1,386,929	(1,386,929)
Net loss		$ (6,256,068)			(6,256,068)																						$ (2,774,307)			(2,774,307)
Ending balance (in shares) at Dec. 31, 2022		27,580,040	27,580,040				(18,127,929)				9,452,111							27,580,040									6,545,000	6,545,000
Ending balance at Dec. 31, 2022		$ (1,507,577)	$ 27,580	10,136,037	(11,671,194)	$ 0	$ (26,635)	$ 26,635	$ (1,507,577)		$ 945		$ 10,162,672		$ (11,671,194)		$ (1,507,577)	$ 27,580	$ 10,136,037	$ (11,671,194)							$ (13,079,474)	$ 655	0	(13,080,129)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)			89,532
Issuance of common stock		1,026,550	$ 9	1,026,541
Stock-based compensation		612,730		612,730
Net loss		(4,588,900)			(4,588,900)
Ending balance (in shares) at Sep. 30, 2023	[1]		9,541,643
Ending balance at Sep. 30, 2023	[1]	$ (4,457,197)	$ 954	11,801,943	(16,260,094)
Beginning balance (in shares) at Dec. 31, 2022		27,580,040	27,580,040				(18,127,929)				9,452,111							27,580,040									6,545,000	6,545,000
Beginning balance at Dec. 31, 2022		$ (1,507,577)	$ 27,580	10,136,037	(11,671,194)	0	$ (26,635)	26,635	(1,507,577)		$ 945		10,162,672		(11,671,194)		$ (1,507,577)	$ 27,580	10,136,037	(11,671,194)							$ (13,079,474)	$ 655	0	(13,080,129)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)			100,000																													261,250
Issuance of common stock		402,000	$ 100	401,900																											$ 1,026,550	$ 261	$ 1,026,289
Stock-based compensation		709,394		709,394
Fair value of warrants		156,505		156,505
Debt discount on note payable to related party																											245,253		245,253
Shares subject to redemption																											(1,893,733)		(1,893,733)
Excise tax liability accrued for common stock redemptions																											(202,341)		(202,341)
Adjustment to deferred underwriting fees																											6,440,000		6,440,000
Net loss		$ (6,098,951)			(6,098,951)																						$ (4,024,591)			(4,024,591)
Ending balance (in shares) at Dec. 31, 2023		9,575,925	27,941,290				(18,365,365)				9,575,925						27,941,290	27,941,290									6,545,000	6,545,000
Ending balance at Dec. 31, 2023		$ (5,312,079)	$ 27,941	12,430,125	(17,770,145)	0	$ (26,983)	26,983	(5,312,079)		$ 958		12,457,108		(17,770,145)		$ (5,312,079)	$ 27,941	12,430,125	(17,770,145)							$ (12,514,886)	$ 655	4,589,179	(17,104,720)
Beginning balance (in shares) at Jun. 30, 2023	[1]		9,541,643
Beginning balance at Jun. 30, 2023	[1]	(3,276,733)	$ 954	11,606,468	(14,884,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		195,475		195,475
Net loss		(1,375,939)
Ending balance (in shares) at Sep. 30, 2023	[1]		9,541,643
Ending balance at Sep. 30, 2023	[1]	$ (4,457,197)	$ 954	11,801,943	(16,260,094)
Beginning balance (in shares) at Dec. 31, 2023		9,575,925	27,941,290				(18,365,365)				9,575,925						27,941,290	27,941,290									6,545,000	6,545,000
Beginning balance at Dec. 31, 2023		$ (5,312,079)	$ 27,941	12,430,125	(17,770,145)	$ 0	$ (26,983)	$ 26,983	$ (5,312,079)		$ 958		$ 12,457,108		$ (17,770,145)		$ (5,312,079)	$ 27,941	$ 12,430,125	$ (17,770,145)							$ (12,514,886)	$ 655	$ 4,589,179	$ (17,104,720)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)																																			1,000,000			180,000			427,477			150,000			1,544,200
Issuance of common stock																																		$ 1,866,284	$ 100	$ 1,866,184	$ 446,333	$ 18	$ 446,315	$ 1,508,993	$ 42	$ 1,508,951	$ 529,500	$ 15	$ 529,485	$ 5,439,857	$ 154	$ 5,439,703
Stock-based compensation		166,187		166,187
Merger recapitalization (in shares)			7,898,954
Merger recapitalization		(9,269,165)	$ 790	(9,269,955)
Issuance of common stock pursuant to a subscription agreement (in shares)			200,000
Issuance of common stock pursuant to a subscription agreement		706,000	$ 20	705,980
Conversion of a note payable/bridge loan (in shares)																						359,266			100,000
Conversion of a note payable/bridge loan																					$ 3,233,388	$ 36	$ 3,233,352	$ 200,000	$ 10	$ 199,990
Net exercise of warrants (in shares)			5,594
Net exercise of warrants		0	$ 1	(1)
Deemed dividend related to modification of equity classified warrants		0		5,185,502	(5,185,502)
Net loss		$ (9,166,958)			(9,166,958)
Ending balance (in shares) at Sep. 30, 2024		21,441,416	21,441,416
Ending balance at Sep. 30, 2024		$ (9,651,660)	$ 2,144	22,468,801	(32,122,605)
Beginning balance (in shares) at Jun. 30, 2024			21,441,416
Beginning balance at Jun. 30, 2024		(6,159,369)	$ 2,144	22,341,598	(28,503,111)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		127,203		127,203
Net loss		$ (3,619,494)
Ending balance (in shares) at Sep. 30, 2024		21,441,416	21,441,416
Ending balance at Sep. 30, 2024		$ (9,651,660)	$ 2,144	$ 22,468,801	$ (32,122,605)
[1] Amounts as of December 31, 2023 and before that date differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (9,166,958)	$ (4,588,900)	$ (6,098,951)	$ (6,256,068)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	204,283	355,682	480,694	651,750
Stock-based compensation	166,187	612,730	709,394	790,755
Warrant modification expense	200,513	0
Change in fair value of warrant liability	(199,624)	0	0	108,100
Induced conversion expense			168,356	0
Debt extinguishment loss			376,086	0
Amortization of debt issuance costs			66,367	39,923
Non-cash operating lease expense			8,246	4,603
Loss on disposal of assets	0	124	124	0
Provision for credit losses	1,290	0
Fair value of common stock issued in exchange for services and in connection with non-redemption agreements	3,718,349	0
Loss on issuance of common stock in connection with a subscription agreement	206,000	0
Non-cash interest	2,404,031	32,319
Non-cash operating lease expense	(20,652)	(6,184)
Change in fair value of derivative liability	(4,800,000)	0
Change in fair value of earnout liability	700,000	0
Changes in operating assets and liabilities:
Accounts receivable	(256,886)	(18,511)	(1,290)	7,753
Inventory	1,525,857	42,252	98,594	553,999
Prepaid expenses and other current assets	(459,804)	(52,382)	(116,103)	(10,576)
Other assets			10,000	0
Accounts payable	(2,061,853)	935,742	876,074	338,554
Accrued expenses and other current liabilities			645,840	178,868
Deferred revenue			347,619	(693,436)
Deferred revenue	(327,778)	300,000
Other liabilities			(205,701)	424,040
Other assets	0	10,000
Accrued expenses and other current liabilities	(768,614)	411,356
Other liabilities	129,257	0
Net cash used in operating activities	(8,806,402)	(1,965,772)	(2,651,143)	(3,861,735)
Cash flows from investing activities:
Purchases of property and equipment	(34,590)	(25,995)	(13,040)	(22,600)
Net cash used in investing activities	(34,590)	(25,995)	(13,040)	(22,600)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net of issuance costs			1,017,850	915,000
Proceeds from long-term debt, net of issuance costs	10,525,000	0	800,000	348,760
Repayment of long-term debt	(1,243,055)	(96,669)	(129,057)	(127,756)
Proceeds from related party notes payable			705,000	1,643,725
Repayment of bridge loans	(800,000)	0	(20,000)	0
Proceeds from related party payable	0	650,000
Proceeds from sale of common stock and warrants, net of issuance costs	0	1,017,850
Proceeds from issuance common stock pursuant to subscription agreement	500,000	0
Proceeds from the Merger, net of transaction costs	1,238,530	0
Net cash provided by financing activities	10,220,475	1,571,181	2,373,793	2,779,729
Net increase (decrease) in cash and restricted cash and cash equivalents	1,379,483	(420,586)	(290,390)	(1,104,606)
Cash and restricted cash and cash equivalents, beginning of year	184,686	475,076	475,076	1,579,682
Cash and restricted cash and cash equivalents, end of year	1,564,169	54,490	184,686	475,076
Supplemental disclosure of cash flow information:
Cash paid for income taxes			0	1,600
Cash paid for interest	537,571	0	3,004	4,305
Supplemental disclosures of noncash investing and financing activities:
Fair value of warrants issued with debt			0	5,066
Purchase of property and equipment included in accounts payable			12,955	0
Equity financing issuance costs included in accrued expenses			0	8,700
Related party convertible notes payable including accrued interest exchanged for common stock			233,644	0
Transfer of inventory to property and equipment	0	262,116	262,116	0
Debt discount included in accounts payable			59,069	0
Transfer of accrued interest to current maturities of long-term debt			635,855	0
Fair value of embedded derivatives upon issuance of convertible debt	5,120,900	0
Fair value of common stock issued with convertible debt	2,312,617	0
Transfer of equipment to inventory	289,214	0
Extinguishment of accrued expenses in exchange for common stock	3,760,000	0
Debt discount included in accrued expenses	40,740	0
Conversion of long-term debt into common stock	3,433,388	0
Deemed dividend	5,185,502	0
GIGCAPITAL5, INC
Cash flows from operating activities:
Net loss			(4,024,591)	(2,774,307)
Adjustment to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability and related party note			(14,953)	(384,108)
Interest earned on cash and marketable securities held in Trust Account			(1,526,860)	(1,630,398)
Amortization on debt discount on note payable to related party			219,686	17,914
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			78,500	567,733
Accounts payable			572,551	166,964
Other assets			0	165,230
Payable to related parties			829,314	708,704
Accrued legal fees			1,342,963	1,931,891
Accrued expenses and other current liabilities			588,145	(117,411)
Other liabilities			(8,859)	86,238
Net cash used in operating activities			(1,944,104)	(1,261,550)
Cash flows from investing activities:
Investment of cash in Trust Account, net			(920,000)	(640,000)
Cash withdrawn from Trust Account			20,839,611	192,881,509
Net cash used in investing activities			19,919,611	192,241,509
Cash flows from financing activities:
Borrowings from related parties			986,360	640,000
Borrowings from related parties at fair value			1,240,000	260,000
Redemption of Public Units			(20,277,625)	(192,138,312)
Payment of offering costs			0	(85,000)
Net cash provided by financing activities			(18,051,265)	(191,323,312)
Net increase (decrease) in cash and restricted cash and cash equivalents			(75,758)	(343,353)
Cash and restricted cash and cash equivalents, beginning of year	$ 2,438	$ 78,196	78,196	421,549
Cash and restricted cash and cash equivalents, end of year			2,438	78,196
Supplemental disclosure of cash flow information:
Cash paid for income taxes			427,977	400,377
Supplemental disclosures of noncash investing and financing activities:
Change in value of common stock subject to possible redemption			1,893,733	1,440,963
Excise tax liability accrued for stock redemptions			202,341	0
Waiver of deferred underwriting fees			6,440,000	0
Debt discount on note payable to related party			$ 245,253	$ 54,034

Description of Organization and

Description of Organization and Business Operations	12 Months Ended
	Dec. 31, 2023
GIGCAPITAL5, INC
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS	DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Organization and General GigCapital5, Inc. (the “Company”) was incorporated in Delaware on January 19, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As of December 31, 2023, the Company had not commenced any operations. All activity for the period from January 19, 2021 (date of inception) through December 31, 2023 relates to the Company’s formation and the initial public offering (the “Offering”), as described in Note 4, and identifying a target Business Combination, as described below. The Company will not generate any operating revenues until after completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Offering. The Company has selected December 31 as its fiscal year end. On September 23, 2021, the registration statement on Form S-1 (File No. 333-254038), as amended, relating to the Offering of the Company was declared effective by the U.S. Securities and Exchange Commission. The Company entered into an underwriting agreement with Wells Fargo Securities, LLC (“Wells Fargo”) and William Blair & Company, L.L.C. (collectively, the “Underwriters”) on September 23, 2021 to conduct the Offering of 20,000,000 units (the “Public Units”) in the amount of $200.0 million in gross proceeds, with a 45-day option provided to the Underwriters to purchase up to 3,000,000 additional Public Units solely to cover over-allotments, if any, in the amount of up to $30.0 million in additional gross proceeds. Each Public Unit consists of one share of the Company’s common stock (a “Public Share”), $0.0001 par value, and one redeemable warrant (a “Public Warrant”). Each Public Warrant is exercisable for one share of common stock at a price of $11.50 per full share. On September 28, 2021, the Company consummated the Offering of 23,000,000 Public Units, including the issuance of 3,000,000 Public Units as a result of the Underwriters exercise in full of their over-allotment option. The Public Units were sold at a price of $10.00 per Public Unit, generating gross proceeds to the Company of $230,000,000. Simultaneously with the closing of the Offering, the Company consummated the closing of a private placement sale (the “Private Placement”) to the Company’s sponsor GigAcquisitions5, LLC, a Delaware limited liability company (the “Founder” or “Sponsor”), of 795,000 units (the “Private Placement Units”), at a price of $10.00 per Private Placement Unit. The Private Placement generated aggregate gross proceeds of $7,950,000. Following the closing of the Offering, net proceeds in the amount of $225,400,000 from the sale of the Units and proceeds in the amount of $6,900,000 from the sale of Private Placement Units, for a total of $232,300,000, were placed in a trust account (the “Trust Account”), which is described further below. Transaction costs amounted to $13,193,740, consisting of $4,600,000 of underwriting fees, $9,200,000 of deferred underwriting fees for the Underwriters, and $843,740 of offering costs, of which $25,000 remains in accounts payable as of December 31, 2023, partially offset by the reimbursement of $1,450,000 of offering expenses by the Underwriters. On March 20, 2023, one of the Underwriters, Wells Fargo, waived all of their portion of the deferred underwriting fees totaling $6,440,000. The Company’s remaining cash after payment of the offering costs will be held outside of the Trust Account for working capital purposes. Extensions The Company’s initial public offering prospectus and Amended and Restated Certificate of Incorporation provided that the Company initially had until September 28, 2022 (the date which was 12 months after the consummation of the Offering) to complete the Business Combination (the “Combination Period”). On September 23, 2022, the Company held a special meeting of its stockholders and the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation that extends the date by which the Company must consummate a Business Combination transaction from September 28, 2022 up to March 28, 2023 in one-month extensions (the “Extension”). The Company’s stockholders elected to redeem 18,985,950 shares of the Company’s common stock, par value $0.0001 per share. Following such redemptions, $192,138,312 was withdrawn from the Trust Account on September 27, 2022. On September 26, 2022, the Company issued an unsecured, non-interest-bearing, non-convertible promissory note (the “Extension Note”) to the Sponsor for a principal amount of $160,000. The proceeds from the Extension Note were deposited into the Trust Account in accordance with the terms of the Company’s Amended and Restated Certificate of Incorporation. The Extension Note matures on the earlier of the date on which the Company consummates its initial Business Combination or the date the Company winds up and may be prepaid without penalty. The Extension Note was subsequently amended and restated five more times on October 26, 2022, November 28, 2022, December 27, 2022, January 25, 2023 and February 27, 2023, respectively, for a collective principal amount of $960,000. The Sponsor deposited such funds into the Company’s Trust Account with Continental Stock Transfer & Trust Company. On March 28, 2023, the Company held the March 2023 special meeting of stockholders. At the March special meeting, the stockholders approved two proposals: (A) to amend the Company’s Amended and Restated Certificate of Incorporation, giving the Company the right to extend the date by which it has to consummate a Business Combination up to six (6) times for an additional one (1) month each time, from March 28, 2023 to September 28, 2023 provided that the Sponsor (or its designees) must deposit into the Trust Account for each one-month extension funds equal to $100,000 (the “Second Extension”); (B) to amend the Company’s investment management trust agreement, dated as of September 23, 2021, by and between the Company and Continental Stock Transfer & Trust Company, allowing the Company to extend the Combination Period up to six (6) times for an additional one (1) month each time from March 28, 2023 to August 28, 2023 by depositing into the Trust Account for each one-month extension, the sum of $100,000. The Extension Note was further amended on March 28, 2023, April 27, 2023, May 25, 2023, June 26, 2023, July 25, 2023 and August 28, 2023 to increase the principal amount to $1,560,000. Also, in conjunction with the special meeting, the stockholders elected to redeem 995,049 Public Shares, which represented approximately 4.3% of the shares that were part of the Public Units sold in the Offering. Following such redemptions, $10,449,625 was withdrawn from the Trust Account. On September 28, 2023, the Company held the September 2023 special meeting of its stockholders. At the September special meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation that extends the date by which the Company must consummate a business combination transaction from September 28, 2023 (the date which is 24 months from the closing date of the Offering) up to December 31, 2023 without any additional payment to the Trust Account. The certificate of amendment was filed with the Delaware Secretary of State and has an effective date of September 28, 2023. Also, in conjunction with the September special meeting, the stockholders elected to redeem 904,023 Public Shares. Following such redemptions, $9,828,000 was withdrawn from the Trust Account. As a result of this redemption, our Founder and management team beneficially own approximately 75.6% of our issued and outstanding common stock. On December 28, 2023, the Company held a special meeting of its stockholders (the “December 2023 Special Meeting”). At the meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation that extends the date by which the Company must consummate a business combination transaction from December 31, 2023 up to March 31, 2024. The certificate of amendment was filed with the Delaware Secretary of State and has an effective date of December 28, 2023. In connection with the December 2023 Special Meeting, stockholders elected to redeem 2,385 shares of the Company’s common stock. Following such redemptions, $26,201 was withdrawn from the Trust Account on January 4, 2024. In conjunction with the Company’s annual meeting on February 20, 2024, stockholders elected to redeem 848,003 shares of the Company’s common stock, which represents approximately 3.7% of the shares that were part of the Public Units sold in the Offering. Following such redemptions, $9,356,221 was withdrawn from the Trust Account. Working Capital Loans On September 26, 2022, the Company issued a convertible, non-interest bearing, unsecured promissory note (the “Working Capital Note”) to the Sponsor for a principal amount of $65,000. The Working Capital Note was subsequently amended and restated eleven more times on October 26, 2022 (an additional $65,000 added to the Working Capital Note), November 28, 2022 (an additional $65,000 added to the Working Capital Note), December 27, 2022 (an additional $65,000 added to the Working Capital Note), January 25, 2023 (an additional $65,000 added to the Working Capital Note), February 27, 2023 (an additional $350,000 added to the Working Capital Note) and March 28, 2023 (an additional $130,000 added to the Working Capital Note), April 27, 2023 (an additional $65,000 added to the Working Capital Note), June 26, 2023 (an additional $130,000 added to the Working Capital Note), July 25, 2023 (an additional $65,000 added to the Working Capital Note), October 27, 2023 (an additional $381,360 added to the Working Capital Note) and December 13, 2023 (an additional $53,640 added to the Working Capital Note), respectively, for a collective principal amount of $1,500,000. The Working Capital Note was issued to provide the Company with additional working capital during the Extension and was not deposited into the Trust Account. The Working Capital Note is convertible at the Sponsor’s election upon the consummation of the initial business combination. Upon such election, the convertible note will convert, at a price of $10.00 per unit, into units identical to the Private Placement Units issued in connection with the Offering. An aggregate of 150,000 Private Placement Units of the Company would be issued if the entire principal balance of the Working Capital Note is converted. Each Private Placement Unit consists of one share of the Company’s common stock, par value $0.0001 per share, and one redeemable warrant. The warrants constituting a part of the Private Placement Units would be exercisable, subject to the terms and conditions of the warrant and during the exercise period as provided in the warrant agreement governing the warrants. The Company has relied upon Section 4(a)(2) of the Securities Act, in connection with the issuance and sale of the convertible promissory note, as it was issued to a sophisticated investor without a view to distribution and was not issued through any general solicitation or advertisement. On December 13, 2023, the Company issued an additional unsecured non-convertible promissory note to the Sponsor for a collective principal amount of $66,360 (the “First Non-Convertible Working Capital Note”). The First Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. On February 7, 2024, the Company amended and restated the First Non-Convertible Working Capital Note (the “Second Non-Convertible Working Capital Note”) to reflect an additional principal amount of $195,887 extended by the Sponsor to the Company for a collective principal amount under the Second Non-Convertible Working Capital Note of $262,247. The Second Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. On February 15, 2024, the Company amended and restated the Second Non-Convertible Working Capital Note (the “Third Non-Convertible Working Capital Note”) to reflect an additional principal amount of $35,000 extended by the Sponsor to the Company for a collective principal amount under the Third Non-Convertible Working Capital Note of $297,247. The Third Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. The Third Non-Convertible Working Capital Note bears no interest and is repayable in full upon the consummation of a Business Combination by the Company. The Company issued the Second and Third Non-Convertible Working Capital Note in consideration for additional loans from the Sponsor to fund the Company’s working capital requirements. The Trust Account The funds in the Trust Account have been invested only in U.S. government treasury bills with a maturity of one hundred and eighty-five (185) days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940 which invest only in direct U.S. government obligations. Funds will remain in the Trust Account until the earlier of (i) the consummation of the Business Combination or (ii) the distribution of the Trust Account as described below. The remaining proceeds from the Offering outside the Trust Account may be used to pay for business, legal and accounting due diligence expenses on acquisition targets and continuing general and administrative expenses. The Company’s Amended and Restated Certificate of Incorporation provides that, other than the withdrawal of interest to pay taxes none of the funds held in the Trust Account will be released until the earlier of: (1) the completion of the Business Combination; (2) the redemption of 100% of the outstanding Public Shares if the Company has not completed an initial Business Combination within 30 months from the closing of the Offering; or (3) the redemption of any Public Shares properly tendered in connection with a stockholder vote to amend the Amended and Restated Certificate of Incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the Company’s Public Shares if the Company does not complete its initial Business Combination within the required time period or (B) with respect to any other provision relating to the Company’s pre-business combination activity and related stockholders’ rights. Business Combination The Company will have 30 months from September 28, 2021, the closing date of the Offering, to complete its initial Business Combination, provided that the extension payment for each one-month extension through February 28, 2023 equal to $160,000 and the extension payment for each one-month extension from March 28, 2023 through August 28, 2023 equal to $100,000 is deposited into the Trust Account on or prior to the date of the same applicable deadline. If the Company does not complete a Business Combination within this period of time, it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares of common stock for a per share pro rata portion of the Trust Account, including interest, but less taxes payable (less up to $100,000 of such net interest to pay dissolution expenses) and (iii) as promptly as possible following such redemption, dissolve and liquidate the balance of the Company’s net assets to its creditors and remaining stockholders, as part of its plan of dissolution and liquidation. The Founder, Brad Weightman, the Company’s Treasurer and Chief Financial Officer, and Interest Solutions, LLC, a Connecticut limited liability company and an affiliate of ICR, LLC, an investor relations firm providing services to the Company (“ICR”) (the “Insiders” as it relates to Mr. Weightman and ICR) entered into letter agreements with the Company, pursuant to which they waived their rights to participate in any redemption with respect to their founder shares, insider shares and private shares, and the Founder waived its redemption right with respect to any Public Shares purchased during or after the Offering. However, if the Founder, the Underwriters or the Insiders or any of the Company’s officers, directors or affiliates acquire units or shares of common stock, previously included in the Public Units, in or after the Offering, they will be entitled to a pro rata share of the Trust Account upon the Company’s liquidation (and in case of the Underwriters and Insiders, upon the Company’s redemption) in the event the Company does not complete a Business Combination within the required time period. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the Offering price per Public Unit in the Offering. Liquidity The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $17,104,720 as of December 31, 2023. During the year ended December 31, 2023, the Company incurred a net loss of $4,024,591 and used $1,944,104 of cash in operating activities. Subsequent to year end, the Company completed its business combination with QT Imaging (referred to as the “Combined Company”) as discussed further in Note 2. The Combined Company is expected to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to support the Combined Company’s cost structure. The Combined Company may never achieve profitability and, unless and until it does, the Combined Company will need to continue to raise additional capital. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In connection with the Business Combination, the Combined Company entered into various agreements to obtain financing through the issuance of debt and through stock subscription agreements. Subsequent to December 31, 2023, the Company received the Pre-Paid Advance, net of issuance costs, of $9,005,000 from Yorkville pursuant to the Standby Equity Purchase Agreement, $500,000 of cash proceeds from an investor related to a stock subscription agreement, and $1,500,000 in cash proceeds through a note payable from Funicular Funds, LP. The Standby Equity Purchase Agreement provides the Company with access to an additional $40 million of potential capital through the issuance of common stock to Yorkville. During the time the Combined Company has a balance under the Pre-Paid Advance, additional advances can be received with written consent of Yorkville or upon a trigger event, which occurs when the daily volume-weighted average price is less than $2.00 per share for five consecutive trading days. Management believes that the additional cash received and financing arrangements at the closing of the Business Combination has alleviated the substantial doubt about the Company’s ability to continue as a going concern and will be sufficient to fund the Combined Company’s current operating plan for at least the next 12 months from the date of issuance of these financial statements.

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies Nature of Operations QT Imaging Holdings, Inc. (the “Company”), formerly known as GigCapital5, Inc. (“GigCapital5”), is incorporated in Delaware with headquarters in Novato, California. The Company is a medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. The Company strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. The Company’s initial product is a breast imaging system. On March 4, 2024 (the “ Closing Date ” or “ Merger Date ” ), QT Imaging, Inc. ( “ QT Imaging ” ), GigCapital5, and QTI Merger Sub, Inc. ( “ QTI Merger Sub ” ) pursuant to the terms of the Business Combination Agreement (the “ Business Combination Agreement ” ) dated December 8, 2022, completed the business combination of QT Imaging and GigCapital5 which was effected by the merger of QTI Merger Sub with and into QT Imaging, with QT Imaging surviving the Merger as a wholly owned subsidiary of GigCapital5 (the “ Merger, ” and, together with the other transaction contemplated by the Business Combination Agreement, the “ Business Combination ” ). Upon completion of the merger on March 4, 2024 , GigCapital5 changed its name to QT Imaging Holdings, Inc. and effectively assumed all of QT Imaging’s material operations. Refer to Note 2 - Business Combination for more information regarding the Merger. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) applicable to interim financial statements. Accordingly, certain information related to significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of QT Imaging for the year ended December 31, 2023 and the related notes which provide a more complete discussion of the Company's accounting policies and certain other informatio n. The December 31, 2023 condensed consolidated balance sheet was derived from QT Imaging's audited consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's condensed consolidated results for the periods presented. The condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period. The share and per share amounts, prior to the Merger, have been retrospectively restated as shares reflecting conversion at the exchange ratio of approximately 0.3427 established in the Business Combination Agreement. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, QT Imaging and QT Ultrasound Labs, Inc. (“QT Labs”). All intercompany balances and transactions are eliminated in consolidation. Liquidity The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $32,122,605 as of September 30, 2024. During the nine months ended September 30, 2024, the Company incurred a net loss of $9,166,958 and used $8,806,402 of cash in operating activities, which includes repayment of net liabilities assumed from the Business Combination. The Company expects to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to support the Company’s cost structure. The Company may never achieve profitability and, unless and until it does, the Company will need to continue to raise additional capital. In connection with the Business Combination, the Company entered into various agreements to obtain financing through the issuance of debt and through stock subscription agreements. On March 4, 2024, the Company received the Pre-Paid Advance (as defined in Note 2), net of issuance costs, of $9,025,000 from YA II PN, LTD (“Yorkville”) pursuant to the Standby Equity Purchase Agreement (the “SEPA”) and issued Yorkville a promissory note (the “Yorkville Note”) in the amount of $10.0 million for such Pre-Paid Advance, $500,000 of cash proceeds from an investor related to a stock subscription agreement, and $1,500,000 in cash proceeds through a note payable from Funicular Funds, LP. See Note 8. Long-Term Debt. The SEPA provides the Company with access to an additional $40 million of potential capital through the issuance of common stock to Yorkville. During the time the Company has a balance under the Yorkville Note, additional advances under the SEPA can be received with written consent of Yorkville or upon a Trigger Event (as defined in Note 8) which, following the effectiveness of the Registration Statement on Form S-1 that the Company filed to register the shares to be issued pursuant to the SEPA, occurs when the daily volume-weighted average price is less than the Floor Price (as such term is defined in the Yorkville Note) for five consecutive trading days, which prior to October 31, 2024, was $0.8768 per share. As previously disclosed in a Current Report on Form 8-K with the SEC on September 13, 2024, a Trigger Event occurred on September 11, 2024, following which on September 13, 2024, the Company made a payment to Yorkville on the Yorkville Note of $1,521,581 which included $1,145,407 as repayment of principal. Additionally, and as previously disclosed in a Current Report on Form 8-K with the SEC on September 30, 2024, the Company and Yorkville executed an amendment on September 26, 2024 to extend the maturity date of the Yorkville Note from June 4, 2025 to December 15, 2025 and decreased the monthly principal payment obligations of $500,000 related to the Trigger Event beginning on January 15, 2025 (see Note 8 for more detail). Subsequently, on October 31, 2024, the Company and Yorkville executed a second amendment to extend the maturity date of the Yorkville Note to March 31, 2026 and reduced the Floor Price to $0.50 per share. On November 4, 2024, Yorkville converted $254,593 in principal amount of the Yorkville Note, and following this conversion and the prior repurchase of principal, the remaining principal balance of the Yorkville Note is $8.6 million (see Note 16). Subsequent to the date of these condensed consolidated financial statements, the Company executed a securities purchase agreement with related parties for the issuance of shares of common stock plus warrants for the purchase of common stock as a Private Investment in Public Equity (the “PIPE”) with an aggregate purchase price of $2.56 million, the closing of which will occur by November 29, 2024. Management believes that the additional cash received from the PIPE and the financing arrangement under the SEPA and the Yorkville Note will be sufficient to fund the Company’s current operating plan for at least the next 12 months. The Company’s future capital requirements will depend on many factors, including the Company’s growth rate, the timing and extent of its spending to support research and development activities, purchasing inventory to meet its growth plan, and the timing and cost to enhance commercialized existing products. In the event that additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to the Company, or at all. Any additional debt financing obtained by the Company in the future could also involve restrictive covenants relating to the Company’s capital-raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if the Company raises additional funds through further issuances of equity, convertible debt securities or other securities convertible into equity, its existing stockholders could suffer significant dilution in their percentage ownership of the Company, and any new equity securities the Company issues could have rights, preferences and privileges senior to those of holders of the Company’s common stock. If the Company is unable to obtain adequate financing or financing on terms satisfactory to the Company when the Company requires it, the Company’s ability to continue to grow or support its business and to respond to business challenges could be significantly limited. Reclassification Certain reclassifications have been made to the prior year condensed consolidated statement of operations and comprehensive loss to conform to the current year presentation. The reclassification had no impact on the previously reported condensed consolidated balance sheet, statement of stockholders’ deficit or cash flows. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on the Company’s operating results. Business Risk and Concentration of Credit Risk and Supply Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and accounts receivable. The majority of the Company’s cash is invested in U.S. dollar deposits with a reputable bank in the United States. Management believes that minimal credit risk exists with respect to the financial institution that holds the Company’s cash. At times, such cash may be in excess of insured limits established by the Federal Deposit Insurance Corporation. The Company performs ongoing credit evaluations of its customers and generally does not require collateral for accounts receivable. Payment terms range from cash in advance to 30 days from delivery of products or services but may fluctuate depending on the terms of each specific contract. Significant customers represent 10% or more of the Company’s total revenue or accounts receivable, net balance for the period ended as of each reporting date. For each significant customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows: Revenue Accounts Receivable, Net Three Months Ended Nine Months Ended September 30, 2024 December 31, 2023 2024 2023 2024 2023 Customers: Customer A 96 % * 96 % * 65 % * Customer B * * * * 23 % * Customer C * * * * 10 % * Customer D, related party * * * * * 18 % Customer E * * * * * 14 % Customer F * 100 % * * * * Customer G * * * 77 % * 54 % Customer H * * * 16 % * 11 % 96 % 100 % 96 % 93 % 98 % 97 % __________________ * Total less than 10% for the period. There are inherent risks whenever a large percentage of total revenue is concentrated in a limited number of customers. Should a significant customer which is a party to a contract with the Company under which the Company derives revenue terminate or fail to renew its contracts with the Company, in whole or in part, for any reason, or experience significant financial or operating difficulties, it could have a material adverse effect on the Company’s financial condition and results of operations. In general, a customer that makes up a significant portion of revenues in one period, may not make up a significant portion in subsequent periods. However, as the Company has entered into a Distribution Agreement with NXC Imaging, Inc. (“NXC”) on June 18, 2024, by which the Company appointed NXC as the exclusive reseller to market, advertise, and resell certain equipment in the U.S. and U.S. territories, the Company expects that NXC will make up a significant portion of revenues in each period in which such Distribution Agreement is in effect. Customer A in the concentration table above is NXC, which resold the Company’s scanner to two clinics during the three months ended September 30, 2024 and six clinics during the nine months ended September 30, 2024. Certain components and services used to manufacture and develop the Company’s products are presently available from only one or a limited number of suppliers or vendors. The Company’s QT Breast Scanner has more than six hundred components, of which less than five components have such dependencies on limited suppliers or vendors. The loss of any of these suppliers or vendors would potentially require a significant level of hardware and/or software development efforts to incorporate the products or services into the Company’s product. Cash and Cash Equivalents The Company considers all short-term investments with a maturity of three months or less when purchased to be cash equivalents. The Company had restricted cash equivalents of $20,000 as of September 30, 2024 and December 31, 2023. Restricted Cash Restricted cash is comprised of cash held in an account subject to a collateral agreement to be used for the Company’s corporate credit card program. Accounts Receivable, Net Accounts receivable are carried at the amount due. Accounts receivable are written off when management deems all realistic efforts to collect the amount outstanding have been exhausted. A provision for credit losses is estimated by management based on evaluations of its historical bad debt and current collection experience. As of September 30, 2024 and December 31, 2023, an allowance for credit losses was not required. Write-offs of accounts receivable were not significant during the three and nine months ended September 30, 2024 and 2023. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the weighted-average cost method. The Company periodically reviews the value of items in inventory and provides write-offs of inventory that is obsolete. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Once inventory has been written down below cost, it is not subsequently written up. Property and Equipment, Net Property and equipment, net are recorded at cost, less accumulated depreciation. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to current operations as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized over the lesser of the term of the related lease or the estimated useful lives of the assets. Leases The Company primarily enters into leases for office space that are classified as operating leases. The Company determines if an arrangement is or contains a lease at inception. The Company accounts for leases by recording right-of-use (“ROU”) assets and lease liabilities on the condensed consolidated balance sheets in the captions operating lease right-of-use assets, net and operating lease liabilities, respectively. The lease term includes the non-cancelable period of the lease plus any additional periods covered by an option to extend that the Company is reasonably certain to exercise. The Company’s leases do not include substantial variable payments based on an index or rates. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants. The Company’s leases do not provide a readily determinable implicit discount rate. The Company’s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The lease payments related to the next 12 months are included in operating lease liabilities, current on the condensed consolidated balance sheets. The Company recognizes a single lease cost on a straight-line basis over the term of the lease, and the Company classifies all cash payments within operating activities in the condensed consolidated statements of cash flows. The Company did not have any finance leases as of September 30, 2024 or December 31, 2023. Intangible Assets, Net The Company’s intangible assets are comprised of patents with a useful life of 12 years. Patents are amortized on a straight-line basis over their useful life. Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by an asset to the carrying value of an asset. If the carrying value of the long-lived asset is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. Management has reviewed the Company’s long-lived assets and recorded no impairment charge for the three and nine months ended September 30, 2024 and 2023. Fair Value Measurements The Company applies the requirements of the fair value measurements framework, which establishes a hierarchy for measuring fair value and requires enhanced disclosures about fair value measurements. The fair value measurement guidance clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement guidance also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy in which these assets and liabilities must be grouped based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Debt and Debt Issuance Costs The Company evaluates its financial instruments to determine if they are freestanding financial instruments. The Company also evaluates its convertible debt for embedded derivatives. Embedded provisions (like conversion options) are assessed to determine if they qualify as embedded derivatives that require separate accounting. Debt issuance costs are recorded as a reduction to the carrying amount of the debt and are amortized to interest expense using the effective interest method. Debt is classified as short-term or long-term based on the term of the note. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods or services. The Company determines revenue recognition through the following steps: 1) Identification of the contract, or contracts, with a customer The Company considers the terms and conditions of the contract in identifying the contracts. The Company determines a contract with a customer to exist when the contract is approved, each party’s rights regarding the goods or services to be transferred can be identified, the payment terms for the goods or services can be identified, it has been determined the customer has the ability and intent to pay, and the contract has commercial substance. At contract inception, the Company will evaluate whether two or more contracts should be combined and accounted for as a single contract and whether the combined or single contract includes more than one performance obligation. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, credit and financial information pertaining to the customer. 2) Identification of the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or services either on its own or together with other resources that are readily available from third parties or from the Company, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. The Company’s performance obligations consist of (i) product sales, (ii) maintenance contracts and (iii) other services including training. 3) Determination of the transaction price The transaction price is determined based on the consideration to which the Company expects to be entitled in exchange for transferring goods or services to the customer. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company’s contracts do not contain a significant financing component. 4) Allocation of the transaction price to the performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price. 5) Recognition of revenue when, or as a performance obligation is satisfied For product sales and services, revenue is recognized at the time the related performance obligation is satisfied by transferring the control of the promised goods or services to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. Training and maintenance services are generally recognized upon invoicing in amounts that correspond directly with the value to the customer of the performance completed to date which primarily includes professional service arrangements entered on a time and materials basis. All of the revenue recognized by the Company during the three and nine months ended September 30, 2024 and 2023 was recognized at a point in time. Revenue recognized during the three and nine months ended September 30, 2024 and 2023 is disaggregated as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Product $ 917,238 $ 6,634 $ 3,882,039 $ 12,881 Service 38,732 18,023 150,129 22,523 $ 955,970 $ 24,657 $ 4,032,168 $ 35,404 Revenue recognized by geography during the three and nine months ended September 30, 2024 and 2023 is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 United States $ 942,265 $ 20,759 $ 4,000,590 $ 31,506 International 13,705 3,898 31,578 3,898 $ 955,970 $ 24,657 $ 4,032,168 $ 35,404 The Company had no contract assets as of September 30, 2024 and December 31, 2023. The Company had contract liabilities of $19,841 as of September 30, 2024, which are expected to be fully recognized as revenue in 2024. The Company had contract liabilities of $347,619 as of December 31, 2023. Revenue recognized during the three and nine months ended September 30, 2024 that was previously included in contract liabilities as of December 31, 2023 was $11,905 and $27,778, respectively, while a $300,000 customer deposit previously deferred was refunded due to an order cancellation during the nine months ended September 30, 2024. Shipping and Handling Costs Shipping and handling activities are typically performed before the customer obtains control of the goods, and the related costs are therefore expensed as incurred. Shipping and handling costs are included in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. Shipping and handling costs incurred for inventory purchases are expensed in cost of revenue when sold. Product Warranty The Company’s products sold to customers are generally subject to warranties up to twelve months, which provides for the repair or replacement of products, at the Company’s option, that fail to perform with stated specifications. The Company estimates future warranty obligations related to those products. To date, product warranty claims have not been significant. Research and Development Costs Research and development costs incurred by the Company include salaries, purchased services, operating materials and supplies, depreciation, and amortization, and are expensed as incurred. These costs amounted to $925,214 and $311,829 for the three months ended September 30, 2024 and 2023, respectively, and $2,492,842 and $1,083,373 for the nine months ended September 30, 2024 and 2023, respectively. Advertising Advertising and promotion costs are expensed as incurred. Advertising expenses were not significant for the three and nine months ended September 30, 2024 and 2023. Grant Income Periodically, the Company is awarded grants on a cost reimbursement basis. Costs are expensed when incurred and reimbursable on a monthly or quarterly basis with the offset booked as a contra-expense to the applicable functional area in the condensed consolidated statements of operations and comprehensive loss. Income Taxes Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets may be reduced by a valuation allowance if it is more-likely-than-not that some or all of the deferred tax asset will not be realized. The Company annually evaluates the realizability of deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the condensed consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. There were no accrued interest and penalties during the three and nine months ended September 30, 2024 and 2023. Stock-Based Compensation Sto ck-based compensation cost is measured at the grant date based on the fair market value of the award. Stock-based compensation is recognized as expense on a ratable basis over the requisite service period of the award. The Company values stock options using the Black-Scholes option pricing model. This model requires the use of highly subjective and complex assumptions which determine the fair value of stock-based awards, including the option’s expected term, stock price volatility and risk-free interest rates. Forfeitures are recorded as they occur. Comprehensive Loss Comprehensive loss is defined as the change in the equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss was equal to net loss for three and nine months ended September 30, 2024 and 2023. Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For the purposes of the diluted net loss per share calculation, common stock equivalents are considered to be potentially dilutive securities. Reconciliation of net loss per share for the three and nine months ended September 30, 2024 and 2023 is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net loss attributable to QT Imaging Holdings, Inc. $ (3,619,494) $ (1,375,939) $ (9,166,958) $ (4,588,900) Deemed dividend related to the modification of equity classified warrants — — (5,185,502) — Net loss attributable to common stockholders $ (3,619,494) $ (1,375,939) $ (14,352,460) $ (4,588,900) Weighted-average number of common shares used in computing net loss per common share (1) 21,441,416 9,541,643 18,712,468 9,533,185 Net loss per share - basic and diluted (1) $ (0.17) $ (0.14) $ (0.77) $ (0.48) The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive as of September 30, 2024 and 2023: September 30, 2024 September 30, 2023 Common stock warrants (1) 23,889,364 401,389 Potential shares from Pre-Paid Advance 10,126,981 — Merger consideration earnout shares 9,000,000 — Potential shares from Cable Car Loan 750,000 — Potential shares from convertible notes (1) 250,224 254,328 Contingently issuable shares to GigCapital5 stockholders (1) — 260,419 Options outstanding (1) 2,072,000 1,350,432 46,088,569 2,266,568 __________________ (1) Amounts as of December 31, 2023 and before that date differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements). Fair Value of Financial Instruments The fair value of the Company’s financial instruments, including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their fair values because of the relatively short maturity of these instruments. The carrying value of the Company’s borrowings approximates fair value based on current rates offered to the Company for instruments with similar terms. Recent Accounting Pronouncements Adopted In August 2020, the	The Company and Summary of Significant Accounting Policies Nature of Operations QT Imaging, Inc. (together with its subsidiary, the “Company”) was incorporated on December 31, 2020. The Company is in the business of developing and commercializing medical ultrasound imaging systems. The Company’s initial product is a breast imaging system. Merger Agreement and Related Activities On December 8, 2022, the Company entered into a definitive business combination agreement (the “Business Combination Agreement”) with GigCapital5, Inc., a publicly traded special purpose acquisition company (“GigCapital5”), and QTI Merger Sub, Inc., a wholly owned subsidiary of GigCapital5 (“Merger Sub”), that resulted in the Company becoming a publicly-listed company on March 4, 2024. Upon closing of the transaction, GigCapital5 was renamed QT Imaging Holdings, Inc. (“QTI Holdings”) and its common stock is traded on the Nasdaq Global Market under the new ticker symbol “QTI.” The closing of the transaction is referred to as Business Combination from this point forward. In late September 2023, the Company, GigCapital5 and certain GigCapital5 shareholders (“Non-Redeeming Shareholders”) entered into non-redemption agreements (each, a “Non-Redemption Agreement”) in exchange for the Non-Redeeming Shareholders not redeeming an agreed upon number of their public shares of GigCapital5 (the “Non-Redeemed Shares”) at GigCapital5’s last annual meeting of shareholders. In exchange, the Non-Redeeming Shareholders will receive, immediately prior to, and substantially concurrently with the closing of the Business Combination, shares of common stock of the Company equivalent to the number of Non-Redeemed Shares multiplied by 0.15 and divided by the Exchange Ratio (as defined in the Business Combination Agreement). On November 10, 2023, the Company, Merger Sub and GigCapital5 entered into a third amendment to the Business Combination Agreement, which, among other things, amended certain definitions of the Business Combination Agreement. On November 10, 2023, the Company entered into a Securities Purchase Agreement and raised a private secured convertible bridge financing in the aggregate amount of $1,000,000 (“Bridge Loan”) from five investors (“Bridge Lenders”) led by Meteora Capital Partners, LP (“Meteora”) and collateralized by all assets of the Company. The notes from the Bridge Loan are interest-free and may convert into that number of shares of the Company which may further convert in the aggregate into 500,000 shares of common stock of QTI Holdings upon the completion of the Business Combination. Alternatively, Bridge Lenders may demand payment at 120% of their note on the maturity date, which is the closing date of the Business Combination. Related to the Bridge Loan, as consideration for their services, Meteora will receive that number of shares of common stock of the Company, which at the completion of the Business Combination will be exchanged for 50,000 shares of common stock of QTI Holdings. The Company and GigCapital5 also entered into subscription agreements dated November 10, 2023 with three of the Bridge Lenders as subscribers for the purchase of shares of stock of the Company in the aggregate amount of $3,000,000 in exchange for that number of shares of the Company which, at the completion of the Business Combination, will be converted in the aggregate into 1,200,000 shares of common stock of QTI Holdings. Each subscriber will also receive that number of shares of common stock of the Company, which, at the completion of the Business Combination, will be exchanged for 50,000 shares of common stock of QTI Holdings. On November 10, 2023, the Company entered into a Fourth Amendment and Termination Agreement (“Fourth Amendment”) of the private placement agreement dated December 15, 2020 with US Capital Global Securities, LLC (“US Capital”), an affiliate of US Capital Global QT Imaging LLC (“USCG”). In conjunction with this Fourth Amendment, the Company, USCG, and Meteora executed a subordination agreement whereby the Company granted USCG a warrant to purchase 25,000 shares of the Company’s common stock with a strike price of $2.50 in exchange for subordinating their senior secured position to Meteora. US Capital was also issued a $200,000 senior secured convertible promissory note by the Company as part of the Bridge Loan to terminate the private placement agreement on a go forward basis, a warrant to purchase 35,329 shares of the Company’s common stock with a strike price of $2.50 and was entitled to a commission payable of $20,000 in connection with the Bridge Loan. On November 15, 2023, the Company entered into a Standby Equity Purchase Agreement with GigCapital5 and YA II PN, Ltd. (“Yorkville”), pursuant to which, upon the closing of the Business Combination, QTI Holdings can sell to Yorkville up to $50.0 million of QTI Holdings’ common stock at QTI Holdings’ request any time during the 36 months following the closing of the Business Combination. In addition, QTI Holdings can also request a pre-paid advance(the “Pre-Paid Advance”) from Yorkville up to an amount of $10.0 million at the closing of the Business Combination in the form of a convertible promissory note. As consideration for the Pre-Paid Advance, immediately prior to, and substantially concurrently with, the closing of the Business Combination, the Company will issue to Yorkville that number of shares of the Company which will further convert in the aggregate into 1,000,000 shares of common stock of QTI Holdings upon the completion of the Business Combination. On November 22, 2023, the Company, Merger Sub and GigCapital5 entered into a fourth amendment to the Business Combination Agreement which extended the Outside Date (as defined in the Business Combination Agreement) from December 31, 2023 to March 31, 2024. The transaction was completed on March 4, 2024. On December 13, 2023, the Company and Exit Strategy Partners, LLC (“Advisor”) entered into an amendment to an agreement dated September 28, 2022, pursuant to which the Company agreed to pay for Advisor’s services in exchange for 250,000 shares of QTI Holdings common stock and a total cash amount of $225,000, of which $125,000 was paid on the closing of the Business Combination and the remaining $100,000 is due on the first anniversary of the closing of the Business Combination. On December 19, 2023, the Company and GigCapital5 entered into an additional stock subscription agreement for the aggregate purchase price of $500,000 in such amount that upon the completion of the Business Combination and the application of the exchange ratio will be exchanged for such consideration as is provided for in the Business Combination Agreement, including that number of shares of QTI Holdings common stock as is equal in the aggregate to 200,000 shares of QTI Holdings common stock. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the consolidated financial statements contain all adjustments necessary for a fair presentation of the Company’s financial position as of the date reported. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, QT Ultrasound Labs, Inc. (“QT Labs”). QT Labs provides personnel and staffing services for the Company. All intercompany balances and transactions are eliminated in consolidation. Liquidity The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $17,770,145 as of December 31, 2023. During the year ended December 31, 2023, the Company incurred a net loss of $6,098,951 and used $2,651,143 of cash in operating activities. The Company expects to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to support the Company’s cost structure. The Company may never achieve profitability and, unless and until it does, the Company will need to continue to raise additional capital. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In connection with the Business Combination, the Company entered into various agreements to obtain financing through the issuance of debt and through stock subscription agreements. Subsequent to December 31, 2023, the Company received the Pre-Paid Advance, net of issuance costs, of $9,005,000 from Yorkville pursuant to the Standby Equity Purchase Agreement, $500,000 of cash proceeds from an investor related to a stock subscription agreement, and $1,500,000 in cash proceeds through a note payable from Funicular Funds, LP. See Note 14. Subsequent Events. The Standby Equity Purchase Agreement provides the Company with access to an additional $40 million of potential capital through the issuance of common stock to Yorkville. During the time the Company has a balance under the Pre-Paid Advance, additional advances can be received with written consent of Yorkville or upon a trigger event, which occurs when the daily volume-weighted average price is less than $2.00 per share for five consecutive trading days. Management believes that the additional cash received and financing arrangements at the closing of the Business Combination has alleviated the substantial doubt about the Company’s ability to continue as a going concern and will be sufficient to fund the Company’s current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements. The Company’s future capital requirements will depend on many factors, including the Company’s growth rate, the timing and extent of its spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the timing and cost to introduce new and enhanced products. In the event that additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to the Company, or at all. Any additional debt financing obtained by the Company in the future could also involve restrictive covenants relating to the Company’s capital-raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if the Company raises additional funds through further issuances of equity, convertible debt securities or other securities convertible into equity, its existing stockholders could suffer significant dilution in their percentage ownership of the Company, and any new equity securities the Company issues could have rights, preferences and privileges senior to those of holders of the Company’s common stock. If the Company is unable to obtain adequate financing or financing on terms satisfactory to the Company when the Company requires it, the Company’s ability to continue to grow or support its business and to respond to business challenges could be significantly limited. Reclassification Certain reclassifications have been made to the prior year consolidated statement of operations and comprehensive loss to conform to the current year presentation. The reclassification had no impact on the previously reported consolidated balance sheet, statement of stockholders’ equity (deficit) or cash flows. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on the Company’s operating results. Business Risk and Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The majority of the Company’s cash is invested in U.S. dollar deposits with a reputable bank in the United States. Management believes that minimal credit risk exists with respect to the financial institution that holds the Company’s cash. At times, such cash may be in excess of insured limits established by the Federal Deposit Insurance Corporation. The Company performs ongoing credit evaluations of its customers and generally does not require collateral for accounts receivable. Payment terms range from cash in advance to 30 days from delivery of products or services but may fluctuate depending on the terms of each specific contract. During the year ended December 31, 2023, one customer represented 49% of revenue. During the year ended December 31, 2022, one customer represented 98% of revenue. As of December 31, 2023, one customer represented 100% of accounts receivable. As of December 31, 2022, there were no customer concentrations in accounts receivable. The Company’s products require approvals from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. The Company’s future products may not receive required approvals. If the Company was denied such approvals, or if such approvals were delayed, it would have a material adverse impact on the Company’s business, results of operations and financial condition. Certain components and services used to manufacture and develop the Company’s products are presently available from only one or a limited number of suppliers or vendors. The loss of any of these suppliers or vendors would potentially require a significant level of hardware and/or software development efforts to incorporate the products or services into the Company’s product. Cash and Cash Equivalents The Company considers all short-term investments with a maturity of three months or less when purchased to be cash equivalents. The Company had restricted cash equivalents of $20,000 as of December 31, 2023 and 2022. Restricted Cash Restricted cash is comprised of cash held in an account subject to a collateral agreement to be used for the Company’s corporate credit card program. Accounts Receivable Accounts receivable are carried at the amount due. Accounts receivable are written off when management deems all realistic efforts to collect the amount outstanding have been exhausted. A provision for credit losses is estimated by management based on evaluations of its historical bad debt and current collection experience. As of December 31, 2023 and 2022, a provision for credit losses was not required. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the weighted-average cost method. The Company periodically reviews the value of items in inventory and provides write-offs of inventory that is obsolete. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Once inventory has been written down below cost, it is not subsequently written up. Property and Equipment, Net Property and equipment, net are recorded at cost, less accumulated depreciation. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to current operations as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized over the lesser of the term of the related lease or the estimated useful lives of the assets. Leases The Company primarily enters into leases for office space that are classified as operating leases. The Company determines if an arrangement is or contains a lease at inception. The Company accounts for leases by recording right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets in the captions operating lease right-of-use assets, net and operating lease liabilities, respectively. The lease term includes the non-cancelable period of the lease plus any additional periods covered by an option to extend that the Company is reasonably certain to exercise. The Company’s leases do not include substantial variable payments based on index or rates. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants. The Company’s leases do not provide a readily determinable implicit discount rate. The Company’s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The lease payments related to the next 12 months are included in operating lease liabilities, current on the consolidated balance sheets. The Company recognizes a single lease cost on a straight-line basis over the term of the lease, and the Company classifies all cash payments within operating activities in the consolidated statements of cash flows. The Company did not have any finance leases as of December 31, 2023 or 2022. Intangible Assets The Company’s intangible assets are comprised of patents with a useful life of 12 years. Patents are amortized on a straight-line basis over their useful life. Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by an asset to the carrying value of an asset. If the carrying value of the long-lived asset is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. Management has reviewed the Company’s long-lived assets and recorded no impairment charge for the years ended December 31, 2023 and 2022. Fair Value Measurements The Company applies the requirements of the fair value measurements framework, which establishes a hierarchy for measuring fair value and requires enhanced disclosures about fair value measurements. The fair value measurement guidance clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement guidance also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy in which these assets and liabilities must be grouped based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s financial assets measured on a recurring basis included certificates of deposit totaling $20,000 as of December 31, 2023 and 2022 and were classified as Level 2 financial assets. The Company did not have any financial liabilities measured on a recurring basis as of December 31, 2023 and 2022. Convertible Debt The Company evaluates its financial instruments to determine if they are freestanding financial instruments. The Company also evaluates its convertible debt for embedded derivatives. Embedded provisions (like conversion options) are assessed to determine if they qualify as embedded derivatives that require separate accounting. Debt issuance costs are recorded as a reduction to the carrying amount of the convertible debt and are amortized to interest expense using the effective interest method. The convertible debt is classified as short-term or long-term based on the term of the note. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods or services. The Company determines revenue recognition through the following steps: 1) Identification of the contract, or contracts, with a customer The Company considers the terms and conditions of the contract in identifying the contracts. The Company determines a contract with a customer to exist when the contract is approved, each party’s rights regarding the goods or services to be transferred can be identified, the payment terms for the goods or services can be identified, it has been determined the customer has the ability and intent to pay, and the contract has commercial substance. At contract inception, the Company will evaluate whether two or more contracts should be combined and accounted for as a single contract and whether the combined or single contract includes more than one performance obligation. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, credit and financial information pertaining to the customer. 2) Identification of the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or services either on its own or together with other resources that are readily available from third parties or from the Company, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. The Company’s performance obligations consist of (i) product sales, (ii) maintenance contracts and (iii) other services including training. 3) Determination of the transaction price The transaction price is determined based on the consideration to which the Company expects to be entitled in exchange for transferring goods or services to the customer. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company’s contracts do not contain a significant financing component. 4) Allocation of the transaction price to the performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price. 5) Recognition of revenue when, or as a performance obligation is satisfied For product sales and services, revenue is recognized at the time the related performance obligation is satisfied by transferring the control of the promised goods or services to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. Training and maintenance services are generally recognized upon invoicing in amounts that correspond directly with the value to the customer of the performance completed to date which primarily includes professional service arrangements entered on a time and materials basis. All of the revenue recognized by the Company during the years ended December 31, 2023 and 2022 was recognized at a point in time. Revenue recognized during the years ended December 31, 2023 and 2022 is disaggregated as follows: 2023 2022 Product $ 17,832 $ 701,092 Service 22,523 7,152 $ 40,355 $ 708,244 Revenue recognized by geography during the years ended December 31, 2023 and 2022 is as follows: 2023 2022 United States $ 35,165 $ 7,200 International 5,190 701,044 $ 40,355 $ 708,244 The Company had no contract assets as of December 31, 2023 and 2022 and no contract liabilities as of December 31, 2022. The Company had contract liabilities of $347,619 as of December 31, 2023, which are expected to be fully recognized in revenue in 2024. Shipping and Handling Costs Shipping and handling activities are typically performed before the customer obtains control of the goods, and the related costs are therefore expensed as incurred. Shipping and handling costs are included in cost of revenue in the accompanying consolidated statements of operations and comprehensive loss. Shipping and handling costs incurred for inventory purchases are expensed in cost of revenue when sold. Product Warranty The Company’s products sold to customers are generally subject to warranties between one and two years, which provides for the repair or replacement of products, at the Company’s option, that fail to perform with stated specifications. The Company estimates future warranty obligations related to those products. To date, product warranty claims have not been significant. Research and Development Costs Research and development costs incurred by the Company include salaries, purchased services, operating materials and supplies, depreciation, and amortization, and are expensed as incurred. These costs for the years ended December 31, 2023 and 2022, amounted to $1,485,636 and $2,386,086, respectively. Advertising Advertising and promotion costs are expensed as incurred. Advertising expenses were not significant for the years ended December 31, 2023 and 2022. Grant Income Periodically, the Company is awarded grants on a cost reimbursement basis. Costs are expensed when incurred and reimbursable on a monthly or quarterly basis with the offset booked as a contra-expense to the applicable functional area in the consolidated statements of operations and comprehensive loss. Income Taxes Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets may be reduced by a valuation allowance if it is more-likely-than-not that some or all of the deferred tax asset will not be realized. The Company annually evaluates the realizability of deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. In accordance with this accounting policy, the Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax benefit. There were no accrued interest and penalties during the years ended December 31, 2023 and 2022. Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair market value of the award. Stock-based compensation is recognized as expense on a ratable basis over the requisite service period of the award. The Company values stock options using the Black-Scholes option pricing model. This model requires the use of highly subjective and complex assumptions which determine the fair value of stock-based awards, including the option’s expected term, stock price volatility and risk-free interest rates. Forfeitures are recorded as they occur. Comprehensive Loss Comprehensive loss is defined as the change in the equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss was equal to net loss for the years ended December 31, 2023 and 2022. Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For the purposes of the diluted net loss per share calculation, common stock equivalents are considered to be potentially dilutive securities. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive as of December 31: 2023 2022 Common stock warrants 1,231,484 905,470 Options outstanding 3,646,922 3,940,536 Potential shares from convertible notes 2,073,554 714,870 Subscription agreements 3,833,912 — 10,785,872 5,560,876 Fair Value of Financial Instruments The fair value of the Company’s financial instruments, including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values because of the relatively short maturity of these instruments. The carrying value of the Company’s borrowings approximates fair value based on current rates offered to the Company for instruments with similar terms. Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , and subsequently issued several supplemental/clarifying ASUs (collectively, “ASC 326”). This ASU requires entities to estimate a lifetime expected credit loss for most financial assets, including trade and other receivables, other long-term financings including available for sale and held-to-maturity debt securities, and loans. The Company adopted ASC 326 on January 1, 2023. This standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the consolidated financial statements.
GIGCAPITAL5, INC
Property, Plant and Equipment [Line Items]
The Company and Summary of Significant Accounting Policies		SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Emerging Growth Company Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when an accounting standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised accounting standard at the time private companies adopt the new or revised standard. Net Loss Per Share of Common Stock The Company’s statements of operations and comprehensive loss include a presentation of income per share for common stock subject to possible redemption in a manner similar to the two-class method of income (loss) per share. Net income per share, basic and diluted, for common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held in the Trust Account by the weighted-average number of common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for non-redeemable common stock is calculated by dividing the net loss, adjusted for income or loss on marketable securities attributable to common stock subject to possible redemption, by the weighted-average number of non-redeemable common stock outstanding for the period, basic and diluted. When calculating its diluted net loss per share, the Company has not considered the effect of (i) the incremental number of shares of common stock to settle warrants sold in the Offering and Private Placement, as calculated using the treasury stock method and (ii) the shares issued to Mr. Weightman subject to forfeiture representing 5,000 shares of common stock underlying a restricted stock award for the period it was outstanding. Since the Company was in a net loss position during the period after deducting net income attributable to common stock subject to redemption, diluted net loss per common share is the same as basic net loss per common share for the periods presented as the inclusion of all potential common shares outstanding would have been anti-dilutive. Reconciliation of Net Loss Per Common Share In accordance with the two-class method, the Company’s net loss is adjusted for net income that is attributable to common stock subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, net loss per common share, basic and diluted, is calculated as follows: Year Ended Year Ended Common stock subject to possible redemption Numerator: Earnings allocable to common stock subject to redemption Interest earned on marketable securities held in Trust Account, net of taxes $ 1,107,741 $ 1,143,783 Net income attributable to common stock subject to possible redemptions $ 1,107,741 $ 1,143,783 Denominator: Weighted-average common shares subject to redemption Basic and diluted weighted-average shares outstanding, common stock subject to possible redemption 3,020,634 17,954,419 Basic and diluted net income per share, common stock subject to possible redemption $ 0.37 $ 0.06 Non-Redeemable common stock Numerator: Net loss minus net earnings - Basic and diluted Net loss $ (4,024,591) $ (2,774,307) Less: net income attributable to common stock subject to redemption (1,107,741) (1,143,783) Net loss attributable to non-redeemable common stock $ (5,132,332) $ (3,918,090) Denominator: Weighted-average non-redeemable common shares Weighted-average non-redeemable common shares outstanding, basic and diluted 6,540,000 6,540,000 Net loss per share, non-redeemable common stock, basic and diluted $ (0.78) $ (0.60) Cash and Cash Equivalents The Company considers all short-term investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains cash balances that at times may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions. There were no cash equivalents as of December 31, 2023 and 2022. Cash and Marketable Securities Held in Trust Account As of December 31, 2023, the assets held in the Trust Account consisted of cash. As of December 31, 2022, the assets held in the Trust Account consisted of money market funds investing in U.S. Treasury Bills and cash. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which at times, may exceed federally insured limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Convertible Promissory Note - Related Party The Company accounts for its Working Capital Note under Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). Under ASC 815-15-25, an election can be made at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825, Financial Instruments. The Company has made such election for its Working Capital Note. Using the fair value option, the Working Capital Note is required to be recorded at its initial fair value on the date of issuance, each drawdown date, and each balance sheet date thereafter. Differences between the face value of the Working Capital Note and fair value at each drawdown date are recognized as either an expense in the statements of operations and comprehensive loss (if issued at a premium) or as a capital contribution (if issued at a discount). Changes in the estimated fair value of the Working Capital Note are recognized as non-cash gains or losses in the statements of operations and comprehensive loss. The Extension Note is not included in the calculation as it does not have a conversion feature. Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Offering Costs Offering costs in the amount of $13,193,740 consist of legal, accounting, underwriting fees and other costs incurred that are directly related to the Offering. Offering costs were charged to stockholders’ deficit and recorded in additional paid-in capital as a reduction to the gross proceeds received upon completion of the Offering. On March 20, 2023, one of the Underwriters, Wells Fargo, waived all of their portion of the deferred underwriting fees totaling $6,440,000. Common Stock Subject to Possible Redemption Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of December 31, 2023 and 2022, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets. As of December 31, 2023 and 2022, 2,114,978 and 4,014,050 shares of common stock, respectively, were issued and outstanding and subject to possible redemption. Stock-based Compensation Stock-based compensation related to restricted stock awards is based on the fair value of common stock on the grant date. The shares underlying the Company’s restricted stock award to Mr. Weightman is subject to forfeiture if he resigns or is terminated for cause prior to the completion of the Business Combination. Therefore, the related stock-based compensation will be recognized upon the completion of a Business Combination, unless the related shares are forfeited prior to a Business Combination occurring. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2023 and 2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Warrant Liability The Company accounts for warrants for shares of the Company’s common stock that are not indexed to its own stock as liabilities at fair value on the balance sheets. The warrants are subject to remeasurement at each balance sheet date and any change in fair value is recognized as a component of other expense on the statements of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the common stock warrants. At that time, the portion of the warrant liability related to the common stock warrants will be reclassified to additional paid-in capital. Recent Accounting Pronouncements

Inventory

Inventory	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Raw materials $ 2,600,114 $ 2,529,364 Work in process 74,540 1,627,802 Finished Goods 506,900 261,031 Total $ 3,181,554 $ 4,418,197	Inventory Inventory consisted of the following as of December 31: 2023 2022 Raw materials $ 2,529,364 $ 2,567,311 Work in process 1,627,802 1,683,341 Finished Goods 261,031 528,254 Total $ 4,418,197 $ 4,778,906

Business Combination and Relate

Business Combination and Related Agreement	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Business Combination	Business Combination As described in Note 1, the Merger with GigCapital5 was consummated on March 4, 2024. On the Merger Date, QT Imaging, GigCapital5, and QT Merger Sub, consummated the closing of the transactions contemplated by the Business Combination Agreement, following the approval at an annual stockholder meeting of the stockholders of GigCapital5 held on February 20, 2024 (the “Stockholder Meeting”). The Business Combination was accounted for as a reverse recapitalization. Under this method of accounting, GigCapital5 was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of QT Imaging issuing shares of the net assets of GigCapital5, accompanied by a recapitalization. The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (approximately 0.3427 shares of the Company's common stock for each share of QT Imaging common stock). The net liabilities of GigCapital5 have been recognized at carrying value, with no goodwill or other intangible assets recorded. QT Imaging has been determined to be the accounting acquirer based on evaluation of the following facts and circumstances: • QT Imaging's stockholders have a majority of the voting power of the Company; • The majority of QT Imaging's board of directors continued to serve as directors of the Company; • The majority of QT Imaging's management continued to serve as management of the Company; • QT Imaging comprises the ongoing operations of the Company; and • QT Imaging is the larger entity based on historical business activity and the larger employee base. The following summarizes the elements of the Merger to the condensed consolidated statements of stockholders’ deficit and cash flows, including the transaction funding, sources, and uses of cash: Recapitalization Cash in GigCapital5 Trust Account, net of redemptions $ 13,952,525 Plus: cash in GigCapital5 operating bank account 4,829 Less: Payments made pursuant to non-redemption agreements (10,791,550) Less: GigCapital5 transaction costs paid from Trust (1,073,667) Less: Repayment of GigCapital5 related party notes (853,607) Net cash proceeds from GigCapital5 1,238,530 Assumed net liabilities from GigCapital5, excluding net cash proceeds (10,507,695) Net impact of the Merger on the condensed consolidated statement of stockholders' deficit $ (9,269,165) Merger Related Activities On November 15, 2023, GigCapital5, QT Imaging and Yorkville, a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP, entered into the SEPA. Upon the closing of the Merger, the Company has the right, provided there is no balance outstanding under the Yorkville Note (as defined below) or, if there is a balance outstanding under a Yorkville Note, with Yorkville’s prior written consent, or upon the occurrence of certain trigger events, to issue and sell to Yorkville, and Yorkville shall purchase from the Company, up to $10,000,000 in aggregate gross purchase price (the “Commitment Amount”) of newly issued shares of the common stock (each such sale, an “Advance”) by delivering written notice to Yorkville (each, an “Advance Notice” and the date on which the Company is deemed to have delivered an Advance Notice, the “Advance Notice Date”). As consideration for a payment of $10,000,000 (the “Pre-Paid Advance”) received on March 4, 2024, the Company issued the Yorkville Note, which was issued with a 6% original issue discount. The Yorkville Note for the Pre-Paid Advance was originally due 15 months from the date of issuance, and interest accrues on the outstanding balance of the Yorkville Note at an annual rate equal to 6%, subject to an increase to 18% upon an event of default. The Yorkville Note is convertible by Yorkville into shares of the Company’s common stock. On March 4, 2024, immediately prior to, and substantially concurrently with, the closing of the Business Combination, QT Imaging issued to Yorkville that number of shares of the Company which converted in the aggregate into 1,000,000 shares of the Company's common stock (the “Company Shares”) upon the completion of the Merger. See Note 8. In February 2024, GigCapital5 and QT Imaging entered into a Note Purchase Agreement (the “Cable Car Loan”) with Funicular Funds, LP (“Cable Car”), pursuant to which Cable Car agreed to advance $1,500,000 at the closing of the Business Combination, as was evidenced by a promissory note that may be convertible in certain circumstances into shares of the Company's common stock at a conversion price of $2.00 per share (the “Loan”), dated March 4, 2024, by and between QT Imaging and Cable Car. The Loan does not bear interest, and is due and payable 13 months after issuance, unless the time for payment is accelerated as a result of an event of default. On March 4, 2024, a s full compensation to Cable Car for the Loan to QT Imaging in lieu of any simple or in-kind interest on the Loan, QT Imaging issued to Cable Car that number of shares of the Company which at the completion of the Business Combination would be converted in accordance with the terms of the Business Combination Agreement into 180,000 shares of the Company's common stock. See Note 8. In February 2024, GigCapital5 and QT Imaging (together the “parties”) entered into a subscription agreement with William Blair & Co., L.L.C. (“William Blair”) for the purchase of shares of common stock of QT Imaging. Pursuant to the subscription agreement, QT Imaging issued to William Blair in satisfaction of certain fees owed to William Blair for its services to the parties, that number of shares of QT Imaging which at the completion of the Business Combination were converted in accordance with the terms of the Business Combination Agreement into 740,000 shares of the Company’s common stock. The issuance of these shares settled $2,410,000 of net assumed liabilities from the business combination with an additional transaction cost expense of $202,200 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. In February 2024, the parties agreed to amend one of the non-redemption agreements that were entered into in September 2023 (“September 2023 Non-Redemption Agreements”), pursuant to which, and in addition to the Company’s common stock issuable Mizuho Securities USA, LLC (“Mizuho”) under the September 2023 Non-Redemption Agreement, Mizuho received from QT Imaging, in exchange for $250,000 of services rendered by Mizuho, that number of QT Imaging’s common stock that converted in accordance with the terms of the Business Combination Agreement into 100,000 shares of the Company’s common stock. The issuance of these shares settled $250,000 of net assumed liabilities from the business combination with an additional transaction expense of $103,000 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. In February 2024, QT Imaging and GigCapital5 entered into two additional subscription agreements with each of Donnelley Financial Solutions, LLC (“DFIN”) and IB Capital LLC (“iBankers”), dated as of February 23, 2024 and February 22, 2024, respectively (together, the “Subscription Agreements”), for the purchase of shares of common stock of QT Imaging. Pursuant to the Subscription Agreements, QT Imaging issued to each of DFIN and iBankers in satisfaction of $500,000 and $600,000 of fees owed to DFIN and iBankers, respectively, for their services, that number of shares of QT Imaging which at the completion of the Business Combination were converted in accordance with the terms of the Business Combination Agreement into 200,000 and 240,000 respective share s of the Company’s common stock. The issuance of these shares settled $1,100,000 of net assumed liabilities from the business combination with an additional transaction expense of $453,200 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. In February 2024, QT Imaging and LionBay Ventures (“LionBay”) entered into a Settlement and Termination Agreement (“Termination Agreement”). Pursuant to the terms of the Termination Agreement, QT Imaging terminated its Service Agreement with LionBay dated May 18, 2021 and the First Amendment of the Service Agreement dated September 9, 2021 (collectively as “Service Agreement”). In exchange for the termination of the Service Agreement and the termination of options to purchase 17,000 shares of common stock with a strike price of $8.50 per option that were issued as part of the Service Agreement, QT Imaging agreed to issue that number of shares that converted into 10,000 shares of the Company’s common stock. The issuance of these shares resulted in an additional transaction expense of $35,300 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. In February 2024, QT Imaging received $500,000 in exchange for that number of shares that converted into 200,000 shares of the Company's common stock in accordance with the terms of the subscription agreement and Business Combination Agreement. The issuance of these shares resulted in an additional transaction expense of $206,000 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. Pursuant to an amendment dated December 13, 2023 , between QT Imaging and Exit Strategy Partners, LLC (“Advisor”), the Company agreed to pay for Advisor’s services in exchange for that number of shares that converted into 250,000 shares of the Company’s common stock and a total cash amount of $225,000, of which $125,000 was paid on the closing of the Business Combination on March 4, 2024 and the remaining $100,000 is due on the first anniversary of the closing of the Business Combination, which is recorded in accrued expenses and other current liabilities within the condensed consolidated balance sheet as of September 30, 2024. The total cash consideration and issuance of shares related to this amendment resulted in a transaction expense of $1,107,500 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. On March 4, 2024 , as consideration for the September 2023 Non-Redemption with certain GigCapital5 stockholders (“Non-Redeeming Stockholders”), QT Imaging issued that number of shares that converted into 427,477 shares of the Company’s common stock to the Non-Redeeming Stockholders. The issuance of these shares resulted in a transaction expense of $1,508,994 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. On March 4, 2024 , the Company issued to subscribers to the Stock Subscription Agreements entered into in November 2023 equal to that number of shares that resulted in such parties as stockholders of QT Imaging receiving pursuant to the Business Combination Agreement 150,000 shares of the Company's common stock. The issuance of these shares resulted in a transaction expense of $529,500 recorded as selling, general and administrative expense within the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. No transaction expense related to this agreement was recorded during the three months ended September 30, 2024. Merger Earnout Consideration Shares Pursuant to the Second Amendment to Business Combination Agreement dated September 21, 2023, the Company is obliged to issue a maximum of 9,000,000 shares of Company's common stock (the “ Merger Consideration Earnout Shares ” ) if certain triggering events and conditions are achieved during 2024, 2025, and 2026. 2024 Earnout Shares Promptly following the date on which Company files its Quarterly Report on Form 10-Q with respect to its fiscal quarter ended September 30, 2024 with the SEC, an aggregate of 2,500,000 Merger Consideration Earnout Shares (the “2024 Earnout Shares”) will be issued to QT Imaging’s former stockholders if, and only if, on or prior to such filing date, the Company has obtained a formal U.S. Food and Drug Administration (“FDA”) clearance for breast cancer screening with respect to its breast scanning systems, which remains in full force and effect as of such filing date; provided, that the 2024 Earnout Shares shall increase by 500,000 (to an aggregate of 3,000,000) Merger Consideration Earnout Shares if, in addition, during the fifteen months ended September 30, 2024, the Company either (A) makes at least eight bona fide placements of its breast scanning systems globally or (B) has revenue of at least $4,400,000 as set forth in the condensed consolidated financial statements included in the periodic reports filed by the Company with the SEC with respect to such fifteen month period. 2025 Earnout Shares Promptly following the date on which the Company files its Quarterly Report on Form 10-Q with respect to its fiscal quarter ended September 30, 2025 with the SEC, an aggregate of 2,500,000 Merger Consideration Earnout Shares (the “2025 Earnout Shares”) will be issued to QT Imaging’s former stockholders if, and only if, during the twelve months ended September 30, 2025, (A) the Company achieves annual revenue of at least $17,100,000 as set forth in the condensed consolidated financial statements included in the periodic reports filed by the Company with the SEC with respect to such twelve month period, and (B) the Company makes at least four placements of its breast scanning systems in the United States; provided, that the 2025 Earnout Shares shall increase by 500,000 (to an aggregate of 3,000,000) Merger Consideration Earnout Shares if at least one of the following milestones is achieved: (x) on or prior to such filing date, the Company has obtained a formal FDA clearance for a new indication for use of its breast scanning systems (other than any indication obtained prior to the beginning of the twelve months ended September 30, 2025), which remains in full force and effect as of such filing date; or (y) the Company achieves clinical-quality patient images with the Company’s open angle scanner no later than the filing date of the Quarterly Report on Form 10-Q for the third quarter of 2025. 2026 Earnout Shares Promptly following the date on which the Company files its Quarterly Report on Form 10-Q with respect to its fiscal quarter ended September 30, 2026 with the SEC, an aggregate of 2,500,000 Merger Consideration Earnout Shares (the “2026 Earnout Shares”) will be issued to QT Imaging’s former stockholders if, and only if, during the twelve months ended September 30, 2026, (A) the Company has revenue of at least $30,000,000 as set forth in the condensed consolidated financial statements included in the periodic reports filed by the Company with the SEC with respect to such twelve month period, or (B) the VWAP of shares of common stock equals or exceeds $15.00 per share for twenty thirty
GIGCAPITAL5, INC
BUSINESS COMBINATION AND RELATED AGREEMENT		BUSINESS COMBINATION AND RELATED AGREEMENT On December 8, 2022, the Company and QTI Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), entered into a Business Combination Agreement (the “Business Combination Agreement”) with QT Imaging, Inc., a Delaware corporation (“QT Imaging”), pursuant to which, and subject to the approval of the stockholders of the Company, Merger Sub will merge with and into QT Imaging, with QT Imaging surviving the merger as a wholly owned subsidiary of the Company (the “Merger” and, together with the other transactions contemplated by the Business Combination Agreement and any other agreement executed and delivered in connection therewith, the Business Combination. Following the closing of the Merger (the “Closing”), the Company, which will be renamed “QT Imaging Holdings, Inc.” Subject to the terms of the Business Combination Agreement, at the effective time of the Merger (the “Effective Time”), each issued and outstanding share of the common stock of QT Imaging, par value $0.001 per share (the “QT Imaging Common Stock”) (excluding each share of QT Imaging Common Stock held in the treasury of QT Imaging which will be cancelled without any conversion of such shares of QT Imaging Common Stock held in the treasury and dissenting shares) will be automatically cancelled and converted into (A) the right to receive a number of shares of common stock, par value $0.0001 per share, of the Company (the “GigCapital5 Common Stock”) calculated based on the Exchange Ratio (as defined below) and (B) the contingent right to receive a portion of additional shares of GigCapital5 Common Stock based on the performance of the Combined Company if certain requirements are achieved in accordance with the terms of the Business Combination Agreement, if, as and when payable. The “Exchange Ratio” means the quotient of (a) the Aggregate Closing Merger Consideration (as defined in the Business Combination Agreement) divided by (b) the QT Imaging Fully Diluted Capital Stock (as defined in the Business Combination Agreement). In addition, at the Effective Time, certain warrants of QT Imaging to purchase QT Imaging common stock will be converted into a warrant to acquire a number of shares of GigCapital5 Common Stock at an adjusted exercise price per share. The shares of the Company common stock are currently listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “GIA,” and from now until the Effective Time, the Public Units and the warrants trade at the OTC Markets Group Inc. under the symbols “GIAFU” and “GIAFW,” respectively. The Company applied for listing of the common stock of the Combined Company and the warrants of the Combined Company on the Nasdaq under the symbols “QTI” and “QTI.WS,” respectively, at the Effective Time. The symbol for the warrants was rejected so only the common stock is trading on the Nasdaq under the symbol GTI. The warrants trade in the over-the-counter market under the symbol QTIWW.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consisted of the following as of September 30, 2024 and December 31, 2023: Useful Life September 30, 2024 December 31, 2023 Scanners 5 Years $ 2,254,548 $ 3,309,957 Computer and lab equipment 3-5 Years 1,384,307 1,359,491 Leasehold improvements Various 421,266 421,266 Software 3 Years 50,374 40,599 Furniture and fixtures 7 Years 82,336 82,336 4,192,831 5,213,649 Less: accumulated depreciation (4,070,679) (4,722,729) $ 122,152 $ 490,920	Property and Equipment, Net Property and equipment, net consisted of the following as of December 31: Useful Life 2023 2022 Scanners 5 Years $ 3,309,957 $ 3,047,841 Computer and lab equipment 3-5 Years 1,359,491 1,346,726 Leasehold improvements Various 421,266 421,266 Software 3 Years 40,599 40,599 Furniture and fixtures 7 Years 82,336 82,336 5,213,649 4,938,768 Less: accumulated depreciation (4,722,729) (4,441,021) $ 490,920 $ 497,747

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Intangible Assets, Net Intangible assets, net consisted of the following as of September 30, 2024: Useful Gross Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 2,230,570 $ — 0.00 Years Intangible assets, net consisted of the following as of December 31, 2023: Useful Gross Carrying Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 2,140,431 $ 90,139 0.50 Years Amortization expense was $0 and $46,470 for each of the three months ended September 30, 2024 and 2023. Amortization expense was $90,139 and $139,410 for each of the nine months ended September 30, 2024 and 2023.	Intangible Assets, Net Intangible assets, net consisted of the following as of December 31, 2023: Useful Gross Carrying Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 2,140,431 $ 90,139 0.50 Years Intangible assets, net consisted of the following as of December 31, 2022: Useful Gross Carrying Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 1,954,550 $ 276,020 1.50 Years Amortization expense was $185,881 for each of the years ended December 31, 2023 and 2022. As of December 31, 2023, future amortization is as follows: Year ending December 31: 2024 $ 90,139

Balance Sheet Details

Balance Sheet Details	9 Months Ended
	Sep. 30, 2024
Offsetting [Abstract]
Balance Sheet Details	Balance Sheet Details Prepaid expenses and other current assets consisted of the following as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Prepaid insurance $ 432,170 $ 9,808 Other 343,415 205,171 Total $ 775,585 $ 214,979 Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Accrued legal $ 1,900,000 $ 24,729 Accrued personnel costs 899,796 120,856 Accrued excise taxes 202,341 — Accrued advisory fee 100,000 — Other 262,080 224,066 Total $ 3,364,217 $ 369,651

Offering

Offering	12 Months Ended
	Dec. 31, 2023
GIGCAPITAL5, INC
OFFERING	OFFERING On September 28, 2021, the Company completed the closing of the Offering whereby the Company sold 23,000,000 Public Units at a price of $10.00 per Public Unit. Each Public Unit consists of one Public Share and one Public Warrant. Each whole Public Warrant is exercisable for one share of common stock at a price of $11.50 per full share. The exercise price of the Public Warrants may be adjusted in certain circumstances as discussed in Note 7. Under the terms of the warrant agreement (the “Warrant Agreement”), the Company has agreed to use its best efforts to file a new registration statement under the Securities Act, following the completion of the Company’s Business Combination. Each Public Warrant will become exercisable on the later of 30 days after the completion of the Company’s Business Combination or 12 months from the closing of the Offering and will expire five years after the completion of the Company’s Business Combination or earlier upon redemption or liquidation. However, if the Company does not complete a Business Combination on or prior to the 30-month period allotted to complete the Business Combination (or such lesser period depending upon the number of one-month extensions which occur), the Public Warrants will expire at the end of such period. If the Company is unable to deliver registered shares of common stock to the holder upon exercise of the Public Warrants during the exercise period, there will be no net cash settlement of these Public Warrants and the Public Warrants will expire worthless, unless they may be exercised on a cashless basis in the circumstances described in the Warrant Agreement. Once the Public Warrants become exercisable, the Company may redeem the outstanding Public Warrants in whole and not in part at a price of $0.01 per Public Warrant upon a minimum of 30 days’ prior written notice of redemption, only in the event that the last sale price of the Company’s shares of common stock equals or exceeds $18.00 per share for any 20 trading days within the 30-trading day period ending on the third trading day before the Company sends the notice of redemption to the Public Warrant holders. On November 1, 2021, the Company announced that the holders of the Company’s Public Units may elect to separately trade the securities underlying such Public Units which commenced on November 4, 2021. Any Public Units not separated continued to trade on the New York Stock Exchange (“NYSE”) under the symbol “GIA.U.” Any underlying shares of common stock and warrants that were separated traded on the NYSE under the symbols “GIA,” and “GIA.WS,” respectively. On April 21, 2023, the Company delisted the Public Units, shares of common stock and warrants from NYSE and listed the shares of the Company common stock on the Nasdaq Global Market (“Nasdaq”) under the symbol

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consisted of the following as of December 31: 2023 2022 Accrued vacation $ 55,683 $ 91,125 Accrued wages 65,173 80,904 Accrued legal 24,729 79,691 Accrued interest 50,037 — Other 174,029 116,646 Total $ 369,651 $ 368,366

Long-Term Debt

Long-Term Debt	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Paycheck Protection Program Loan On February 24, 2021 and May 5, 2020, the Company received loans (“PPP Loans”) from US Bank in the amounts of $1,158,265 (“Loan 2”) and $1,158,266 (“Loan 1”), respectively, to fund payroll, rent and utilities through the Paycheck Protection Program (“PPP”). Original loan terms were revised by the PPP Flexibility Act of 2020. Under the terms of the PPP, up to 100% of the loan and related interest was forgivable if the proceeds were used for covered expenses and certain other requirements related to wage rates were met. For Loan 1, the Company applied for forgiveness on June 7, 2021, and received forgiveness of $873,151 in principal and $9,823 in interest from the Small Business Administration (“SBA”) on June 14, 2021. For Loan 2, the Company applied for forgiveness on November 9, 2021, and received forgiveness of $930,246 in principal and $6,822 in interest on November 15, 2021. The remaining balance of Loan 1 of $285,115 is payable in monthly installments of $6,400, including interest at 1%, beginning August 5, 20 21, with the final payment due May 5, 2025. As of September 30, 2024, the total principal outstanding under Loan 1 was $51,008, all of which was current. As of December 31, 2023, the total principal outstanding under Loan 1 was $107,979, of which $76,058 was current and $31,921 was noncurrent. The remaining balance of Loan 2 of $228,019 is payable in monthly installments of $4,605, including interest at 1%, beginning December 27, 2021, with the final payment due February 27, 2026. As of September 30, 2024, the total principal outstanding under Loan 2 was $77,691, of which $54,725 was current and $22,966 was noncurrent. As of December 31, 2023, the total principal outstanding under Loan 2 was $118,369, of which $54,308 was current and $64,061 was noncurrent. Interest expense for Loan 1 and Loan 2 for the three months ended September 30, 2024 and 2023 was $384 and $716, respectively. Interest expense for Loan 1 and Loan 2 for the nine months ended September 30, 2024 and 2023 was $1,397 and $2,377 , respectively. The SBA may undertake a review of a loan of any size during the six-year period following forgiveness or repayment of the loan. The review may include the loan forgiveness application, as well as whether the Company received the proper loan amount. The timing and outcome of any SBA review is not known. Convertible Notes Payable In June 2021, the Company entered into a convertible promissory note agreement (the “Note”) with USCG for advances of up to $10,000,000. The Company could have made advances on the Note up to six months after the inception of the Note unless extensions for advances were mutually agreed between both parties. The Note bore interest at 12% per annum on any amounts drawn with a maturity date of July 6, 2024. The Note was collateralized by all assets of the Company and was guaranteed by QT Labs. The terms of the Note include non-financial covenants and, as of March 4, 2024 when the Note converted, the Company was in compliance with those covenants. Through December 31, 2023, the Company issued warrants in connection with the note to purchase a total of 5,091 shares of common stock which 3,540 shares are exercisable at a price of $12.40 per share and 1,551 shares are exercisable at a price of $11.67 per share. The fair value of the warrants, along with financing fees, were recorded as debt issuance costs and presented in the condensed consolidated balance sheets as a deduction from the carrying amount of the Note. On March 4, 2024, these warrants were terminated in accordance with the Business Combination Agreement. The Note was convertible, at the Company’s option, before the Note matured upon the closing of a single transaction or a series of transactions with a minimum of $15,000,000 of cash proceeds raised in the aggregate. If elected, the conversion price is 90% of the price per share in the qualified financing. Management assessed whether the embedded features in the Note should have been bifurcated from the debt host and concluded that none of the features required to be accounted for separately from the debt instrument. In November 2023 and in connection with the Fourth Amendment and issuance of the senior secured convertible promissory note to US Capital as part of the Securities Purchase Agreement as described below (the “US Capital Note”), the outstanding loan balances of the Note of $2,495,000 with accrued interest of $635,854 were considered extinguished. In November 2023, the Company recorded $376,086 as a loss on extinguishment in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss, and includes a commission paid of $20,000, remaining unamortized debt issuance costs on the Note of $32,828 and the fair value of warrants to purchase 16,320 shares of common stock of $156,505. As of December 31, 2023, the total Note and US Capital Note balance was $3,294,659 net of unamortized debt issuance costs of $36,194, and accrued interest of $50,037. Interest expense, including amortization of debt issuance costs, for the three and nine months ended September 30, 2024 was $ 0 and $88,692, respectively. Interest expense, including amortization of debt issuance costs, for the three and nine months ended September 30, 2023 was $86,238 and $256,253, respectively. On March 4, 2024, the Note principal and related accrued interest balance of $3,233,388 and the US Capital Note principal balance of $200,000 was converted into 359,266 and 100,000 shares of common stock, respectively. Additionally, warrants to purchase 16,320 shares of the Company's common stock were net settled into 5,594 shares of common stock. Bridge Loan In November 2023, the Company entered into a Securities Purchase Agreement and raised a private secured convertible bridge financing in the aggregate amount of $1,000,000 (“Bridge Loan”) from five investors (“Bridge Lenders”). Each Bridge Loan of $200,000 bore no interest but had a cash option value at the date of maturity of 120%, or $240,000, of the Bridge Loan at each Bridge Lender’s option. The maturity date was the closing date of the Business Combination as defined in Note 1. The Bridge Loan conversion price was at $2.00 per share on a post-business combination. On March 4, 2024, four of the five Bridge Loan holders elected the cash option and were paid an aggregate of $960,000 on the Merger Date. Interest expense related to the payment premium was $0 and $160,000 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, there was no amount outstanding for the Bridge Loan. As of December 31, 2023, the outstanding amount of the Bridge Loan, excluding the US Capital Note, was $774,337, net of unamortized debt issuance costs of $25,663. Interest expense from the amortization of debt issuance costs for the three and nine months ended September 30, 2024 was $0 and $25,663, respectively. Yorkville Pre-Paid Advance On March 4, 2024, the Company received the Pre-Paid Advance of $10,000,000 from Yorkville and issued Yorkville the Yorkville Note in the amount of $10,000,000 for such Pre-Paid Advance that was originally due 15 months from the date of issuance, and interest shall accrue on the outstanding balance of the Yorkville Note at an annual rate equal to 6%, subject to an increase to 18% upon an event of default as described in the Yorkville Note. The Yorkville Note is convertible by Yorkville into shares of the Company's common stock. As consideration for the Pre-Paid Advance, immediately prior to, and substantially concurrently with, the closing of the Business Combination, QT Imaging issued to Yorkville that number of shares of QT Imaging which converted in the aggregate into 1,000,000 shares of the Company's common stock upon the completion of the Business Combination. In accordance with Accounting Standards Codification (“ASC”) 470-20, the proceeds of $10,000,000 were recorded between the promissory note and common stock less debt origination costs of $975,000, consisting of a $375,000 commitment fee for the SEPA and an original issue discount of 6% for the Yorkville Note, on a relative fair value basis. Expenses related to a structuring fee was $0 and $20,000 for the three and nine months ended September 30, 2024, respectively, and was included in other income (expense), net in the condensed consolidated statement of operations and comprehensive loss. As noted in Note 3, the Pre-Paid Advance contained Derivatives that were bifurcated and recorded a separate instrument. The initial value of the Derivatives of the $5,120,900 was recorded as a debt discount against the Pre-Paid Advance. Under the terms of the original Yorkville Note, a “Trigger Event” shall occur if the daily VWAP is less than the Floor Price for five trading days during a period of seven consecutive trading days (a “Floor Price Trigger” and the last such day of such occurrence, a “Trigger Date”). If, at any time six months after the issuance of the Yorkville Note, a Trigger Event occurs, then the Company will be obligated to make monthly payments in an amount equal to the sum of (i) $1,500,000 of principal in the aggregate among all promissory notes issued to Yorkville (or the outstanding principal if less than such amount) (the “Triggered Principal Amount”), plus (ii) a payment premium of 5% in respect of such Triggered Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date beginning on the 5th trading day after the Trigger Date and continuing on the same day of each successive calendar month to Yorkville pursuant to the terms of the Yorkville Note. However, in the event that the Company shall be required to make such cash payments to Yorkville under the Yorkville Note as a result of the occurrence of a Trigger Event, the Company shall be entitled upon written notice to Yorkville, to direct that Yorkville (i) if Yorkville has sold the Company Shares that it received upon the completion of the Merger to apply, in accordance with the terms of the Yorkville Note, up to 50% of Yorkville’s net sale proceeds of the Company Shares to satisfy, in part or in whole, the Triggered Principal Amount of such cash payments due to Yorkville or (ii) or if Yorkville has not sold the Company Shares, to apply up to 50% of the value of the Company Shares on such date the cash payment is due based on the VWAP as quoted by Bloomberg LP of the Company Shares as an offset of the Triggered Principal Amount of the cash payments due to Yorkville. The obligation of the Company to make monthly prepayments due to the occurrence of a Floor Price Triger shall cease (with respect to any payment that has not yet come due) if any time after the Trigger Date (a) the Company reduces the Floor Price to an amount that is at least 50% of the daily VWAP of the common stock or (b) the daily VWAP is greater than 110% of the Floor Price for a period of five consecutive trading days, unless a subsequent Trigger Event occurs. Furthermore, within one trading day of a Floor Price Trigger that remains after application of all amounts related to the Company Shares as described above, the Company shall reduce the Floor Price to an amount that is at least 50% of the daily VWAP of the common stock, and provide Yorkville written confirmation of such reduction of the Floor Price or be obligated to make the above monthly cash payments. Following the effectiveness of the Registration Statement on Form S-1 that the Company filed to register the shares to be issued pursuant to the SEPA, the Floor Price for Yorkville was $0.8768 per share (See Note 16 for current Floor Price). For the first five trading days commencing after six months after the issuance of the Yorkville Note, which ended on September 11, 2024, the daily VWAP of the common stock was less than the Floor Price, and as a result, September 11, 2024 constitutes a Trigger Date, and on that Trigger Date, a Trigger Event occurred due to a Floor Price Trigger. Accordingly, on September 13, 2024, the Company made the initial payment due to Yorkville as a result of the Trigger Event that occurred on September 11, 2024 in an amount totaling $1,521,581, the calculation of which reflects a reduction to the Triggered Principal Amount by 50% of the net sale proceeds of the Company Shares by Yorkville following the closing of the Business Combination. The total payment of $1,521,581 comprised of $1,145,407 of principal, $318,904 of accrued interest, and $57,270 of 5% early payment premium. The Company recognized the 5% early payment premium as interest expense within the condensed consolidated statement of operations and comprehensive loss during the three and nine months ended September 30, 2024. On September 26, 2024, the Company and Yorkville entered into an Omnibus Amendment (the “Omnibus Amendment”), pursuant to which the Company and Yorkville agreed to amend certain terms of the Yorkville Note to reduce the Company’s obligations resulting from the occurrence of the Trigger Event. Pursuant to the Omnibus Amendment, the maturity date of the Yorkville Note was extended approximately six months from June 4, 2025 to December 15, 2025. Further, the Omnibus Amendment acknowledges the Company’s obligation to make monthly payments to Yorkville in the amount of the Trigger Principal Amount due to the occurrence of the Trigger Event and revised the Yorkville Note to provide that no further monthly payments will be owed during the period beginning on the date of the Omnibus Amendment and ending on January 15, 2025. In exchange for this relief, beginning on January 15, 2025, and continuing on the same day of each successive calendar month until and including November 15, 2025, whether or not a Trigger Event has occurred and is continuing as of such dates, the Company will make monthly payments in an amount equal to $500,000 plus the payment premium of 5% plus accrued and unpaid interest under the Yorkville Note as of each such payment date. Such monthly payments will not be reduced or offset by any amount, including, but not limited to, any net sales proceeds of the Company Shares or any value of the Company Shares based on the VWAP as quoted by Bloomberg, LP. The Omnibus Amendment also provided that 100% of the proceeds of the sale of the remaining 400,000 Company Shares held at the time of entry into the Omnibus Amendment by Yorkville shall be retained by Yorkville and shall not be used to offset or reduce any amounts owed under the Yorkville Note, or to otherwise benefit the Company in any way. The Omnibus Amendment also provides that in the event that the Company’s common stock is delisted from trading on the Nasdaq Stock Market, Yorkville consents to the occurrence of such delisting from the Nasdaq Stock Market, if it is to happen, and that it will not constitute an Event of Default as defined per the Omnibus Amendment, provided that (i) the Company uses its best efforts to have its common stock relisted on the Nasdaq Stock Market as soon as possible and (ii) the Company’s common stock is listed on the OTC Markets’ OTCQX market tier within 30 days in the event that a delisting from the Nasdaq Stock Market occurs. The Omnibus Amendment was accounted for as a troubled debt restructuring, resulting in a prospective adjustment to the effective interest rate in accordance with ASC 470-60. As of September 30, 2024 , the outstanding amount of the Yorkville Note was $2,980,159 net of the unamortized debt discount of $5,874,434, and accrued interest of $24,744 . Interest expense, including amortization of debt issuance costs, for the three and nine months ended September 30, 2024 was $1,244,332 and $2,431,398 , respectively. Cable Car Loan In February 2024, GigCapital5 and QT Imaging entered into the Cable Car Loan with Cable Car, pursuant to which Cable Car agreed to advance $1,500,000 at the closing of the Business Combination, as was evidenced by the Loan, dated March 4, 2024, by and between QT Imaging and Cable Car. The Loan does not bear interest, and is due and payable 13 months after issuance, unless the time for payment is accelerated as a result of an event of default. As full compensation to Cable Car for the Loan to QT Imaging in lieu of any simple or in-kind interest on the Loan, QT Imaging issued to Cable Car that number of shares of QT Imaging which at the completion of the Business Combination would be converted in accordance with the terms of the Business Combination Agreement into 180,000 shares of the Company's common stock. In accordance with ASC 470-20, the proceeds of $1,500,000 were recorded between the promissory note and common stock less debt origination costs of $40,740, consisting of legal fees, on a relative fair value basis. As of September 30, 2024 , the outstanding amount of the Cable Car Loan was $1,247,374, net of unamortized issuance costs of $252,626. Interest expense, including amortization of debt issuance costs, for the three and nine months ended September 30, 2024 was $108,706 and $234,445, respectively. Future principal payments on the long-term debt as of September 30, 2024 are as follows: Year ending December 31: 2024 (remaining) $ 32,718 2025 10,441,377 2026 9,197 Total payments 10,483,292 Less: Unamortized debt issuance costs (6,127,060) Less: Current maturities of long-term debt (887,321) Long-term debt $ 3,468,911	Long-Term Debt Paycheck Protection Program Loan On February 24, 2021 and May 5, 2020, the Company received loans (“PPP Loans”) from US Bank in the amounts of $1,158,265 (“Loan 2”) and $1,158,266 (“Loan 1”), respectively, to fund payroll, rent and utilities through the Paycheck Protection Program (“PPP”). Original loan terms were revised by the PPP Flexibility Act of 2020. Under the terms of the PPP, up to 100% of the loan and related interest was forgivable if the proceeds were used for covered expenses and certain other requirements related to wage rates were met. For Loan 1, the Company applied for forgiveness on June 7, 2021, and received forgiveness of $873,151 in principal and $9,823 in interest from the Small Business Administration (“SBA”) on June 14, 2021. For Loan 2, the Company applied for forgiveness on November 9, 2021, and received forgiveness of $930,246 in principal and $6,822 in interest on November 15, 2021. The remaining balance of Loan 1 of $285,115 is payable in monthly installments of $6,400, including interest at 1%, beginning August 5, 2021, with the final payment due May 5, 2025. As of December 31, 2023, the total principal outstanding under Loan 1 was $107,979, of which $76,058 was current and $31,921 was noncurrent. As of December 31, 2022, the total principal outstanding under Loan 1 was $183,273, of which $75,294 was current and $107,979 was noncurrent. The remaining balance of Loan 2 of $228,019 is payable in monthly installments of $4,605, including interest at 1%, beginning December 27, 2021, with the final payment due February 27, 2026. As of December 31, 2023, the total principal outstanding under Loan 2 was $118,369, of which $54,308 was current and $64,061 was noncurrent. As of December 31, 2022, the total principal outstanding under Loan 2 was $172,132, of which $53,763 was current and $118,369 was noncurrent. Interest expense for Loan 1 and Loan 2 for the years ended December 31, 2023 and 2022 was $3,004 and $4,305, respectively. The SBA may undertake a review of a loan of any size during the six-year period following forgiveness or repayment of the loan. The review may include the loan forgiveness application, as well as whether the Company received the proper loan amount. The timing and outcome of any SBA review is not known. Convertible Notes Payable In June 2021, the Company entered into a convertible promissory note agreement (the “Note”) with USCG for advances of up to $10,000,000. Advances on the Note can be made to the Company up to six months after the inception of the Note unless extensions for advances to be made is mutually agreed between both parties. The Note bears interest at 12% per annum on any amounts drawn and matures on July 6, 2024. The Note is collateralized by all assets of the Company and is guaranteed by QT Labs. The terms of the Note include non-financial covenants and, as of December 31, 2023, the Company was in compliance with those covenants. Through December 31, 2023, the Company issued warrants in connection with the note to purchase a total of 14,854 shares of common stock which 10,329 shares are exercisable at a price of $4.25 per share and 4,525 shares are exercisable at a price of $4.00 per share. The fair value of the warrants, along with financing fees, were recorded as debt issuance costs and presented in the consolidated balance sheets as a deduction from the carrying amount of the Note. The Note is convertible, at the Company’s option, before the Note matures upon the closing of a single transaction or a series of transactions with a minimum of $15,000,000 of cash proceeds raised in the aggregate. If elected, the conversion price would be 90% of the price per share in the qualified financing. Management assessed whether the embedded features in the Note should have been bifurcated from the debt host and concluded that none of the features required to be accounted for separately from the debt instrument. In connection with the Fourth Amendment and issuance of the senior secured convertible promissory note to US Capital as part of the Bridge Loan (the “US Capital Note”), the outstanding loan balances of the Note of $2,495,000 with accrued interest of $635,854 was considered extinguished. The Company recorded $376,086 as a loss on extinguishment in other expenses in the consolidated statements of operations and comprehensive loss, and includes a commission paid of $20,000, remaining unamortized debt issuance costs on the Note of $32,828 and the fair value of warrants to purchase 60,329 shares of common stock of $156,505. As of December 31, 2023, the total Note and US Capital Note balance was $3,294,659 net of unamortized debt issuance costs of $36,194, and accrued interest of $50,037. As of December 31, 2022, the outstanding amount of the Note was $2,426,263, net of unamortized debt issuance costs of $68,737. Interest expense, including amortization of debt issuance costs, for the years ended December 31, 2023 and 2022 was $340,758 and $326,255, respectively. Bridge Loan In November 2023, the Company entered into a Bridge Loan with the Bridge Lenders in aggregate amount of $1,000,000. Each Bridge Loan of $200,000 bears no interest but has a cash option value at the date maturity of 120% or $240,000 of the Bridge Loan at each Bridge Lender’s option. Maturity date is the closing date of the Business Combination as defined in Note 1. The Bridge Loan conversion is at $2.00 per share on a post-business combination and, as of December 31, 2023, an aggregate of 1,369,255 shares of common stock would be issued if the entire Bridge Loan was converted. As of December 31, 2023, the outstanding amount of the Bridge Loan, excluding the US Capital Note, was $774,337, net of unamortized debt issuance costs of $25,663. Interest expense from the amortization of debt issuance costs for the year ended December 31, 2023 was $21,592. Future principal payments on the long-term debt as of December 31, 2023 are as follows: Year ending December 31: 2024 $ 4,261,221 2025 86,784 2026 9,196 Total Payments 4,357,201 Less: Unamortized debt issuance costs (61,857) Less: Current maturities of long-term debt (4,199,362) Long-term debt $ 95,982

Leases

Leases	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Leases	Leases The Company leases its operating facilities in Novato, California, under a non-cancelable operating lease through May 31, 2027. There are no options or rights to extend the term of this lease. The following table reflects the Company’s ROU assets and lease liabilities as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Assets: Operating lease ROU assets, net $ 1,020,947 $ 1,267,121 Liabilities: Operating lease liabilities, current $ 394,208 $ 361,305 Operating lease liabilities 762,904 1,062,633 $ 1,157,112 $ 1,423,938 The following table presents supplemental cash flow information related to the Company’s operating leases for the three and nine months ended: Three Months Ended Nine Months Ended September 30, 2024 2023 2024 2023 Operating cash flows from operating leases $ 116,994 $ 110,278 $ 345,302 $ 330,833 As of September 30, 2024, the maturity of operating lease liabilities was as follows: Year ending December 31: 2024 (remaining) $ 116,994 2025 476,164 2026 490,449 2027 206,864 Total payments 1,290,471 Less: Interest (133,359) Present value of obligations $ 1,157,112 The operating lease expense for the three months ended September 30, 2024 and 2023 was $113,748 and $113,536, respectively, of which $5,532 and $5,319, respectively, were related to leases with a term of less than 12 months. The operating lease expense for the nine months ended September 30, 2024 and 2023 was $341,031 and $340,354, respectively, of which $16,383 and $15,705, respectively, were related to leases with a term of less than 12 months.	Leases The Company leases its operating facilities in Novato, California, under a non-cancelable operating lease through May 31, 2027. There are no options or rights to extend the term of this lease. The following table reflects the Company’s ROU assets and lease liabilities as of December 31: 2023 2022 Assets: Operating lease ROU assets, net $ 1,267,121 $ 1,572,323 Liabilities: Operating lease liabilities, current $ 361,305 $ 313,448 Operating lease liabilities 1,062,633 1,423,938 $ 1,423,938 $ 1,737,386 The following table presents supplemental cash flow information related to the Company’s operating leases for the years ended December 31: 2023 2022 Operating cash flows from operating leases $ 441,111 $ 428,263 As of December 31, 2023, the maturity of operating lease liabilities was as follows: Year ending December 31: 2024 $ 462,295 2025 476,164 2026 490,449 2027 206,864 Total payments 1,635,772 Less: Interest (211,834) Present value of obligations $ 1,423,938 The operating lease expense for the years ended December 31, 2023 and 2022, was $453,889 and $452,894, respectively, of which $21,024 and $20,029, respectively, were related to leases with a term of less than 12 months.

Contingencies

Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Other Commitments [Line Items]
Contingencies	Contingencies Litigation The Company is subject to occasional lawsuits, investigations, and claims arising out of the normal conduct of business. As of the date the condensed consolidated financial statements were available to be issued, management is not aware of any pending claims that will have a material impact on the Company’s condensed consolidated financial statements.	Contingencies Litigation
GIGCAPITAL5, INC
Other Commitments [Line Items]
Contingencies		COMMITMENTS AND CONTINGENCIES Registration Rights On September 23, 2021, the Company entered into a registration rights agreement with its Founder and Insiders. These holders will be entitled to make up to two demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements. There will be no penalties associated with delays in registering the securities under the registration rights agreement. Underwriters Agreement The Company granted the underwriters a 45-day option to purchase up to 3,000,000 additional Public Units to cover any over-allotments, at the Offering price less underwriting discounts and commissions. On September 28, 2021, the over-allotment was exercised in full by the Underwriters. The Company paid an underwriting discount of $0.20 per Public Unit to the Underwriters at the closing of the Offering. The underwriting discount was paid in cash. In addition, the Company has agreed to pay deferred underwriting commissions of $0.40 per Public Unit, or $9,200,000 in the aggregate, including the Underwriters’ over-allotment option which was exercised in full. The deferred underwriting commission will become payable to the Underwriters from the amount held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement, including the performance of services described therein. On March 20, 2023, one of the Underwriters, Wells Fargo, waived all of their portion of the deferred underwriting fees totaling $6,440,000. The Underwriters will use their commercially reasonable efforts to provide the Company with the following services: 1) originating and introducing the Company to potential targets for a Business Combination; 2) arranging non-deal roadshows on behalf of the Company in connection with a proposed Business Combination; 3) assisting the Company in meeting its securities exchange listing requirements following the closing of the Offering; and 4) providing capital markets advice and liquidity to the Company following the closing of the Offering. If the Company uses its best efforts (and the Underwriters use commercially reasonable efforts) to obtain financing in private placements or privately negotiated transactions, but notwithstanding such efforts, the Company does not have sufficient cash necessary to consummate the Business Combination and pay the deferred underwriting commission, the Company and the Underwriters will cooperate in good faith to come to a mutually-satisfactory solution with respect to the payment of the deferred underwriting commission so as to ensure that the Company’s obligation to pay the deferred underwriting commission shall not impede the closing of the Business Combination. Non-Redemption Agreements QT Imaging, the Company and certain investors led by Meteora Capital Partners, LP (all investors participating in such financing, the “Stock Subscription Investors”), have entered into definitive subscription agreements (the “Stock Subscription Agreements”), pursuant to which the Stock Subscription Investors have subscribed for the purchase of shares of QT Imaging Common Stock in such amount that upon the completion of the Merger and the application of the Exchange Ratio will be exchanged for such consideration as is provided for in the Business Combination Agreement, including that number of shares of common stock of the Combined Company (“Combined Company Common Stock”) as is equal in the aggregate to 1,400,000 shares of Combined Company Common Stock. Meteora Capital Partners, LP, has an economic interest in the sponsor of the Company, GigAcquisitions5, LLC. The aggregate gross proceeds under the Stock Subscription Agreements to QT Imaging will be $3,500,000 (although this amount could be increased by additional subscriptions). In addition, certain Stock Subscription Investors that collectively subscribed to purchase the equivalent of 1,200,000 shares of Combined Company Common Stock pursuant to the Stock Subscription Agreements in November 2023 have separately entered into with the Company a non-redemption agreement (the “November 2023 Non-Redemption Agreements”) pursuant to which each such Stock Subscription Investor has agreed to not redeem up to 400,000 shares of GigCapital5 Common Stock in exchange for a cash payment by the Company with cash from its Trust Account in a per share amount equal to the redemption price less $2.50 per share. For each share of GigCapital5 Common Stock that a Stock Subscription Investor does not redeem pursuant to the terms of a November 2023 Non-Redemption Agreement, the obligation of such Stock Subscription Investor to purchase shares of QT Imaging Common Stock pursuant to the Stock Subscription Agreements will be correspondingly reduced in an equal amount with respect to the number of shares of Combined Company Common Stock that would be received upon the exchange that occurs at the closing of the Merger. Furthermore, for each share of GigCapital5 Common Stock that a Stock Subscription Investor does not redeem pursuant to the terms of a November 2023 Non-Redemption Agreement, the aggregate number of shares of Combined Company Common Stock issued as consideration to the securities holders of QT Imaging in the Merger shall also be correspondingly reduced. Yorkville Agreement On November 15, 2023, the Company entered into a Standby Equity Purchase Agreement with QT Imaging and YA II PN, Ltd. (“Yorkville”), pursuant to which, upon the closing of the Merger, QTI Holdings can sell to Yorkville up to $50.0 million of QTI Holdings’ common stock at QTI Holdings’ request any time during the 36 months following the closing of the Merger. In addition, QTI Holdings can also request a pre-paid advance (the “Pre-Paid Advance”) from Yorkville up to an amount of $10.0 million at the closing of the Merger in the form of a convertible promissory note. As consideration for the Pre-Paid Advance, immediately prior to, and substantially concurrently with, the closing of the Merger, QT Imaging will issue to Yorkville that number of shares which will further convert in the aggregate into 1,000,000 shares of common stock of QTI Holdings upon the completion of the Merger.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders’ Deficit	Stockholders’ Deficit Common Stock The Company's common stock trades on the Nasdaq Stock Exchange under the symbol “QTI ” . Pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company is authorized and has available for issuance 500,000,000 shares of common stock. Immediately following the Merger, there were 21,437,216 shares of common stock outstanding with a par value of $0.0001. The holder of each share of common stock is entitled to one vote. The Company retroactively adjusted the shares issued and outstanding prior to March 4, 2024 to give effect to the exchange ratio established in the Business Combination Agreement to determine the number of shares of common stock into which they were converted. Common stock reserved for future issuance as of September 30, 2024 is as follows: Common stock warrants 23,889,364 Potential shares from Pre-Paid Advance 10,126,981 Merger earnout consideration shares 9,000,000 Options outstanding under the 2024 Incentive Plan 2,072,000 Options available under the 2024 Incentive Plan 286,093 Potential shares from Cable Car Loan 750,000 Potential shares from convertible notes 250,224 46,374,662 Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.0001, with such designations, voting and other rights and preferences as may be determined from time to time by the Board of Directors. As of September 30, 2024 and December 31, 2023, there were no shares of preferred stock issued and outstanding. The Board has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the Delaware General Corporation Law. The issuance of preferred stock could have the effect of decreasing the trading price of common stock, restricting dividends on the capital stock of the Company, diluting the voting power of the common stock, impairing the liquidation rights of the capital stock of the Company, or delaying or preventing a change in control of the Company. QT Imaging Private Placement Warrants In November 2022, the Company initiated an offering to sell to a select group of accredited investors only, on a private placement basis, 342,703 units for a purchase price of $11.67 per unit (the “Units”), each Unit consisting of one share of common stock and one warrant to purchase one share of common stock (the “QT Imaging Private Placement Warrants”) with an exercise price of $11.67 (the “2022 Offering”). As of December 31, 2023, the Company has issued 167,925 Units for net proceeds of $1,932,850, which 0 and 89,532 Units were issued during the three and nine months ended September 30, 2023, respectively, for total net proceeds of $0 and $1,026,550, respectively. The re were no Units issued during the three and nine months ended September 30, 2024 . On March 4, 2024, all outstanding QT Imaging Private Placement Warrants were deemed out of the money and terminated in accordance with the Business Combination Agreement. QT Imaging Warrants for Common Stock In addition to the warrants sold as part of the Units in the 2022 Offering, the Company also issued warrants to consultants and to placement agents in association with debt issuances and past private offerings. At the option of the warrant holders, the warrants can be fully settled in shares of common stock, or converted via net share settlement, in which the warrant holder will receive shares equal to the number of shares purchasable under the warrants multiplied by the difference between the fair market value of the shares and the exercise price, divided by the fair market value of the shares. The following table represents the QT Imaging warrant activity as follows for the nine months ended September 30, 2024: Number of Outstanding, January 1, 2024 422,064 Exercised (16,320) Terminated pursuant to business combination agreement (405,744) Outstanding, September 30, 2024 — The fair value of the QT Imaging warrants issued as part of the 2022 Offering and included in stockholders’ deficit in the condensed consolidated balance sheets was $0 and $462,413 for the three and nine months ended September 30, 2023, respectively. The fair value of the remaining warrant granted during the nine months ended September 30, 2023 was $15,317 and was recorded as issuance costs against the proceeds received from the 2022 Offering. There were no QT Imaging warrants issued during the three and nine months ended September 30, 2024 or during the three months ended September 30, 2023. On March 4, 2024 and in accordance with the terms of the Business Combination Agreement, the Company cancelled and terminated all outstanding warrants that were deemed out of the money with an exercise price of or above $11.67 per warrant, including all warrants sold as part of the Units in the 2022 Offering and warrants that were issued to consultants and placement agents in association with debt issuances and past private offerings. Warrants (Public Warrants, Private Placement Warrants and Working Capital Note Warrants) Warrants will be exercisable at $11.50 per share, and pursuant to the terms of the warrant agreement governing such warrants (the “Warrant Agreement”), the exercise price and number of warrant shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation of the Company. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s Board of Directors, and in the case of any such issuance to the Company’s Founder or its affiliates, without taking into account any Founder Shares held by it prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 65% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the consummation of its initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading-day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities. Each warrant will become exercisable on the later of 30 days after the completion of the Merger and will expire five years after the completion of the Merger. If the Company is unable to deliver registered shares of common stock to the holder upon exercise of the warrants during the exercise period, there will be no net cash settlement of these warrants and the warrants will expire worthless, unless they may be exercised on a cashless basis in the circumstances described in the Warrant Agreement. Once the warrants become exercisable, the Company may redeem the outstanding warrants in whole and not in part at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, only in the event that the last sale price of the Company’s shares of common stock equals or exceeds $18.00 per share for any 20 trading days within the 30 -trading day period ending on the third trading day before the Company sends the notice of redemption to the warrant holders. Under the terms of the Warrant Agreement, the Company has agreed to use its best efforts to file a new registration statement under the Securities Act of 1933, as amended (the “Securities Act”), following the completion of the Merger, for the registration of the shares of common stock issuable upon exercise of the warrants included in the public units issued in the Company’s initial public offering (the “Public Units”), the private placement units undertaken by the Company concurrently with its initial public offering (the “Private Placement Units”) and the private placement units that were issued upon conversion of working capital notes issued by the Company prior to the Merger, which conversion occurred concurrent with the Merger. The new registration statement was filed on April 1, 2024, and was declared effective by the SEC on May 22, 2024. As of September 30, 2024, there were 23,889,364 warrants outstanding from those that were initially included as a constituent security of the Public Units and the Private Placement Units (the “ PubCo Warrants ” ) with an exercise price of $11.50 per warrant and expiring on March 4, 2029. On May 13, 2024, the exercise price of PubCo Warrants was reduced from $11.50 to $2.30 per warrant and the price per share related to the redemption events described above decreased from $18.00 per share to $3.60 per share in accordance with the terms of the Warrant Agreement as discussed above. The modification in exercise price related to the Public Warrants, which are equity classified, was accounted as a deemed dividend, which resulted in an adjustment of $5,185,502 to accumulated deficit during the nine months ended September 30, 2024. The effect of the modification in exercise price related to the Private Placement Warrants and Working Capital Note Warrants, which are liability classified, was recorded in other income (expense), net within the statements of operations and comprehensive loss and amounted to $200,513 during the nine months ended September 30, 2024.	Stockholders’ Deficit Common Stock The Company is authorized to issue 100,000,000 shares of common stock, with a par value of $0.001. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of December 31, 2023 and 2022, there were 27,941,290 and 27,580,040 shares of common stock issued and outstanding, respectively. Future dividends may be paid on the outstanding shares of common stock as and when declared by the Board of Directors out of funds legally available therefor; provided, however, that no dividends shall be made with respect to the common stock until any preferential dividends required to be paid or set apart for any shares of preferred stock have been paid or set apart. Common stock reserved for future issuance as of December 31, 2023 is as follows: Common stock warrants 1,231,484 Options outstanding 3,646,922 Options available under the Plan 3,353,078 Potential shares from convertible notes 2,073,554 Subscription agreements 3,833,912 14,138,960 Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.001, with such designations, voting and other rights and preferences as may be determined from time to time by the Board of Directors. As of December 31, 2023 and 2022, there were no shares of preferred stock issued and outstanding. Private Placement In November 2022, the Company initiated an offering to sell to a select group of accredited investors only, on a private placement basis, 1,000,000 units for a purchase price of $4.00 per unit (the “Units”), each Unit consisting of one share of common stock and one warrant to purchase one share of common stock with an exercise price of $4.00 (the “2022 Offering”). As of December 31, 2023, the Company has issued 490,000 Units for net proceeds of $1,932,850, which 261,250 Units were issued in 2023 for total net proceeds of $1,026,550 and 228,750 Units were issued in 2022 for net proceeds of $906,300 in 2022. Warrants for Common Stock In addition to the warrants sold as part of the Units in the 2022 Offering, the Company also issued warrants to consultants and to placement agents in association with debt issuances and past private offerings. At the option of the warrant holders, the warrants can be fully settled in shares of common stock, or converted via net share settlement, in which the warrant holder will receive shares equal to the number of shares purchasable under the warrants multiplied by the difference between the fair market value of the shares and the exercise price, divided by the fair market value of the shares. The following table represents the warrant activity as follows: Number of Warrants Outstanding, January 1, 2022 624,508 Granted 280,962 Outstanding, December 31, 2022 905,470 Granted 326,104 Outstanding, December 31, 2023 1,231,574 As of December 31, 2023, outstanding warrants to purchase shares of common stock by exercise price are as follows: Exercise Price Exercisable For Expiration Date(s) Number of $ 10.00 Common Stock March 2025 516,391 $ 8.50 Common Stock August 2030 150,000 $ 4.25 Common Stock July 2027 to September 2028 10,329 $ 4.00 Common Stock November 2027 to March 2029 494,525 $ 2.50 Common Stock November 1, 2028 60,329 1,231,574 The determination of the fair value of warrants to purchase common stock issued during the years ended December 31, 2023 and 2022 is computed using the Black-Scholes option pricing model with the following weighted-average assumptions: 2023 2022 Expected warrant term (years) 5.0 5.6 Expected volatility 60.2 % 62.3 % Risk-free rate of return 4.0 % 3.6 % Expected annual dividend yield — — The fair value of warrants issued as part of the 2022 Offering and included in stockholders’ deficit in the consolidated balance sheets was $462,413 and $404,888 for the years ended December 31, 2023 and 2022, respectively. The fair value of the warrants granted to USCG in connection with the convertible debt described in Note 6. Long-Term Debt, which was included as part of debt issuance costs, was $15,317 and $5,066 for the years ended December 31, 2023 and 2022, respectively. The fair value warrants granted in exchange for services was $0 and $108,100 the years ended December 31, 2023 and 2022, respectively, and was included in selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss. The fair value of the remaining warrants granted during the year ended December 31, 2023 to USCG and US Capital in connection with the Fourth Amendment was $156,505.
GIGCAPITAL5, INC
Stockholders’ Deficit		STOCKHOLDERS’ DEFICIT Common Stock The authorized common stock of the Company includes up to 100,000,000 shares. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of December 31, 2023 and 2022, there were 6,545,000 shares of common stock issued and outstanding and not subject to possible redemption. There were 2,114,978 and 4,014,050 shares of common stock subject to possible redemption issued and outstanding as of December 31, 2023 and 2022, respectively. As of December 31, 2023, common stock reserved for future issuance was 23,945,000, which included warrants to purchase 23,795,000 shares of common stock and 150,000 potential shares of common stock to be issued if the Working Capital Note is converted in full. Preferred Stock The Company is authorized to issue 1,000,000 shares of preferred stock with such designations, voting and other rights and preferences as may be determined from time to time by the Board of Directors. As of December 31, 2023 and 2022, there were no shares of preferred stock issued and outstanding. Warrants (Public Warrants and Private Placement Warrants) Warrants will be exercisable at $11.50 per share, and the exercise price and number of warrant shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation of the Company. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s Board of Directors, and in the case of any such issuance to the Company’s Founder or its affiliates, without taking into account any Founder Shares held by it prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 65% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the consummation of its initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading-day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities. Each warrant will become exercisable on the later of 30 days after the completion of the Company’s initial Business Combination or 12 months from the closing of the Offering and will expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption. However, if the Company does not complete its initial Business Combination on or prior to the 30-month period allotted to complete the Business Combination, (or such lesser period depending upon the number of one-month extensions which occur), the Private Placement Warrants will expire at the end of such period. If the Company is unable to deliver registered shares of common stock to the holder upon exercise of the warrants during the exercise period, there will be no net cash settlement of these warrants and the warrants will expire worthless, unless they may be exercised on a cashless basis in the circumstances described in the Warrant Agreement. Once the warrants become exercisable, the Company may redeem the outstanding warrants in whole and not in part at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, only in the event that the last sale price of the Company’s shares of common stock equals or exceeds $18.00 per share for any 20 trading days within the 30-trading day period ending on the third trading day before the Company sends the notice of redemption to the warrant holders. Under the terms of the Warrant Agreement, the Company has agreed to use its best efforts to file a new registration statement under the Securities Act, following the completion of the Company’s initial Business Combination, for the registration of the shares of common stock issuable upon exercise of the warrants included in the Public Units and Private Placement Units. As of December 31, 2023 and 2022, there were 23,795,000 warrants outstanding. Stock-based Compensation Included in the outstanding shares of common stock are 15,000 Insider shares, of which 5,000 Insider shares were issued to Mr. Weightman, the Company’s Treasurer and Chief Financial Officer, and 10,000 Insider shares were issued to ICR solely in consideration of future services pursuant to the Insider Shares Grant Agreements dated September 23, 2021, between the Company and each of the Insiders. The 5,000 Insider shares issued to Mr. Weightman are subject to forfeiture as described in Note 5 while the 10,000 Insider shares issued to ICR are not subject to forfeiture. The grant date fair value of the 10,000 shares was expensed upon issuance. If an initial Business Combination occurs and the 5,000 shares have not been previously forfeited, the fair value of the common stock on the date the shares vest will be recognized as stock-based compensation in the Company’s statements of operations and comprehensive loss when the completion of the Business Combination becomes probable.

Stock Incentive Plan

Stock Incentive Plan	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock Incentive Plans	Stock Incentive Plans 2024 Equity Incentive Plan On February 15, 2024, at the Annual Meeting, the GigCapital5 stockholders considered and approved the 2024 Equity Incentive Plan (the “2024 Incentive Plan”) and reserved 2,358,093 shares of common stock for issuance thereunder. The 2024 Incentive Plan became effective immediately upon the Closing of the Business Combination on March 4, 2024. The term of the 2024 Incentive Plan is 10 years. The number of shares of common stock reserved for issuance under the 2024 Incentive Plan will automatically increase on January 1 of each year, beginning on January 1, 2025 and continuing through January 1, 2035, by 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board of Directors. Under the 2024 Incentive Plan, the Company may issue stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and performance awards (“PAs”). The term of stock options may not exceed 10 years and is subject to vesting conditions, which is subject to the option holder’s continued service to the Company. The exercise price of any stock option award cannot be less than fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the total combined voting power of all classes of stock of the Company or any parent or subsidiary, must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. There were 2,072,000 options outstanding under the 2024 Incentive Plan as of September 30, 2024. QT Imaging Incentive Plan In September 2021, the Board of Directors approved and the Company adopted the Plan (the “QT Imaging Plan”). The maximum aggregate number of shares of common stock that the Company may award under the QT Imaging Plan was 7,000,000. The term of the QT Imaging Plan was originally 10 years. The QT Imaging Plan was administered by the compensation committee of the Company’s Board of Directors (the “Administrator”). The Company may grant awards to eligible participants which may take the form of stock options (both incentive stock options and non-qualified stock options), stock purchase rights, restricted stock, restricted stock units and performance stock awards. Awards may be granted to employees, directors, and consultants (as defined in the QT Imaging Plan.) The term of any stock option award may not exceed 10 years and may be subject to vesting conditions, as determined by the Administrator. Incentive stock options may only be granted to employees of the Company or any subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award cannot be less than fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the total combined voting power of all classes of stock of the Company or any parent or subsidiary, must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. Vesting is subject to the option holder’s continued service to the Company, ranging up to a four-year period. Unvested options are subject to forfeiture upon termination of employment. On March 4, 2024, the QT Imaging Plan was terminated in accordance with the terms of the Business Combination Agreement and the options to purchase 1,237,681 shares of common stock were cancelled at the close of the Business Combination in accordance with the terms of the Business Combination Agreement. The following table summarizes information regarding activity in the QT Imaging Plan and the 2024 Incentive Plan during the nine months ended September 30, 2024: Number of Weighted- Weighted-Average Outstanding, January 1, 2024 1,249,809 $ 24.80 6.9 Granted under the 2024 Incentive Plan 2,072,000 $ 0.74 Cancelled (12,128) $ 22.40 Terminated pursuant to Business Combination Agreement (1,237,681) $ 24.83 Outstanding, September 30, 2024 2,072,000 $ 0.74 9.8 Exercisable as of September 30, 2024 — $ — — Vested and expected to vest as of September 30, 2024 2,072,000 $ 0.74 9.8 During the three and nine months ended September 30, 2024, a total of 2,072,000 options were granted to employees and nonemployees with a weighted-average grant date fair value of $0.47 per share. There were no options granted during three and nine months ended September 30, 2023. The determination of the fair value of options granted during the three and nine months ended September 30, 2024 is computed using the Black-Scholes option pricing model with the following weighted-average assumptions: Stock price per share $ 0.74 Expected option term (years) 5.7 Expected volatility 67.9 % Risk-free rate of return 4.3 % Expected annual dividend yield — % Option pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on the analysis of volatilities of the Company’s selected public peer group over a period commensurate with the expected term of the options. The expected term of employee options represents the weighted-average period the options are expected to remain outstanding and was derived using the simplified method for awards that qualify for its “plain-vanilla” options. All awards that are outstanding are qualified for “plain-vanilla” options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term in consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and do not anticipate issuing any dividends in the future. The following table shows stock-based compensation expense by functional area in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine months ended September 30, 2024 2023 2024 2023 Research and development $ 22,248 $ 26,313 $ 36,198 $ 78,941 Selling, general and administrative 104,955 169,162 129,989 533,789 $ 127,203 $ 195,475 $ 166,187 $ 612,730 No stock-based compensation expense was capitalized to inventory for three and nine months ended September 30, 2024 and 2023. As of September 30, 2024, the total unrecognized compensation cost related to all nonvested stock options was $846,533 and the weighted-average period over which it is expected to be recognized is 2.3 years.	Stock Incentive Plan In September 2021, the Board of Directors approved and the Company adopted the Plan (the “Plan”). The maximum aggregate number of shares of common stock that the Company may award under the Plan is 7,000,000. The term of the Plan is 10 years. The Plan is administered by a committee of the Company’s Board of Directors (the “Administrator”). The Company may grant awards to eligible participants which may take the form of stock options (both incentive stock options and non-qualified stock options), stock purchase rights, restricted stock, restricted stock units and performance stock awards. Awards may be granted to employees, directors, and consultants (as defined in the Plan.) The term of any stock option award may not exceed 10 years and may be subject to vesting conditions, as determined by the Administrator. Incentive stock options may only be granted to employees of the Company or any subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award cannot be less than fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the total combined voting power of all classes of stock of the Company or any parent or subsidiary, must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. Vesting is subject to the option holder’s continued service to the Company, ranging up to a four-year period. Unvested options are subject to forfeiture upon termination of employment. Subsequent to December 31, 2023, the Plan was terminated in accordance with the terms of the Business Combination Agreement and the options to purchase 3,646,921 shares of common stock were cancelled at the close of the Business Combination in accordance with the terms of the Business Combination Agreement. See Note 14. Subsequent Events. The following table represents the total number of shares available for grant under the Plan: Available for Grant Balance as of December 31, 2021 3,578,276 Granted (541,208) Cancelled 22,396 Balance as of December 31, 2022 3,059,464 Cancelled 293,615 Balance as of December 31, 2023 3,353,079 The following table summarizes information regarding activity in the Plan during the years ended December 31, 2023 and 2022: Number of Options Weighted-Average Exercise Price Weighted- Average Remaining Contractual Life (years) Outstanding, December 31, 2021 3,421,724 $ 8.77 9.2 Granted 541,208 6.50 Cancelled (22,396) 8.50 Outstanding, December 31, 2022 3,940,536 8.46 8.4 Cancelled (293,615) 7.90 Outstanding, December 31, 2023 3,646,921 $ 8.50 6.9 Vested and exercisable and expected to vest, December 31, 2023 3,433,227 $ 8.54 6.7 Vested and exercisable, December 31, 2023 3,371,096 $ 8.57 6.8 The options outstanding and exercisable as of December 31, 2023 were as follows: Exercise Prices Number Outstanding Weighted-Average Remaining Contractual Life (years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $ 6.50 453,323 8.4 $ 6.50 341,559 $ 6.50 8.50 2,585,671 6.6 8.50 2,421,609 8.50 10.00 607,927 7.0 10.00 607,928 10.00 3,646,921 6.9 $ 8.50 3,371,096 $ 8.57 The determination of the fair value of options granted during the year ended December 31, 2022 is computed using the Black-Scholes option pricing model with the following weighted-average assumptions: 2022 Expected option term (years) 7.4 Expected volatility 69.1 % Risk-free rate of return 2.5 % Expected annual dividend yield — There were no options granted during the year ended December 31, 2023. The weighted-average grant date fair value of options granted was $2.27 per share for the year ended December 31, 2022. Option pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on the analysis of volatilities of the Company’s selected public peer group over a period commensurate with the expected term of the options. The expected term of the employee stock options represents the weighted-average period the stock options are expected to remain outstanding and is based on the contractual terms, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term in consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and do not anticipate issuing any dividends in the future. The following table shows stock-based compensation expense by functional area in the consolidated statements of operations and comprehensive loss for the years ended December 31: 2023 2022 Research and development $ 105,255 $ 142,118 Selling, general and administrative 604,139 648,637 $ 709,394 $ 790,755 No stock-based compensation expense was capitalized to inventory for the years ended December 31, 2023 and 2022.

National Institutes Of Health S

National Institutes Of Health Subaward	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Receivables [Abstract]
National Institutes of Health Subaward	National Institutes of Health Subaward On August 18, 2022, the Company was awarded a grant of up to $1,078,347 as a subaward through the Board of Trustees of the University of Illinois for the purpose of developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy. The grant is a cost reimbursement subaward that is allocated annually over five years, subject to the availability of funds and satisfactory progress of the project. The award expires July 31, 2027 and may be terminated by either party with 30 days written notice. Any grant proceeds received do not require repayment. As of September 30, 2024 , the Company incurred total costs of $385,280 against the year one allocation of $351,994 and against the year two allocation of $194,566. During the three months ended September 30, 2024 , the Company incurred costs of $3,359, of which $3,359 of grant income was recognized as an offset to research and development expense and $0 was recognized as an offset to selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. During the three months ended September 30, 2023, the Company incurred costs of $151,996, of which $128,769 of grant income was recognized as an offset to research and development expense and $23,227 was recognized as an offset to selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. During the nine months ended September 30, 2024 , the Company incurred costs of $36,226 , of which $20,430 of grant income was recognized as an offset to research and development expense and $15,796 was recognized as an offset to selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. During the nine months ended September 30, 2023, the Company incurred costs of $250,713 , of which $215,616 of grant income was recognized as an offset to research and development expense and $35,097 was recognized as an offset to selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. As of September 30, 2024 and December 31, 2023 , the grant receivable was $10,349 and $161,638, respectively, and is included in prepaid expenses and other current assets on the condensed consolidated balance sheets.	National Institutes of Health Subaward On August 18, 2022, the Company was awarded a grant of up to $1,078,347 as a subaward through the Board of Trustees of the University of Illinois for the purpose of developing a quantitative ultrasound breast scanner for identifying early response of breast cancer to chemotherapy. The grant is a cost reimbursement subaward that is allocated annually over five years, subject to the availability of funds and satisfactory progress of the project. The award expires July 31, 2027 and may be terminated by either party with 30 days written notice. Any grant proceeds

Fair Value Measurements

Fair Value Measurements	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Measurements	Fair Value Measurements The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs which are supported by little or no market activity and which are significant to the fair value of the assets or liabilities. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description: Level September 30, 2024 December 31, 2023 Assets: Certificate of deposit 2 $ 20,000 $ 20,000 Liabilities: Warrant liability 2 $ 9,783 $ — Earnout liability 3 $ 700,000 $ — Derivative liability 3 $ 320,900 $ — Warrant Liability The Company has determined that the warrants that were a constituent part of (i) the private placement units that were issued in a private placement sale by GigCapital5 prior to the Merger (“Private Placement Warrants”) and (ii) the private placement units that were issued upon conversion of working capital notes issued by GigCapital5 prior to the Merger, which conversion occurred concurrent with the Merger (“Working Capital Note Warrants”) are subject to treatment as a liability, as the transfer of the warrants to anyone other than the purchasers or their permitted transferees would result in these warrants having substantially the same terms as the warrants included in the public units that were issued by GigCapital5 prior to the Merger (“Public Warrants”). The Company determined that the fair value of each Private Placement Warrant and the Working Capital Note Warrants approximates the fair value of a Public Warrant. Accordingly, the Private Placement Warrants and Working Capital Note Warrants are valued upon observable data and have been classified as Level 2 financial instruments. As of September 30, 2024 , a total of 889,364 Private Placement Warrants and Working Capital Note Warrants were outstanding at an approximate fair value of $0.011 per warrant. See Note 11. The activity for the fair value of the warrant liability during the three and nine months ended September 30, 2024 was as follows: Warrant Liability Beginning balance, January 1, 2024 $ — Net liabilities assumed from GigCapital5 8,894 Change in fair value 23,123 Ending balance, March 31, 2024 32,017 Increase due to warrant modification 200,513 Change in fair value (213,942) Ending balance, June 30, 2024 18,588 Change in fair value (8,805) Ending balance, September 30, 2024 $ 9,783 The effect of the modification of the Private Placement Warrants and the Working Capital Note Warrants as further described in Note 11 was included within other income (expense), net in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2024. Earnout Liability The fair value of the Merger Consideration Earnout shares was calculated using a Monte Carlo simulation. The simulation used as significant inputs the Company's management’s current assessment of placements of breast scanning systems in 2024 and 2025, likely expected values for revenues from 2024 through 2026, probabilities for regulatory approvals including FDA clearances, and probabilities of other triggering events related to the open angle scanner. The probabilities of the non-revenue triggers generally range from 0 to 25 percent with the exception of the FDA clearance for a new indication by November 14, 2025 , as defined in the Business Combination Agreement, which is at 100 percent. The revenue forecast for the respective measurement periods are generally in line with the revenue triggers as defined in the Business Combination Agreement, as amended. Additional significant inputs into the simulation include the volatility of Company's equity, assets, and revenue that was derived in a manner as would be common for such simulation, and published industry operating profitability metrics. A weighted average cost of capital (“WACC”) was estimated based on a venture capital rates of return on debt and equity. This WACC was used as the discount rate applicable to revenue, after applying a delivering factor to convert it from being applicable to earnings before interest and tax (“EBIT”) to being applicable to revenue. This EBIT to revenue delivering factor was estimated using published industry operating profit and cost metrics. The Monte Carlo simulation developed a distribution of projected revenues for 2024 through 2026 using a Geometric Brownian Motion framework based on a standard normal distribution of returns. The simulation also developed a distribution of potential daily common stock prices for 2026 using a Geometric Brownian Motion framework. The resulting fair value is based on the average of the number of shares that will be paid out for each triggering event over a statistically significant number of simulations. Significant assumptions used in the valuation of the fair value of the earnout liability as of issuance on March 4, 2024 and as of September 30, 2024 were as follows: March 4, 2024 September 30, 2024 Fair value of common stock $ 3.53 $ 0.71 Volatility of revenue 26.0 % 23.0 % Discount rate applicable to revenue 7.0 % 7.0 % Risk-free rate 4.5 % 3.7 % Risk premium 2.5 % 3.3 % Cost of debt 15.5 % 15.5 % Credit risk spread 11.0 % 11.9 % Equity volatility 130.0 % 115.0 % The activity for the fair value of the earnout liability for the three and nine months ended September 30, 2024 was as follows: Earnout Liability Beginning balance, January 1, 2024 $ — Change in fair value 1,060,000 Ending balance, March 31, 2024 1,060,000 Change in fair value (310,000) Ending balance, June 30, 2024 750,000 Change in fair value (50,000) Ending balance, September 30, 2024 $ 700,000 Derivative Liability In March 2024 , the Company recorded a derivative liability related to the Pre-Paid Advance issued on March 4, 2024 pursuant to the SEPA, dated November 15, 2023 , between QT Imaging and Yorkville (See Note 2 and Note 8). The Pre-Paid Advance contained the following derivative features (“Derivatives”) as defined in the SEPA that were recognized at fair value: • Monthly Payment Premium: if, any time after the Issuance Date, and from time to time thereafter, a Trigger Event occurs, then the Company shall make monthly payments of Triggered Principal Amount, Payment Premium and accrued and unpaid interest. • Monthly Payment Discount: if, any time after the Issuance Date, and from time to time thereafter, a Trigger Event occurs, then the Company shall make monthly payments of Triggered Principal Amount minus the lesser of (x) $1,500,000 and (y) such amount of fifty percent ( 50% ) of the Investor’s net sales proceeds of the Company Shares or fifty percent ( 50% ) of the value of the Company Shares on such date the cash payment is due. • Variable Price Conversion Right: subject to certain limitations, at any time or times on or after the Issuance Date, the Yorkville shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount into fully paid and nonassessable Common Stock in accordance with Section (3)(b), at the Conversion Price of 95% of the lowest VWAP of the Company’s Common Stock during the 5 consecutive Trading Days immediately preceding the Conversion Date or the date the Holder submits an Investor Notice pursuant to and as defined in the SEPA, as applicable, or other date of determination, but not lower than the Floor Price. • Failure to Timely Convert: if within three ( 3 ) Trading Days after the Company’s receipt of an email copy of a Conversion Notice the Company shall fail to issue and deliver a certificate to the Yorkville or credit Yorkville’s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon such Yorkville’s conversion of any Conversion Amount (a “Conversion Failure”), and if on or after such Trading Day the Yorkville purchases (in an open market transaction or otherwise) Common Stock to deliver in satisfaction of a sale by the Yorkville of Common Stock issuable upon such conversion that the Yorkville anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three ( 3 ) Business Days after the Yorkville’s request and in the Yorkville’s discretion, either (i) pay cash to Yorkville in an amount equal to Yorkville’s total purchase price (including brokerage commissions and other out of pocket expenses, if any) for the Common Stock so purchased (the “Buy-In Price”), or (ii) promptly honor its obligation to deliver to the Yorkville a certificate or certificates representing such Common Stock and pay cash to the Yorkville in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Price on the Conversion Date. • Corporate Events: in addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder’s option, (i) in addition to the Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such Common Stock had such Common Stock been held by the Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii) in lieu of the Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form of such consideration (as opposed to Common Stock) at a conversion rate for such consideration commensurate with the Conversion Price. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Required Holders. The initial fair value of the above Derivatives was calculated using a Monte Carlo simulation. The simulation used significant inputs, including volatility of Company's equity that was derived based on a comparable peer group of publicly traded companies and the company’s stock price on the valuation date. The total value of the derivatives reflected the combined value of the monthly payment premium, reduction to that premium by the payment discount, and the value of the conversion right. The values of the failure to timely convert and corporate event features were deemed to be de minimis. Significant assumptions used in the valuation of the fair value of the derivative liability as of issuance on March 4, 2024 and as of September 30, 2024 were as follows: March 4, 2024 September 30, 2024 Fair value of common stock $ 3.53 $ 0.71 Term in years 1.25 1.23 Volatility 130.0 % 115.0 % Risk-free rate 4.9 % 3.9 % Debt discount 30.0 % 30.0 % The activity for the fair value of the derivative liability during the three and nine months ended September 30, 2024 was as follows: Derivative Liability Beginning balance, January 1, 2024 $ — Fair value at issuance 5,120,900 Change in fair value (2,983,100) Ending balance, March 31, 2024 2,137,800 Change in fair value (1,729,700) Ending balance, June 30, 2024 408,100 Change in fair value (87,200) Ending balance, September 30, 2024 $ 320,900
GIGCAPITAL5, INC
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Measurements		FAIR VALUE MEASUREMENTS The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs which are supported by little or no market activity and which are significant to the fair value of the assets or liabilities. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2023 and 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description: Level December 31, 2023 December 31, 2022 Assets: Marketable securities held in Trust Account 1 $ — $ 41,561,656 Liabilities: Warrant liability 2 $ 7,950 $ 31,800 Note payable to related party at fair value 3 $ 1,506,389 $ 257,492 The marketable securities held in the Trust Account are considered trading securities as they are generally used with the objective of generating profits on short-term differences in price and therefore, the realized and unrealized gain and loss are recorded in the statements of operations and comprehensive loss for the periods presented. Additionally, there was $0 and $133,211 of interest accrued, but not yet credited to the Trust Account, which was recorded in the balance sheets in interest receivable on cash and marketable securities held in Trust Account as of December 31, 2023 and 2022, respectively. The Company has determined that the Private Placement Warrants are subject to treatment as a liability, as the transfer of the warrants to anyone other than the purchasers or their permitted transferees would result in these warrants having substantially the same terms as the Public Warrants. The Public Warrants did not start trading separately until November 4, 2021, so the Company initially determined the fair value of each warrant using a Black-Scholes option-pricing model, which requires the use of significant unobservable market values. Accordingly, the Private Placement Warrants were initially classified as Level 3 financial instruments. After the Public Warrants started trading separately, the Company determined that the fair value of each Private Placement Warrant approximates the fair value of a Public Warrant. Accordingly, the Private Placement Warrants are valued upon observable data and have been reclassified as Level 2 financial instruments. The Working Capital Note was valued using a combination of the Black-Scholes option pricing model and present value method, which is considered to be a Level 3 fair value measurement. The estimated fair value of the Working Capital Note was based on the following ranges of significant inputs at issuance for advances made under the Working Capital Note during the year ended December 31, 2023 and as of December 31, 2023 and 2022 for all advances made under the Working Capital Note: Assumptions At Issuance As of As of Expected term 0.7 - 0.8 0.7 0.9 Volatility 65 % 65.0 % 65.0 % Risk free rate 4.5% - 5.5% 5.1 % 4.7 % Discount rate 9.7% - 25.8% 11.3 % 24.4% - 29.4% Probability of conversion 25.0% - 55.0% 25.0 % 65.0 % The following table presents information about the change in fair value of the Company’s Level 3 Working Capital Note during the years ended December 31, 2023 and 2022: Year Ended Year Ended Fair value - beginning of period $ 257,492 $ — Additions 1,240,000 260,000 Change in fair value 8,897 (2,508) Fair value - end of period $ 1,506,389 $ 257,492

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Income Taxes [Line Items]
Income Taxes	Income Taxes For the interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% for the three and nine months ended September 30, 2024 and 2023. The Company expects that its effective tax rate for the full year 2024 will be 0%.	Income Taxes Loss before income tax expense consisted of the following for the years ended December 31: 2023 2022 United States $ (6,097,351) $ (6,254,468) International — — Total loss before income tax expense $ (6,097,351) $ (6,254,468) Income tax expense consisted of the following for the years ended December 31: 2023 2022 Current: Federal $ — $ — State 1,600 1,600 Foreign — — Total current tax expense 1,600 1,600 Deferred: Federal — — State — — Foreign — — Total deferred tax expense — — Total income tax expense $ 1,600 $ 1,600 Income tax expense differed from the amount computed by applying the federal statutory income tax rate to pretax loss as a result of the following for the years ended December 31: 2023 2022 Federal tax at statutory rate $ (1,280,444) $ (1,313,438) State taxes (22,915) (542,562) Change in valuation allowance 1,080,617 1,846,087 Other 224,342 11,513 Total income tax expense $ 1,600 $ 1,600 The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are related to the following as of December 31: 2023 2022 Deferred tax assets: Net operating losses $ 3,070,085 $ 2,280,097 Stock-based compensation 856,902 784,932 Operating lease liabilities 386,588 516,031 Section 174 expenses, net 487,860 476,842 Accruals and reserves 489,382 227,221 Intangible assets 118,691 214,100 Property and equipment 90,104 44,128 Gross deferred tax assets 5,499,612 4,543,351 Valuation allowance (5,155,597) (4,074,980) Net deferred tax assets 344,015 468,371 Deferred tax liabilities: Operating lease right-of-use assets (344,015) (468,371) Net deferred tax assets $ — $ — As of December 31, 2023, based on the Company’s recent history of losses and its forecasted losses, management believes on the more-likely-than-not basis that a full valuation allowance is required. Accordingly, the Company provided a full valuation allowance on its federal and state deferred tax assets. During the years ended December 31, 2023, and 2022, the valuation allowance increased by $1,080,617 and $1,846,087. As of December 31, 2023, the Company had federal and state net operating loss (“NOL”) carryforwards of $10,700,000 and $12,448,000 respectively. The federal NOL will not expire and the state NOL will begin to expire in 2040. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is a follows as of December 31: 2023 2022 Balance as the beginning of the year $ 49,255 $ — Increases related to prior year tax positions — 47,882 Increases related to current year tax positions — 1,373 Balance as the end of the year $ 49,255 $ 49,255 The unrecognized tax benefits for the year ended December 31, 2023, if recognized, would not affect the effective income tax rate due to the valuation allowance that currently offsets the deferred tax assets. It is reasonably possible that the unrecognized tax benefits balance will change within twelve months by a range of zero to $49,255 due to the Company’s intent to file a tax accounting method change.
GIGCAPITAL5, INC
Income Taxes [Line Items]
Income Taxes		INCOME TAX The sources of loss before provision for income taxes are as follows for the year ended December 31, 2023 and 2022: Year Ended Year Ended Domestic $ (3,605,472) $ (2,287,692) Foreign — — Total $ (3,605,472) $ (2,287,692) The provision for income taxes was comprised of the following for the year ended December 31, 2023 and 2022: Year Ended Year Ended Current: Federal $ 285,990 $ 342,216 State and local 133,129 144,399 Foreign — — Total current 419,119 486,615 Deferred: Federal — — State and local — — Foreign — — Total deferred — — Total provision for income taxes $ 419,119 $ 486,615 Reconciliation of the federal statutory income tax rate to the effective income tax rate is as follows: Year Ended Year Ended Statutory income tax benefit $ (757,149) $ (480,415) State income taxes, net of federal (236,036) (184,760) Warrant and note payable revaluation 47,377 (75,812) Valuation allowance on start-up costs 1,364,927 1,227,602 Provision for income taxes $ 419,119 $ 486,615 For the year ended December 31, 2023 and 2022, the effective tax rate differs from the U.S. statutory rate primarily due to the valuation allowance on the start-up costs. The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities as of December 31, 2023 and 2022 were as follows: December 31, December 31, Deferred tax assets: Start-up costs $ 2,895,226 $ 1,530,299 Valuation allowance (2,895,226) (1,530,299) Net deferred tax assets (liabilities) $ — $ —

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Related Party Transactions	Related Party Transactions Convertible Notes Payable In July 2020, the Company issued three convertible notes to three of its stockholders for advances up to $3,500,000 in principal (the “2020 Notes”) and bearing annual interest of 5% on any amounts drawn. An additional note was issued in March 2022 as part of the 2020 Notes, but with an annual interest rate of 8%. All principal and interest payments are due on or before July 1, 2025. The 2020 Notes are convertible, at the holder’s option, into shares of common stock of the Company at the lower of $14.59 per share or the offering price in a financing of at least $5,000,000 in equity from unaffiliated parties. As of September 30, 2024, an aggregate o f 250,224 s hares of common stock would be issued if the entire principal and interest under the 2020 Notes was converted. Management assessed whether the embedded features in the 2020 Notes should have been bifurcated from the debt host and concluded that none of the features were required to be accounted for separately from the debt instruments. As of September 30, 2024 and December 31, 2023, the outstanding amount of the 2020 Notes was $3,143,725 and accrued interest of $507,029 and $377,772, respectively. Interest expense for the three months ended September 30, 2024 and 2023, was $43,400 and $45,921, respectively. Interest expen se for the nine months ended September 30, 2024 and 2023, was $129,257 and $136,265, respectively. Working Capital Loan and Extension Note On May 3, 2023, the Company issued a promissory note (the “Working Capital Note”) to a stockholder for a principal amount of $250,000. The Working Capital Note was subsequently amended and restated six times on June 12, 2023 to add an additional principal amount of $100,000, August 15, 2023 to add an additional principal amount of $75,000, August 29, 2023 to add an additional principal amount of $100,000, September 12, 2023 to add an additional principal amount of $75,000, September 15, 2023 to add an additional principal amount of $50,000, and October 26, 2023 to add an additional principal amount of $55,000, for an aggregate principal amount outstanding as of September 30, 2024 under the Working Capital Note of $705,000. The Working Capital Note was issued to provide the Company with additional working capital during the period prior to consummation of the Business Combination Agreement with GigCapital5. The Working Capital Note is interest-free and originally matured on the earlier of (i) the date on which the Company consummated the Business Combination with GigCapital5; (ii) the date the Company winds up; or (iii) December 31, 2023. The Working Capital Note may be prepaid without penalty. On March 4, 2024, the holder of the Working Capital Note agreed to extend and subordinate the promissory note pursuant to and in accordance with the terms of the Business Combination Agreement. Effective on the Closing of the Business Combination, the Working Capital Note cannot be repaid prior to the repayment or conversion of the Yorkville Note received from Yorkville (see Note 8). On March 4, 2024, the Company assumed the $1,560,000 outstanding debt balance due to a related party (the “Extension Note”) pursuant to the Business Combination Agreement. The Extension Note does not bear any interest and cannot be repaid prior to the repayment of the Yorkville Note received from Yorkville. See Note 16 regarding the surrender and cancellation of the Extension Note. Management Services and Business Associate Agreement In September 2020, QT Imaging entered into a Management Services Agreement (the “Agreement”) and a Business Associate Agreement with John C. Klock, M.D., a California sole proprietorship operating as the QT Imaging Center (the “Practice”). John C. Klock, M.D. was the Chief Executive Officer of QT Imaging, serves on its Board of Directors, and was the largest single stockholder of QT Imaging. The Practice provided medical imaging to patients using the QT Breast Scanner. Under the terms of the Agreement, the Company agreed to provide business services to the Practice including use of the facility which formerly operated as the Marin Breast Health Trial Center, including furniture and medical equipment, as well as use of certain personnel. In exchange for those services, the Practice agreed to pay the Company a management fee. Fees paid to QT Imaging during the three months ended September 30, 2024 and 2023 were $0 and $12,000, respectively. Fees paid to QT Imaging during the nine months ended September 30, 2024 and 2023 were $12,000 and $36,000, respectively. These fees were recorded as a reduction to selling, general and administrative expenses on the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024 and 2023, there were no significant purchases made by the Practice. As of September 30, 2024 and December 31, 2023, there were no significant amounts due from the Practice. This Agreement was terminated and replaced by the Space and Equipment Sublease Agreement on April 17, 2024 and Services Agreement on April 5, 2024. Services Agreement On April 5, 2024, the Company entered into that certain Services Agreement (the “Services Agreement”) with the Practice dated as of April 1, 2024 pursuant to which the Practice agreed to provide its services to the Company, including but not limited to providing healthcare services to patients, assisting with clinical trials and studies and assisting with drafting of institutional review board approved clinical protocols, assisting with the performance of research and development activities on behalf of the Company, providing comprehensive multi-day training on the operation of breast imaging technology for radiologist customers and other customer staff such as technicians, performing clinical validation of imaging software changes which may include recruiting patients, training personnel on the operation of the Company’s imaging technology, as well as other services as specified in the Services Agreement. The term of the Services Agreement is one year unless earlier terminated and shall auto-renew for successive one-year periods, unless otherwise terminated. During the three and nine months ended September 30, 2024, the Company incurred $19,350 and $29,871 in accordance with the Services Agreement with a related party, respectively. Space and Equipment Sublease Agreement On April 17, 2024, the Company entered into a Space and Equipment Sublease Agreement (the “Space and Equipment Sublease”) with the Practice, pursuant to which the Practice will sublease certain medical equipment and space, currently leased from Hamilton Landing Novato LLC by the Company, to the Practice for use in its operations, on a full-time and exclusive basis. The Practice shall pay to the Company a $5,666 rental fee (the “Rent”) for the Subleased Space (as defined in the Space and Equipment Sublease) on a monthly basis, payable on the first day of each month and no later than ten days thereafter, with the Rent to be pro-rated for any partial month. The parties have determined that the Rent equals the fair market value of the Subleased Space and Subleased Equipment (as defined in the Space and Equipment Sublease), without taking into account the proximity of the parties or the space to any source, volume or value of referrals between the parties or any patient thereof. Further, the Practice shall pay when due all sales, use, personal property, leasing, excise or other fees, taxes, charges or withholdings of any kind imposed against the Company, the Practice or the Subleased Equipment with respect to the Space and Equipment Sublease, the Subleased Equipment, or any related fees, receipts or earnings, including local taxes and personal property taxes. The term of the Space and Equipment Sublease is one year unless terminated and shall auto-renew for successive one-year periods, unless otherwise terminated. During the three and nine months ended September 30, 2024, the Company recorded $16,998 and $33,996 of sublease income in other income (expense), net within the condensed consolidated statements of operations and comprehensive loss, respectively. Deferred Revenue In July 2023, an order was placed and a downpayment of $200,000 was made for a breast imaging system by 303 Development Corporation (the “Foundation”). The executive director of the Foundation is a current investor and a was a previous board member of the Company. In September 2023, an additional $100,000 was paid towards the purchase. In June 2024, the Company cancelled this order and refunded the full deposit of $300,000 to the related party. As of September 30, 2024 and December 31, 2023, the Company had a deferred revenue balance of zero and $300,000, respectively, related to this order.	Related Party Transactions Convertible Notes Payable In July 2020, the Company issued three convertible notes to three of its stockholders for advances up to $3,500,000 in principal (the “2020 Notes”) and bearing annual interest of 5% on any amounts drawn. An additional note was issued in March 2022 as part of the 2020 Notes, but with an annual interest rate of 8%. All principal and interest payments are due on or before July 1, 2025. The 2020 Notes are convertible, at the holder’s option, into shares of common stock of the Company at the lower of $5.00 per share or the offering price in a financing of at least $5,000,000 in equity from unaffiliated parties. As of December 31, 2023, an aggregate of 704,299 shares of common stock would be issued if the entire principal and interest under the 2020 Notes was converted. Management assessed whether the embedded features in the 2020 Notes should have been bifurcated from the debt host and concluded that none of the features were required to be accounted for separately from the debt instruments. In November 2023, $200,000 of the 2020 Notes plus accrued interest of $33,644 was converted through a negotiated induced conversion to 100,000 shares of common stock, which resulted in an induced conversion expense of $168,356 to other expenses in the consolidated statements of operations and comprehensive loss. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2020 Notes. As of December 31, 2023 and 2022, the outstanding amount of the 2020 Notes was $3,143,725 and $3,343,725 and accrued interest of $377,772 and $230,627, respectively. Interest expense for the years ended December 31, 2023 and 2022 was $180,789 and $137,709, respectively. Working Capital Loans On May 3, 2023, the Company issued a promissory note (the “Working Capital Note”) to a shareholder for a principal amount of $250,000. The Working Capital Note was subsequently amended and restated six times on June 12, 2023 to add an additional principal amount of $100,000, August 15, 2023 to add an additional principal amount of $75,000, August 29, 2023 to add an additional principal amount of $100,000, September 12, 2023 to add an additional principal amount of $75,000, September 15, 2023 to add an additional principal amount of $50,000, and October 26, 2023 to add an additional principal amount of $55,000, for an aggregate principal amount outstanding as of December 31, 2023 under the Working Capital Note of $705,000. The Working Capital Note was issued to provide the Company with additional working capital during the period prior to consummation of the Business Combination Agreement with GigCapital5. The Working Capital Note is interest-free and matures on the earlier of (i) the date on which the Company consummates the Business Combination with GigCapital5; (ii) the date the Company winds up; or (iii) December 31, 2023. The Working Capital Note may be prepaid without penalty. The Company determined that the imputed interest on the Working Capital Note was not significant for the year ended December 31, 2023. Subsequent to December 31, 2023, the related party to the Working Capital Note agreed to extend and subordinate the promissory note pursuant to and in accordance with the terms of the Business Combination Agreement. Effective on the Closing of the Business Combination, the Working Capital Note cannot be repaid prior to the repayment or conversion of the Pre-Paid Advance received from Yorkville (see Note 14. Subsequent Events). Management Services and Business Associate Agreement In September 2020, the Company entered into a Management Services Agreement (the “Agreement”) and a Business Associate Agreement with John C. Klock, M.D., a California sole proprietorship (the “Practice”). John C. Klock, M.D. is the Chief Executive Officer of the Company, serves on its Board of Directors, and is the largest single shareholder of the Company. The Practice provides medical imaging to patients using the QT Breast Scanner. Under the terms of the Agreement, the Company agreed to provide business services to the Practice including use of the facility which formerly operated as the Marin Breast Health Trial Center, including furniture and medical equipment, as well as use of certain personnel. In exchange for those services, the Practice agreed to pay the Company a management fee. Fees paid to the Company during the years ended December 31, 2023 and 2022 were $48,000 each year, and were recorded as a reduction to selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss. Additionally, during the years ended December 31, 2023 and 2022, the Practice made product purchases from the Company of $8,100 and $7,200, respectively. As of December 31, 2023 and 2022, there were no amounts due to or due from the Practice. Deferred Revenue
GIGCAPITAL5, INC
Related Party Transaction [Line Items]
Related Party Transactions		RELATED PARTY TRANSACTIONS Founder Shares During the period from January 19, 2021 (date of inception) to December 31, 2021, the Founder purchased 5,735,000 shares of common stock (the “Founder Shares”), after giving effect to the forfeiture on September 23, 2021 of 4,312,500 Founder Shares, for an aggregate purchase price of $25,000, or $0.0043592 per share. The Company also issued 5,000 shares of common stock, solely in consideration of future services, to Mr. Weightman, its Treasurer and Chief Financial Officer, pursuant to the Insider Shares Grant Agreements dated September 23, 2021 between the Company and Mr. Weightman. The 5,000 shares granted to Mr. Weightman are subject to forfeiture and cancellation if he resigns or the services are terminated for cause prior to the completion of the Business Combination. The Founder Shares are identical to the common stock included in the Public Units sold in the Offering except that the Founder Shares are subject to certain transfer restrictions, as described in more detail below. Private Placement The Founder purchased from the Company an aggregate of 795,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a Private Placement that occurred simultaneously with the completion of the closing of the Offering. Each Private Placement Unit consists of one share of the Company’s common stock and one warrant (a “Private Placement Warrant”). Each whole Private Placement Warrant will be exercisable for $11.50 per share, and the exercise price of the Private Placement Warrants may be adjusted in certain circumstances as described in Note 7. Under the terms of the Warrant Agreement, the Company has agreed to use its best efforts to file a new registration statement under the Securities Act, following the completion of the Company’s Business Combination. Each Private Placement Warrant will become exercisable on the later of 30 days after the completion of the Company’s Business Combination or 12 months from the closing of the Offering and will expire five years after the completion of the Company’s Business Combination or earlier upon redemption or liquidation. However, if the Company does not complete a Business Combination on or prior to the 30-month period allotted to complete the Business Combination (or such lesser period depending upon the number of one-month extensions which occur), the Private Placement Warrants will expire at the end of such period. If the Company is unable to deliver registered shares of common stock to the holder upon exercise of the Private Placement Warrants during the exercise period, there will be no net cash settlement of these Private Placement Warrants and the Private Placement Warrants will expire worthless, unless they may be exercised on a cashless basis in the circumstances described in the Warrant Agreement. Once the Private Placement Warrants become exercisable, the Company may redeem the outstanding Private Placement Warrants in whole and not in part at a price of $0.01 per Private Placement Warrant upon a minimum of 30 days’ prior written notice of redemption, only in the event that the last sale price of the Company’s shares of common stock equals or exceeds $18.00 per share for any 20 trading days within the 30-trading day period ending on the third trading day before the Company sends the notice of redemption to the Private Placement Warrant holders. The Company’s Founder, Insiders and Underwriters have agreed not to transfer, assign or sell any of their respective Founder Shares, shares held by the Insiders, Private Placement Units, shares or other securities underlying such Private Placement Units that they may hold until the date that is (i) in the case of the Founder Shares or shares held by the Insiders, the earlier of (A) six months after the date of the consummation of the Company’s initial Business Combination or (B) subsequent to the Company’s initial Business Combination, (x) the date on which the last sale price of the Company’s common stock equals or exceeds $11.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 90 days after the Company’s initial Business Combination or (y) the date on which the Company consummates a liquidation, merger, stock exchange or other similar transaction after the Company’s Business Combination that results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property, and (ii) in the case of the Private Placement Units and shares or other securities underlying such Private Placement Units, until 30 days after the completion of the Company’s Business Combination. Unlike the Public Warrants included in the Public Units sold in the Offering, if held by the original holder or its permitted transferees, the Private Placement Warrants are not redeemable by the Company and, subject to certain limited exceptions, will be subject to transfer restrictions until one year following the consummation of the Business Combination. If the Private Placement Warrants are held by holders other than the initial holders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by holders on the same basis as the Public Warrants. If the Company does not complete a Business Combination, then a portion of the proceeds from the sale of the Private Placement Units will be part of the liquidating distribution to the public stockholders. Administrative Services Agreement and Other Agreements The Company agreed to pay $30,000 a month for office space, administrative services and secretarial support to an affiliate of the Founder, GigManagement, LLC. Services commenced on September 24, 2021, the date the securities were first listed on the NYSE, and will terminate upon the earlier of the consummation by the Company of a Business Combination or the liquidation of the Company. The amount unpaid as of December 31, 2023 for such fees is $780,000. The Company has agreed to pay advisory fees to directors for board committee service and administrative and analytical services, including certain activities on the Company’s behalf, such as identifying and investigating possible business targets and business combinations. All such amounts in the aggregate of $696,000 were unpaid as of December 31, 2023. On September 23, 2021, the Company entered into a Strategic Services Agreement with Mr. Weightman, its Treasurer and Chief Financial Officer, who holds 5,000 Insider shares. Mr. Weightman is initially receiving $2,500 per month for his services and such amount could increase to up to $15,000 per month dependent upon the scope of services provided, as may be mutually agreed by the parties. The Company will pay Mr. Weightman for services rendered since September 23, 2021 and on a monthly basis thereafter for all services rendered after the consummation of the Offering. Working Capital Loans On September 26, 2022, the Company issued the Working Capital Note to the Sponsor for a principal amount of $65,000. The Working Capital Note was subsequently amended and restated eleven more times on October 26, 2022 (an additional $65,000 added to the Working Capital Note), November 28, 2022 (an additional $65,000 added to the Working Capital Note), December 27, 2022 (an additional $65,000 added to the Working Capital Note), January 25, 2023 (an additional $65,000 added to the Working Capital Note), February 27, 2023 (an additional $350,000 added to the Working Capital Note) and March 28, 2023 (an additional $130,000 added to the Working Capital Note), April 27, 2023 (an additional $65,000 added to the Working Capital Note), June 26, 2023 (an additional $130,000 added to the Working Capital Note), July 25, 2023 (an additional $65,000 added to the Working Capital Note), October 27, 2023 (an additional $381,360 added to the Working Capital Note) and December 13, 2023 (an additional $53,640 added to the Working Capital Note), respectively, for a collective principal amount of $1,500,000. The Working Capital Note was issued to provide the Company with additional working capital during the Extension and was not deposited into the Trust Account. The Working Capital Note is convertible at the Sponsor’s election upon the consummation of the initial business combination. Upon such election, the convertible note will convert, at a price of $10.00 per unit, into units identical to the Private Placement Units issued in connection with the Offering. An aggregate of 150,000 Private Placement Units of the Company would be issued if the entire principal balance of the Working Capital Note is converted. Each Private Placement Unit consists of one share of the Company’s common stock, par value $0.0001 per share, and one redeemable warrant. The warrants constituting a part of the Private Placement Units would be exercisable, subject to the terms and conditions of the warrant and during the exercise period as provided in the warrant agreement governing the warrants. The Company has relied upon Section 4(a)(2) of the Securities Act, in connection with the issuance and sale of the convertible promissory note, as it was issued to a sophisticated investor without a view to distribution and was not issued through any general solicitation or advertisement. On December 13, 2023, the Company issued the First Non-Convertible Working Capital Note for a collective principal amount of $66,360 (the “First Non-Convertible Working Capital Note”). The First Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. On February 7, 2024, the Company amended and restated the First Non-Convertible Working Capital Note to reflect an additional principal amount of $195,887 extended by the Sponsor to the Company for a collective principal amount under the Second Non-Convertible Working Capital Note of $262,247. The Second Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. On February 15, 2024, the Company amended and restated the Second Non-Convertible Working Capital Note with the Third Non-Convertible Working Capital Note to reflect an additional principal amount of $35,000 extended by the Sponsor to the Company for a collective principal amount under the Third Non-Convertible Working Capital Note of $297,247. The Third Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. The Third Non-Convertible Working Capital Note bears no interest and is repayable in full upon the consummation of a Business Combination by the Company. The Company issued the Second and Third Non-Convertible Working Capital Note in consideration for additional loans from the Sponsor to fund the Company’s working capital requirements. The Company has determined that the convertible Working Capital Note contains only one embedded feature, which is the conversion option. The conversion option is an embedded derivative that would require bifurcation pursuant to ASC 815-15-25-1, so the instrument qualifies for the fair value option. The Company has elected to value the Working Capital Note under the fair value option at $1,506,389 as of December 31, 2023. The change in the fair value of the Working Capital Note was $8,897 for the year ended December 31, 2023 and was recorded in other income (expense) on the statements of operations and comprehensive loss. Extension Notes

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
Subsequent Events	Subsequent Events On October 31, 2024 , the Company and Yorkville executed the Second Omnibus Amendment (the “Second Amendment”), pursuant to which the maturity date of the Yorkville Note was extended from December 15, 2025 to March 31, 2026 . Further, the Second Amendment acknowledges the Company’s obligation to make monthly payments to Yorkville in the amount of the Trigger Principal Amount due to the occurrence of the Trigger Event and no further monthly payments will be owed during the period beginning on the date of the Second Amendment and ending on February 15, 2025 . In exchange for this relief, beginning on February 15, 2025 , and continuing on the same day of each successive calendar month until and including February 15, 2026 , whether or not a Trigger Event has occurred and is continuing as of such dates, the Company will make monthly payments in an amount equal to $500,000 plus the Payment Premium plus accrued and unpaid interest as of each such payment date. Such monthly payments will not be reduced or offset by any amount, including, but not limited to, any net sales proceeds of the Company Shares or any value of the Company Shares based on the VWAP as quoted by Bloomberg, LP. Further, pursuant to the terms of the Second Amendment, the Company has elected to reduce the Floor Price to $0.50 per share, effective as of the date of the Second Amendment. The Second Amendment also provides that in the event that the Company’s common stock is delisted from trading on the Nasdaq Stock Market, Yorkville consents to the occurrence of such delisting from the Nasdaq Stock Market, if it is to happen, and that it will not constitute an Event of Default as defined per the Omnibus Amendment, provided that (i) the Company uses its best efforts to have its common stock relisted on the Nasdaq Stock Market as soon as possible and (ii) the Company’s common stock is listed on the OTC Markets’ OTCQX or OTCQB market tiers within 30 days in the event that a delisting from the Nasdaq Stock Market occurs. On November 4, 2024 , Yorkville converted $254,593 of outstanding principal into 384,059 shares of common stock with an applicable conversion price of $0.6629 per share . The principal balance of the Yorkville Note was $8,600,000 following the conversion notice received from Yorkville. On November 12, 2024, the Company and certain related parties entered into a securities purchase agreement as a PIPE for the issuance of shares of common stock plus warrants for the purchase of common stock with an aggregate purchase price of $2,560,000 in exchange for 4,383,558 shares of common stock at an issuance price of $0.584 per share and 4,383,558 warrants with an exercise price of $0.672 per share, the closing of which sale will occur by November 29, 2024. The holder of the Extension Note is one of the purchasers under the securities purchase agreement and will be surrendering the Extension Note for cancellation in its entirety in exchange for the purchase of shares of common stock and warrants for the purchase of common stock with a purchase price of $1,560,000.	Subsequent Events Subsequent events were evaluated through March 22, 2024, which is the date the consolidated financial statements were available to be issued. Merger Agreement and Related Activities In February 2024, GigCapital5 and the Company (together the “parties”) entered into a subscription agreement with William Blair & Co., L.L.C. (“William Blair”) for the purchase of shares of common stock of the Company. Pursuant to the subscription agreement, the Company issued to William Blair in satisfaction of certain fees owed to William Blair for its services to the parties, that number of shares of the Company which at the completion of the Business Combination would be converted in accordance with the terms of the Business Combination Agreement into 740,000 shares of QTI Holdings common stock. In February 2024, the parties agreed to amend one of the September 2023 Non-Redemption Agreements, pursuant to which, and in addition to the QT Holdings common stock issuable Mizuho Securities USA, LLC (“Mizuho”) under the September 2023 Non-Redemption Agreement, Mizuho shall receive from the Company, in exchange for $250,000 of services rendered by Mizuho, that number of Company’s common stock that will be converted in accordance with the terms of the Business Combination Agreement into 100,000 shares of QTI Holdings common stock. In February 2024, the Company and GigCapital5 entered into two additional subscription agreements with each of Donnelley Financial Solutions, LLC (“DFIN”) and IB Capital LLC (“iBankers”), dated as of February 23, 2024 and February 22, 2024, respectively (together, the “Subscription Agreements”), for the purchase of shares of common stock of the Company. Pursuant to the Subscription Agreements, the Company will issue to each of DFIN and iBankers in satisfaction of $500,000 and $600,000 of fees owed to DFIN and iBankers, respectively, for their services, that number of shares of the Company which at the completion of the Business Combination will be converted in accordance with the terms of the Business Combination Agreement into 200,000 and 240,000 respective shares of QTI Holdings common stock. In February 2024, GigCapital5 and the Company entered into a Note Purchase Agreement (“Cable Car NPA”) with Funicular Funds, LP (“Cable Car”), pursuant to which Cable Car agreed to advance $1,500,000 at the closing of the Business Combination, as was evidenced by a promissory note that may be convertible in certain circumstances into shares of QTI Holdings common stock at a conversion price of $2.00 per share (the “Loan”), dated March 4, 2024, by and between the Company and Cable Car. The Loan does not bear interest, and is due and payable 13 months after issuance, unless the time for payment is accelerated as a result of an event of default. As full compensation to Cable Car for the Loan to QTI Holdings in lieu of any simple or in-kind interest on the Loan, the Company issued to Cable Car that number of shares of the Company which at the completion of the Business Combination would be converted in accordance with the terms of the Business Combination Agreement into 180,000 shares of QTI Holdings common stock. The Company, and its wholly owned subsidiary, QT Ultrasound Labs, Inc., at the closing also provided a guaranty (the “Cable Car Guaranty”), whereby each of them unconditionally guaranteed, as primary obligor and not merely as surety, the prompt and complete payment and performance when due, whether by demand, acceleration or otherwise, of the obligations of QTI Holdings under the Loan in the currency in which and as such obligations are to be paid or performed. Furthermore, QTI Holdings and the parties to the Cable Car Guaranty (the “Grantors”) granted a security interest in certain of their assets, which among other things, do not include their intellectual property assets, pursuant to the terms of a Security Agreement, dated March 4, 2024, by and between the Grantors and Cable Car. In February 2024, the Company and LionBay Ventures (“LionBay”) entered into a Settlement and Termination Agreement (“Termination Agreement”). Pursuant to the terms of the Termination Agreement, the Company terminated its Service Agreement with LionBay dated May 18, 2021 and the First Amendment of the Service Agreement dated September 1, 2021 (collectively as “Service Agreement”). In exchange for the termination of the Service Agreement and the termination of options to purchase 17,000 shares of common stock with a strike price of $8.50 per option that were issued as part of the Service Agreement, the Company agreed to issue 10,000 shares of QTI Holdings common stock. On March 1, 2024, the Company received $500,000 in exchange for 583,596 shares of the Company’s common stock, which converted into 200,000 shares of QTI Holdings common stock in accordance with the terms of the subscription agreement and Business Combination Agreement on March 4, 2024. On March 4, 2024, QTI Holdings (f/k/a GigCapital5) consummated its Business Combination with the Company, pursuant to the Business Combination Agreement, dated as of December 8, 2022. On March 4, 2024 and in accordance with the terms of the Business Combination Agreement, the Company cancelled and terminated all outstanding warrants that were deemed out of the money with an exercise price of or above $4.00 per share, including all warrants sold as part of the Units in the 2022 Offering and warrants that were issued to consultants and placement agents in association with debt issuance and past private offerings. On March 4, 2024, the Company terminated the Plan and cancelled 3,646,921 of outstanding options under the Plan in accordance with the terms of the Business Combination Agreement. On March 4, 2024, the Company received the Pre-Paid Advance of $9,005,000 of net proceeds from Yorkville (“Yorkville Note”) that will be due 15 months from the date of issuance, and interest shall accrue on the outstanding balance of the Yorkville Note at an annual rate equal to 6%, subject to an increase to 18% upon an event of default as described in the Yorkville Note. The Yorkville Note shall be convertible by Yorkville into shares of QTI Holdings common stock. As consideration for the Pre-Paid Advance, immediately prior to, and substantially concurrently with, the closing of the Business Combination, the Company issued to Yorkville that number of shares of the Company which converted in the aggregate into 1,000,000 shares of common stock of QTI Holdings upon the completion of the Business Combination. On March 4, 2024, the Note principal and related accrued interest balance of $3,233,388 and the US Capital Note principal balance of $200,000 was converted into 1,048,330 and 291,798 shares of Company common stock, respectively. Additionally, warrants to purchase 60,329 shares of the Company’s common stock were net settled into 16,320 shares of the Company’s common stock. On March 4, 2024, as consideration for the September 2023 Non-Redemption, the Company issued 427,477 shares of QTI Holdings common stock to Non-Redeeming Shareholders.
GIGCAPITAL5, INC
Subsequent Event [Line Items]
Subsequent Events		SUBSEQUENT EVENTS On February 7, 2024, the Company amended and restated the First Non-Convertible Working Capital Note to reflect an additional principal amount of $195,887 extended by the Sponsor to the Company for a collective principal amount under the Second Non-Convertible Working Capital Note of $262,247. The Second Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. The Company issued the Second Non-Convertible Working Capital Note in consideration for an additional loan from the Sponsor to fund the Company’s working capital requirements. The Second Non-Convertible Working Capital Note bears no interest and is repayable in full upon the consummation of a Business Combination by the Company. On February 7, 2024, the Company filed a joint definitive proxy statement/prospectus (the “BCA Proxy Statement”) for the solicitation of proxies in connection with the upcoming annual meeting to consider and vote on its proposed business combination and other matters as described in the BCA Proxy Statement relating to the offer of the securities to be issued to the stockholders of QT Imaging, Inc. in connection with the Merger. On February 15, 2024, the Company amended and restated the Second Non-Convertible Working Capital Note into the Third Non-Convertible Working Capital Note to reflect an additional principal amount of $35,000 extended by the Sponsor to the Company for a collective principal amount under the Third Non-Convertible Working Capital Note of $297,247. The Third Non-Convertible Working Capital Note was issued to provide the Company with additional working capital and will not be deposited into the Trust Account. The Third Non-Convertible Working Capital Note bears no interest and is repayable in full upon the consummation of a Business Combination by the Company. In conjunction with the Company’s annual meeting on February 20, 2024, stockholders elected to redeem 848,003 shares of the Company’s common stock, which represents approximately 3.7% of the shares that were part of the Public Units sold in the Offering. Following such redemptions, $9,356,221 was withdrawn from the Trust Account. On February 21, 2024, the Company, QT Imaging and Mizuho Securities USA LLC (“Mizuho”) agreed to amend the Prior Non-Redemption Agreement (as amended, the “Amended Non-Redemption Agreement”) to provide that in addition to the Merger Consideration QTI Holdings Shares issuable to Mizuho under the Prior Non-Redemption Agreement, Mizuho shall receive from QT Imaging, in exchange for $250,000 of services rendered by Mizuho, that number of QTI Shares (the “Services Share Issuance”) that will be converted in accordance with the terms of the BCA into 100,000 shares of QTI Holdings Common Stock. The Company and QT Imaging entered into two additional subscription agreements with each of Donnelley Financial Solutions, LLC (“DFIN”) and IB Capital LLC (“iBankers”), dated as of February 23, 2024 and February 22, 2023, respectively (the “DFIN Subscription Agreement,” and the “iBankers Subscription Agreement,” respectively, and together, the “Subscription Agreements”), for the purchase of shares of common stock of QT Imaging. Pursuant to the Subscription Agreements, QT Imaging will issue to each of DFIN and iBankers in satisfaction of $500,000 and $600,000 of fees owed to DFIN and iBankers, respectively, for their services, that number of shares of QT Imaging which at the completion of the Merger will be converted in accordance with the terms of the BCA into 200,000 and 240,000 respective shares of QTI Holdings Common Stock. On February 26, 2024, Mr. Weightman, the Company’s then Treasurer and Chief Financial Officer, voluntarily surrendered 5,000 Insider Shares previously granted pursuant to the Insider Shares Grant Agreement dated September 23, 2021 and the shares were cancelled. On February 28, 2024, the Company and QT Imaging entered into a subscription agreement (the “Subscription Agreement”) with William Blair & Co., L.L.C. (“William Blair”) for the purchase of shares of common stock of QT Imaging. Pursuant to the Subscription Agreement, QT Imaging issued to William Blair in satisfaction of certain fees owed to William Blair for its services to the parties, that number of shares of QT Imaging which at the completion of the Business Combination would be converted in accordance with the terms of the Business Combination Agreement into 740,000 shares of Combined Company Common Stock. On February 29, 2024, the Company and QT Imaging entered into a Note Purchase Agreement (“Cable Car NPA”) with Funicular Funds, LP (“Cable Car”), pursuant to which Cable Car agreed to advance $1,500,000 to the Combined Company upon the closing of the Merger (the “Loan”), as was evidenced by a promissory note that may be convertible in certain circumstances into shares of Combined Company Common Stock at a conversion price of $2.00 per share (the “Cable Car Promissory Note”), dated March 4, 2024, by and between the Combined Company and Cable Car. The Cable Car Promissory Note does not bear interest, and is due and payable 13 months after issuance, unless the time for payment is accelerated as a result of an event of default. As full compensation to Cable Car for the loan to the Combined Company in lieu of any simple or in-kind interest on the Cable Car Promissory Note, QT Imaging issued to Cable Car that number of shares of QT Imaging which at the completion of the Merger would be converted in accordance with the terms of the Business Combination Agreement into 180,000 shares of Combined Company Common Stock. QT Imaging, and its wholly owned subsidiary, QT Ultrasound Labs, Inc., at the Closing also provided a guaranty (the “Cable Car Guaranty”), whereby each of them unconditionally guaranteed, as primary obligor and not merely as surety, the prompt and complete payment and performance when due, whether by demand, acceleration or otherwise, of the obligations of the Combined Company under the Cable Car Promissory Note in the currency in which and as such obligations are to be paid or performed. Furthermore, the Combined Company and the parties to the Cable Car Guaranty (the “Grantors”) granted a security interest in certain of their assets, which among other things, do not include their intellectual property assets, pursuant to the terms of a Security Agreement, dated March 4, 2024, by and between the Grantors and Cable Car. On March 4, 2024, QT Imaging Holdings, Inc. (f/k/a GigCapital5) consummated its Merger with QT Imaging, pursuant to certain Business Combination Agreement, dated as of December 8, 2022, by and among the Company, Merger Sub, and QT Imaging. On March 4, 2024, the Combined Company received the Pre-Paid Advance, net of various costs, of $9.0 million from Yorkville (“Yorkville Note”). The principal of $10 million that will be due 15 months from the date of issuance, and interest shall accrue on the outstanding balance of the Yorkville Note at an annual rate equal to 6%, subject to an increase to 18% upon an event of default as described in the Yorkville Note. The Yorkville Note shall be convertible by Yorkville into shares of QTI Holdings common stock. As consideration for the Pre-Paid Advance, immediately prior to, and substantially concurrently with, the closing of the Merger, the Company issued to Yorkville that number of shares of the Company which converted in the aggregate into 1,000,000 shares of common stock of QTI Holdings upon the completion of the Merger. On March 4, 2024, the Company and the Sponsor agreed to amend and restate the Extension Note to extend the date of maturity until March 4, 2025. As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2023, the Company issued that certain Eleventh Amended and Restated Working Capital Note (the “Working Capital Note”) to GigAcquisitions5 for an aggregate principal amount of $1,500,000, the terms of which provide that GigAcquisitions5 may elect to convert the Working Capital Note, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s initial public offering. In connection with the Closing, (i) GigAcquisitions5 elected to partially convert (the “Conversion”) $943,640 in principal balance outstanding under the Working Capital Note into 94,364 shares of Combined Company Common Stock and 94,364 warrants (together, the “Warrants”) of the Combined Company, and (ii) the Combined Company repaid the remaining principal balance of $556,360 to GigAcquisitions5 concurrently with the Conversion, such that the Combined Company’s obligations under the Working Capital Note have been satisfied in full.

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) applicable to interim financial statements. Accordingly, certain information related to significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of QT Imaging for the year ended December 31, 2023 and the related notes which provide a more complete discussion of the Company's accounting policies and certain other informatio n. The December 31, 2023 condensed consolidated balance sheet was derived from QT Imaging's audited consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's condensed consolidated results for the periods presented. The condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period. The share and per share amounts, prior to the Merger, have been retrospectively restated as shares reflecting conversion at the exchange ratio of approximately 0.3427 established in the Business Combination Agreement.	Basis of Presentation
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, QT Imaging and QT Ultrasound Labs, Inc. (“QT Labs”). All intercompany balances and transactions are eliminated in consolidation.	Principles of Consolidation
Liquidity	Liquidity The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $32,122,605 as of September 30, 2024. During the nine months ended September 30, 2024, the Company incurred a net loss of $9,166,958 and used $8,806,402 of cash in operating activities, which includes repayment of net liabilities assumed from the Business Combination. The Company expects to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to support the Company’s cost structure. The Company may never achieve profitability and, unless and until it does, the Company will need to continue to raise additional capital. In connection with the Business Combination, the Company entered into various agreements to obtain financing through the issuance of debt and through stock subscription agreements. On March 4, 2024, the Company received the Pre-Paid Advance (as defined in Note 2), net of issuance costs, of $9,025,000 from YA II PN, LTD (“Yorkville”) pursuant to the Standby Equity Purchase Agreement (the “SEPA”) and issued Yorkville a promissory note (the “Yorkville Note”) in the amount of $10.0 million for such Pre-Paid Advance, $500,000 of cash proceeds from an investor related to a stock subscription agreement, and $1,500,000 in cash proceeds through a note payable from Funicular Funds, LP. See Note 8. Long-Term Debt. The SEPA provides the Company with access to an additional $40 million of potential capital through the issuance of common stock to Yorkville. During the time the Company has a balance under the Yorkville Note, additional advances under the SEPA can be received with written consent of Yorkville or upon a Trigger Event (as defined in Note 8) which, following the effectiveness of the Registration Statement on Form S-1 that the Company filed to register the shares to be issued pursuant to the SEPA, occurs when the daily volume-weighted average price is less than the Floor Price (as such term is defined in the Yorkville Note) for five consecutive trading days, which prior to October 31, 2024, was $0.8768 per share. As previously disclosed in a Current Report on Form 8-K with the SEC on September 13, 2024, a Trigger Event occurred on September 11, 2024, following which on September 13, 2024, the Company made a payment to Yorkville on the Yorkville Note of $1,521,581 which included $1,145,407 as repayment of principal. Additionally, and as previously disclosed in a Current Report on Form 8-K with the SEC on September 30, 2024, the Company and Yorkville executed an amendment on September 26, 2024 to extend the maturity date of the Yorkville Note from June 4, 2025 to December 15, 2025 and decreased the monthly principal payment obligations of $500,000 related to the Trigger Event beginning on January 15, 2025 (see Note 8 for more detail). Subsequently, on October 31, 2024, the Company and Yorkville executed a second amendment to extend the maturity date of the Yorkville Note to March 31, 2026 and reduced the Floor Price to $0.50 per share. On November 4, 2024, Yorkville converted $254,593 in principal amount of the Yorkville Note, and following this conversion and the prior repurchase of principal, the remaining principal balance of the Yorkville Note is $8.6 million (see Note 16). Subsequent to the date of these condensed consolidated financial statements, the Company executed a securities purchase agreement with related parties for the issuance of shares of common stock plus warrants for the purchase of common stock as a Private Investment in Public Equity (the “PIPE”) with an aggregate purchase price of $2.56 million, the closing of which will occur by November 29, 2024. Management believes that the additional cash received from the PIPE and the financing arrangement under the SEPA and the Yorkville Note will be sufficient to fund the Company’s current operating plan for at least the next 12 months. The Company’s future capital requirements will depend on many factors, including the Company’s growth rate, the timing and extent of its spending to support research and development activities, purchasing inventory to meet its growth plan, and the timing and cost to enhance commercialized existing products. In the event that additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to the Company, or at all. Any additional debt financing obtained by the Company in the future could also involve restrictive covenants relating to the Company’s capital-raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if the Company raises additional funds through further issuances of equity, convertible debt securities or other securities convertible into equity, its existing stockholders could suffer significant dilution in their percentage ownership of the Company, and any new equity securities the Company issues could have rights, preferences and privileges senior to those of holders of the Company’s common stock. If the Company is unable to obtain adequate financing or financing on terms satisfactory to the Company when the Company requires it, the Company’s ability to continue to grow or support its business and to respond to business challenges could be significantly limited.	Liquidity The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $17,770,145 as of December 31, 2023. During the year ended December 31, 2023, the Company incurred a net loss of $6,098,951 and used $2,651,143 of cash in operating activities. The Company expects to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to support the Company’s cost structure. The Company may never achieve profitability and, unless and until it does, the Company will need to continue to raise additional capital. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In connection with the Business Combination, the Company entered into various agreements to obtain financing through the issuance of debt and through stock subscription agreements. Subsequent to December 31, 2023, the Company received the Pre-Paid Advance, net of issuance costs, of $9,005,000 from Yorkville pursuant to the Standby Equity Purchase Agreement, $500,000 of cash proceeds from an investor related to a stock subscription agreement, and $1,500,000 in cash proceeds through a note payable from Funicular Funds, LP. See Note 14. Subsequent Events. The Standby Equity Purchase Agreement provides the Company with access to an additional $40 million of potential capital through the issuance of common stock to Yorkville. During the time the Company has a balance under the Pre-Paid Advance, additional advances can be received with written consent of Yorkville or upon a trigger event, which occurs when the daily volume-weighted average price is less than $2.00 per share for five consecutive trading days. Management believes that the additional cash received and financing arrangements at the closing of the Business Combination has alleviated the substantial doubt about the Company’s ability to continue as a going concern and will be sufficient to fund the Company’s current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements.
Reclassification	Reclassification Certain reclassifications have been made to the prior year condensed consolidated statement of operations and comprehensive loss to conform to the current year presentation. The reclassification had no impact on the previously reported condensed consolidated balance sheet, statement of stockholders’ deficit or cash flows.	Reclassification
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on the Company’s operating results.	Use of Estimates
Business Risk and Concentration of Credit Risk and Supply Risk	Business Risk and Concentration of Credit Risk and Supply Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and accounts receivable. The majority of the Company’s cash is invested in U.S. dollar deposits with a reputable bank in the United States. Management believes that minimal credit risk exists with respect to the financial institution that holds the Company’s cash. At times, such cash may be in excess of insured limits established by the Federal Deposit Insurance Corporation. The Company performs ongoing credit evaluations of its customers and generally does not require collateral for accounts receivable. Payment terms range from cash in advance to 30 days from delivery of products or services but may fluctuate depending on the terms of each specific contract. There are inherent risks whenever a large percentage of total revenue is concentrated in a limited number of customers. Should a significant customer which is a party to a contract with the Company under which the Company derives revenue terminate or fail to renew its contracts with the Company, in whole or in part, for any reason, or experience significant financial or operating difficulties, it could have a material adverse effect on the Company’s financial condition and results of operations. In general, a customer that makes up a significant portion of revenues in one period, may not make up a significant portion in subsequent periods. However, as the Company has entered into a Distribution Agreement with NXC Imaging, Inc. (“NXC”) on June 18, 2024, by which the Company appointed NXC as the exclusive reseller to market, advertise, and resell certain equipment in the U.S. and U.S. territories, the Company expects that NXC will make up a significant portion of revenues in each period in which such Distribution Agreement is in effect. Customer A in the concentration table above is NXC, which resold the Company’s scanner to two clinics during the three months ended September 30, 2024 and six clinics during the nine months ended September 30, 2024. Certain components and services used to manufacture and develop the Company’s products are presently available from only one or a limited number of suppliers or vendors. The Company’s QT Breast Scanner has more than six hundred components, of which less than five components have such dependencies on limited suppliers or vendors. The loss of any of these suppliers or vendors would potentially require a significant level of hardware and/or software development efforts to incorporate the products or services into the Company’s product.	Business Risk and Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The majority of the Company’s cash is invested in U.S. dollar deposits with a reputable bank in the United States. Management believes that minimal credit risk exists with respect to the financial institution that holds the Company’s cash. At times, such cash may be in excess of insured limits established by the Federal Deposit Insurance Corporation. The Company performs ongoing credit evaluations of its customers and generally does not require collateral for accounts receivable. Payment terms range from cash in advance to 30 days from delivery of products or services but may fluctuate depending on the terms of each specific contract. During the year ended December 31, 2023, one customer represented 49% of revenue. During the year ended December 31, 2022, one customer represented 98% of revenue. As of December 31, 2023, one customer represented 100% of accounts receivable. As of December 31, 2022, there were no customer concentrations in accounts receivable. The Company’s products require approvals from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. The Company’s future products may not receive required approvals. If the Company was denied such approvals, or if such approvals were delayed, it would have a material adverse impact on the Company’s business, results of operations and financial condition.
Cash and Cash Equivalents, Restricted Cash	Cash and Cash Equivalents The Company considers all short-term investments with a maturity of three months or less when purchased to be cash equivalents. The Company had restricted cash equivalents of $20,000 as of September 30, 2024 and December 31, 2023. Restricted Cash Restricted cash is comprised of cash held in an account subject to a collateral agreement to be used for the Company’s corporate credit card program.	Cash and Cash Equivalents The Company considers all short-term investments with a maturity of three months or less when purchased to be cash equivalents. The Company had restricted cash equivalents of $20,000 as of December 31, 2023 and 2022. Restricted Cash Restricted cash is comprised of cash held in an account subject to a collateral agreement to be used for the Company’s corporate credit card program.
Accounts Receivable, Net	Accounts Receivable, Net	Accounts Receivable
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the weighted-average cost method. The Company periodically reviews the value of items in inventory and provides write-offs of inventory that is obsolete. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Once inventory has been written down below cost, it is not subsequently written up.	Inventory
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net are recorded at cost, less accumulated depreciation. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to current operations as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized over the lesser of the term of the related lease or the estimated useful lives of the assets.	Property and Equipment, Net
Leases	Leases The Company primarily enters into leases for office space that are classified as operating leases. The Company determines if an arrangement is or contains a lease at inception. The Company accounts for leases by recording right-of-use (“ROU”) assets and lease liabilities on the condensed consolidated balance sheets in the captions operating lease right-of-use assets, net and operating lease liabilities, respectively. The lease term includes the non-cancelable period of the lease plus any additional periods covered by an option to extend that the Company is reasonably certain to exercise. The Company’s leases do not include substantial variable payments based on an index or rates. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants. The Company’s leases do not provide a readily determinable implicit discount rate. The Company’s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The lease payments related to the next 12 months are included in operating lease liabilities, current on the condensed consolidated balance sheets. The Company recognizes a single lease cost on a straight-line basis over the term of the lease, and the Company classifies all cash payments within operating activities in the condensed consolidated statements of cash flows.	Leases The Company primarily enters into leases for office space that are classified as operating leases. The Company determines if an arrangement is or contains a lease at inception. The Company accounts for leases by recording right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets in the captions operating lease right-of-use assets, net and operating lease liabilities, respectively. The lease term includes the non-cancelable period of the lease plus any additional periods covered by an option to extend that the Company is reasonably certain to exercise. The Company’s leases do not include substantial variable payments based on index or rates. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants. The Company’s leases do not provide a readily determinable implicit discount rate. The Company’s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The lease payments related to the next 12 months are included in operating lease liabilities, current on the consolidated balance sheets. The Company recognizes a single lease cost on a straight-line basis over the term of the lease, and the Company classifies all cash payments within operating activities in the consolidated statements of cash flows.
Intangible Assets, Net	Intangible Assets, Net The Company’s intangible assets are comprised of patents with a useful life of 12 years. Patents are amortized on a straight-line basis over their useful life.	Intangible Assets
Long-Lived Assets	Long-Lived Assets	Long-Lived Assets
Fair Value Measurements	Fair Value Measurements The Company applies the requirements of the fair value measurements framework, which establishes a hierarchy for measuring fair value and requires enhanced disclosures about fair value measurements. The fair value measurement guidance clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement guidance also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy in which these assets and liabilities must be grouped based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.	Fair Value Measurements The Company applies the requirements of the fair value measurements framework, which establishes a hierarchy for measuring fair value and requires enhanced disclosures about fair value measurements. The fair value measurement guidance clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement guidance also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy in which these assets and liabilities must be grouped based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.
Debt and Debt Issuance Costs	Debt and Debt Issuance Costs The Company evaluates its financial instruments to determine if they are freestanding financial instruments. The Company also evaluates its convertible debt for embedded derivatives. Embedded provisions (like conversion options) are assessed to determine if they qualify as embedded derivatives that require separate accounting. Debt issuance costs are recorded as a reduction to the carrying amount of the debt and are amortized to interest expense using the effective interest method. Debt is classified as short-term or long-term based on the term of the note.	Convertible Debt The Company evaluates its financial instruments to determine if they are freestanding financial instruments. The Company also evaluates its convertible debt for embedded derivatives. Embedded provisions (like conversion options) are assessed to determine if they qualify as embedded derivatives that require separate accounting.
Revenue Recognition	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods or services. The Company determines revenue recognition through the following steps: 1) Identification of the contract, or contracts, with a customer The Company considers the terms and conditions of the contract in identifying the contracts. The Company determines a contract with a customer to exist when the contract is approved, each party’s rights regarding the goods or services to be transferred can be identified, the payment terms for the goods or services can be identified, it has been determined the customer has the ability and intent to pay, and the contract has commercial substance. At contract inception, the Company will evaluate whether two or more contracts should be combined and accounted for as a single contract and whether the combined or single contract includes more than one performance obligation. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, credit and financial information pertaining to the customer. 2) Identification of the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or services either on its own or together with other resources that are readily available from third parties or from the Company, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. The Company’s performance obligations consist of (i) product sales, (ii) maintenance contracts and (iii) other services including training. 3) Determination of the transaction price The transaction price is determined based on the consideration to which the Company expects to be entitled in exchange for transferring goods or services to the customer. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company’s contracts do not contain a significant financing component. 4) Allocation of the transaction price to the performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price. 5) Recognition of revenue when, or as a performance obligation is satisfied For product sales and services, revenue is recognized at the time the related performance obligation is satisfied by transferring the control of the promised goods or services to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. Training and maintenance services are generally recognized upon invoicing in amounts that correspond directly with the value to the customer of the performance completed to date which primarily includes professional service arrangements entered on a time and materials basis. All of the revenue recognized by the Company during the three and nine months ended September 30, 2024 and 2023 was recognized at a point in time.	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods or services. The Company determines revenue recognition through the following steps: 1) Identification of the contract, or contracts, with a customer The Company considers the terms and conditions of the contract in identifying the contracts. The Company determines a contract with a customer to exist when the contract is approved, each party’s rights regarding the goods or services to be transferred can be identified, the payment terms for the goods or services can be identified, it has been determined the customer has the ability and intent to pay, and the contract has commercial substance. At contract inception, the Company will evaluate whether two or more contracts should be combined and accounted for as a single contract and whether the combined or single contract includes more than one performance obligation. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s historical payment experience or, in the case of a new customer, credit and financial information pertaining to the customer. 2) Identification of the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or services either on its own or together with other resources that are readily available from third parties or from the Company, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. The Company’s performance obligations consist of (i) product sales, (ii) maintenance contracts and (iii) other services including training. 3) Determination of the transaction price The transaction price is determined based on the consideration to which the Company expects to be entitled in exchange for transferring goods or services to the customer. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company’s contracts do not contain a significant financing component. 4) Allocation of the transaction price to the performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price. 5) Recognition of revenue when, or as a performance obligation is satisfied For product sales and services, revenue is recognized at the time the related performance obligation is satisfied by transferring the control of the promised goods or services to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. Training and maintenance services are generally recognized upon invoicing in amounts that correspond directly with the value to the customer of the performance completed to date which primarily includes professional service arrangements entered on a time and materials basis. All of the revenue recognized by the Company during the years ended December 31, 2023 and 2022 was recognized at a point in time. Revenue recognized during the years ended December 31, 2023 and 2022 is disaggregated as follows: 2023 2022 Product $ 17,832 $ 701,092 Service 22,523 7,152 $ 40,355 $ 708,244 Revenue recognized by geography during the years ended December 31, 2023 and 2022 is as follows: 2023 2022 United States $ 35,165 $ 7,200 International 5,190 701,044 $ 40,355 $ 708,244
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling activities are typically performed before the customer obtains control of the goods, and the related costs are therefore expensed as incurred. Shipping and handling costs are included in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. Shipping and handling costs incurred for inventory purchases are expensed in cost of revenue when sold.	Shipping and Handling Costs
Product Warranty	Product Warranty The Company’s products sold to customers are generally subject to warranties up to twelve months, which provides for the repair or replacement of products, at the Company’s option, that fail to perform with stated specifications. The Company estimates future warranty obligations related to those products. To date, product warranty claims have not been significant.	Product Warranty
Research and Development Costs	Research and Development Costs	Research and Development Costs
Advertising	Advertising	Advertising
Grant Income	Grant Income Periodically, the Company is awarded grants on a cost reimbursement basis. Costs are expensed when incurred and reimbursable on a monthly or quarterly basis with the offset booked as a contra-expense to the applicable functional area in the condensed consolidated statements of operations and comprehensive loss.	Grant Income
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets may be reduced by a valuation allowance if it is more-likely-than-not that some or all of the deferred tax asset will not be realized. The Company annually evaluates the realizability of deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets.	Income Taxes Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets may be reduced by a valuation allowance if it is more-likely-than-not that some or all of the deferred tax asset will not be realized. The Company annually evaluates the realizability of deferred tax assets by assessing the valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include the Company’s forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets.
Stock-Based Compensation	Stock-Based Compensation Sto ck-based compensation cost is measured at the grant date based on the fair market value of the award. Stock-based compensation is recognized as expense on a ratable basis over the requisite service period of the award. The Company values stock options using the Black-Scholes option pricing model. This model requires the use of highly subjective and complex assumptions which determine the fair value of stock-based awards, including the option’s expected term, stock price volatility and risk-free interest rates. Forfeitures are recorded as they occur.	Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair market value of the award. Stock-based compensation is recognized as expense on a ratable basis over the requisite service period of the award.
Comprehensive Loss	Comprehensive Loss	Comprehensive Loss
Net Loss per Share	Net Loss per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For the purposes of the diluted net loss per share calculation, common stock equivalents are considered to be potentially dilutive securities. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive as of December 31: 2023 2022 Common stock warrants 1,231,484 905,470 Options outstanding 3,646,922 3,940,536 Potential shares from convertible notes 2,073,554 714,870 Subscription agreements 3,833,912 — 10,785,872 5,560,876
Fair Value of Financial Instruments		Fair Value of Financial Instruments
Recent Accounting Pronouncements Adopted	Recent Accounting Pronouncements Adopted In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 reduces the number of accounting models for convertible instruments and allows more contracts to qualify for equity classification. The Company adopted this guidance effective January 1, 2024, and there was no material impact on the Company’s condensed consolidated financial statements upon adoption. Recent Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the condensed consolidated financial statements. In September 2024, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU’s amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard for annual financial statements that have not yet been issued or made available for issuance. Adoption is either prospectively or retrospectively, the Company will adopt this ASU on a prospective basis. The Company is currently evaluating the impact of the new standard on the condensed consolidated financial statements and related disclosures.	Recent Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the consolidated financial statements.
Recently Adopted Accounting Standards		Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s financial instruments, including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their fair values because of the relatively short maturity of these instruments. The carrying value of the Company’s borrowings approximates fair value based on current rates offered to the Company for instruments with similar terms.
GIGCAPITAL5, INC
Property, Plant and Equipment [Line Items]
Basis of Presentation		Basis of Presentation
Use of Estimates		Use of Estimates
Business Risk and Concentration of Credit Risk and Supply Risk		Concentration of Credit Risk
Cash and Cash Equivalents		Cash and Cash Equivalents
Income Taxes		Income Taxes The Company follows the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Stock-Based Compensation		Stock-based Compensation
Net Loss per Share		Net Loss Per Share of Common Stock The Company’s statements of operations and comprehensive loss include a presentation of income per share for common stock subject to possible redemption in a manner similar to the two-class method of income (loss) per share. Net income per share, basic and diluted, for common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held in the Trust Account by the weighted-average number of common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for non-redeemable common stock is calculated by dividing the net loss, adjusted for income or loss on marketable securities attributable to common stock subject to possible redemption, by the weighted-average number of non-redeemable common stock outstanding for the period, basic and diluted.
Recent Accounting Pronouncements Adopted		Recent Accounting Pronouncements
Emerging Growth Company		Emerging Growth Company
Reconciliation of Net Loss Per Common Share		Reconciliation of Net Loss Per Common Share In accordance with the two-class method, the Company’s net loss is adjusted for net income that is attributable to common stock subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, net loss per common share, basic and diluted, is calculated as follows: Year Ended Year Ended Common stock subject to possible redemption Numerator: Earnings allocable to common stock subject to redemption Interest earned on marketable securities held in Trust Account, net of taxes $ 1,107,741 $ 1,143,783 Net income attributable to common stock subject to possible redemptions $ 1,107,741 $ 1,143,783 Denominator: Weighted-average common shares subject to redemption Basic and diluted weighted-average shares outstanding, common stock subject to possible redemption 3,020,634 17,954,419 Basic and diluted net income per share, common stock subject to possible redemption $ 0.37 $ 0.06 Non-Redeemable common stock Numerator: Net loss minus net earnings - Basic and diluted Net loss $ (4,024,591) $ (2,774,307) Less: net income attributable to common stock subject to redemption (1,107,741) (1,143,783) Net loss attributable to non-redeemable common stock $ (5,132,332) $ (3,918,090) Denominator: Weighted-average non-redeemable common shares Weighted-average non-redeemable common shares outstanding, basic and diluted 6,540,000 6,540,000 Net loss per share, non-redeemable common stock, basic and diluted $ (0.78) $ (0.60)
Cash and Marketable Securities Held in Trust Account		Cash and Marketable Securities Held in Trust Account
Convertible Promissory Note - Related Party		Convertible Promissory Note - Related Party The Company accounts for its Working Capital Note under Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). Under ASC 815-15-25, an election can be made at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825, Financial Instruments. The Company has made such election for its Working Capital Note. Using the fair value option, the Working Capital Note is required to be recorded at its initial fair value on the date of issuance, each drawdown date, and each balance
Fair Value of Financial Instruments		Financial Instruments
Offering Costs		Offering Costs
Common Stock Subject to Possible Redemption		Common Stock Subject to Possible Redemption
Warrant Liability		Warrant Liability

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedules of Concentration of Risk, by Risk Factor	For each significant customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows: Revenue Accounts Receivable, Net Three Months Ended Nine Months Ended September 30, 2024 December 31, 2023 2024 2023 2024 2023 Customers: Customer A 96 % * 96 % * 65 % * Customer B * * * * 23 % * Customer C * * * * 10 % * Customer D, related party * * * * * 18 % Customer E * * * * * 14 % Customer F * 100 % * * * * Customer G * * * 77 % * 54 % Customer H * * * 16 % * 11 % 96 % 100 % 96 % 93 % 98 % 97 % __________________ * Total less than 10% for the period.
Disaggregation of Revenue	Revenue recognized during the three and nine months ended September 30, 2024 and 2023 is disaggregated as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Product $ 917,238 $ 6,634 $ 3,882,039 $ 12,881 Service 38,732 18,023 150,129 22,523 $ 955,970 $ 24,657 $ 4,032,168 $ 35,404	Revenue recognized during the years ended December 31, 2023 and 2022 is disaggregated as follows: 2023 2022 Product $ 17,832 $ 701,092 Service 22,523 7,152 $ 40,355 $ 708,244
Revenue from External Customers by Geographic Areas	Revenue recognized by geography during the three and nine months ended September 30, 2024 and 2023 is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 United States $ 942,265 $ 20,759 $ 4,000,590 $ 31,506 International 13,705 3,898 31,578 3,898 $ 955,970 $ 24,657 $ 4,032,168 $ 35,404	Revenue recognized by geography during the years ended December 31, 2023 and 2022 is as follows: 2023 2022 United States $ 35,165 $ 7,200 International 5,190 701,044 $ 40,355 $ 708,244
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive as of September 30, 2024 and 2023: September 30, 2024 September 30, 2023 Common stock warrants (1) 23,889,364 401,389 Potential shares from Pre-Paid Advance 10,126,981 — Merger consideration earnout shares 9,000,000 — Potential shares from Cable Car Loan 750,000 — Potential shares from convertible notes (1) 250,224 254,328 Contingently issuable shares to GigCapital5 stockholders (1) — 260,419 Options outstanding (1) 2,072,000 1,350,432 46,088,569 2,266,568 __________________ (1) Amounts as of December 31, 2023 and before that date differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).	The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive as of December 31: 2023 2022 Common stock warrants 1,231,484 905,470 Options outstanding 3,646,922 3,940,536 Potential shares from convertible notes 2,073,554 714,870 Subscription agreements 3,833,912 — 10,785,872 5,560,876
Schedule of Earnings Per Share, Basic and Diluted	Reconciliation of net loss per share for the three and nine months ended September 30, 2024 and 2023 is as follows: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net loss attributable to QT Imaging Holdings, Inc. $ (3,619,494) $ (1,375,939) $ (9,166,958) $ (4,588,900) Deemed dividend related to the modification of equity classified warrants — — (5,185,502) — Net loss attributable to common stockholders $ (3,619,494) $ (1,375,939) $ (14,352,460) $ (4,588,900) Weighted-average number of common shares used in computing net loss per common share (1) 21,441,416 9,541,643 18,712,468 9,533,185 Net loss per share - basic and diluted (1) $ (0.17) $ (0.14) $ (0.77) $ (0.48)
GIGCAPITAL5, INC
Schedule of Earnings Per Share, Basic and Diluted		In accordance with the two-class method, the Company’s net loss is adjusted for net income that is attributable to common stock subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, net loss per common share, basic and diluted, is calculated as follows: Year Ended Year Ended Common stock subject to possible redemption Numerator: Earnings allocable to common stock subject to redemption Interest earned on marketable securities held in Trust Account, net of taxes $ 1,107,741 $ 1,143,783 Net income attributable to common stock subject to possible redemptions $ 1,107,741 $ 1,143,783 Denominator: Weighted-average common shares subject to redemption Basic and diluted weighted-average shares outstanding, common stock subject to possible redemption 3,020,634 17,954,419 Basic and diluted net income per share, common stock subject to possible redemption $ 0.37 $ 0.06 Non-Redeemable common stock Numerator: Net loss minus net earnings - Basic and diluted Net loss $ (4,024,591) $ (2,774,307) Less: net income attributable to common stock subject to redemption (1,107,741) (1,143,783) Net loss attributable to non-redeemable common stock $ (5,132,332) $ (3,918,090) Denominator: Weighted-average non-redeemable common shares Weighted-average non-redeemable common shares outstanding, basic and diluted 6,540,000 6,540,000 Net loss per share, non-redeemable common stock, basic and diluted $ (0.78) $ (0.60)

Inventory - Schedule of Invento

Inventory - Schedule of Inventory, Current (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consisted of the following as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Raw materials $ 2,600,114 $ 2,529,364 Work in process 74,540 1,627,802 Finished Goods 506,900 261,031 Total $ 3,181,554 $ 4,418,197	Inventory consisted of the following as of December 31: 2023 2022 Raw materials $ 2,529,364 $ 2,567,311 Work in process 1,627,802 1,683,341 Finished Goods 261,031 528,254 Total $ 4,418,197 $ 4,778,906

Business Combination (Tables)

Business Combination (Tables)	9 Months Ended
	Sep. 30, 2024
Reverse Recapitalization [Abstract]
Schedule of Reverse Recapitalization	The following summarizes the elements of the Merger to the condensed consolidated statements of stockholders’ deficit and cash flows, including the transaction funding, sources, and uses of cash: Recapitalization Cash in GigCapital5 Trust Account, net of redemptions $ 13,952,525 Plus: cash in GigCapital5 operating bank account 4,829 Less: Payments made pursuant to non-redemption agreements (10,791,550) Less: GigCapital5 transaction costs paid from Trust (1,073,667) Less: Repayment of GigCapital5 related party notes (853,607) Net cash proceeds from GigCapital5 1,238,530 Assumed net liabilities from GigCapital5, excluding net cash proceeds (10,507,695) Net impact of the Merger on the condensed consolidated statement of stockholders' deficit $ (9,269,165)

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment, net consisted of the following as of September 30, 2024 and December 31, 2023: Useful Life September 30, 2024 December 31, 2023 Scanners 5 Years $ 2,254,548 $ 3,309,957 Computer and lab equipment 3-5 Years 1,384,307 1,359,491 Leasehold improvements Various 421,266 421,266 Software 3 Years 50,374 40,599 Furniture and fixtures 7 Years 82,336 82,336 4,192,831 5,213,649 Less: accumulated depreciation (4,070,679) (4,722,729) $ 122,152 $ 490,920	Property and equipment, net consisted of the following as of December 31: Useful Life 2023 2022 Scanners 5 Years $ 3,309,957 $ 3,047,841 Computer and lab equipment 3-5 Years 1,359,491 1,346,726 Leasehold improvements Various 421,266 421,266 Software 3 Years 40,599 40,599 Furniture and fixtures 7 Years 82,336 82,336 5,213,649 4,938,768 Less: accumulated depreciation (4,722,729) (4,441,021) $ 490,920 $ 497,747

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net consisted of the following as of September 30, 2024: Useful Gross Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 2,230,570 $ — 0.00 Years Intangible assets, net consisted of the following as of December 31, 2023: Useful Gross Carrying Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 2,140,431 $ 90,139 0.50 Years	Intangible assets, net consisted of the following as of December 31, 2023: Useful Gross Carrying Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 2,140,431 $ 90,139 0.50 Years Intangible assets, net consisted of the following as of December 31, 2022: Useful Gross Carrying Accumulated Net Carrying Useful Life Patents 12 Years $ 2,230,570 $ 1,954,550 $ 276,020 1.50 Years
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense		As of December 31, 2023, future amortization is as follows: Year ending December 31: 2024 $ 90,139

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	9 Months Ended
	Sep. 30, 2024
Offsetting [Abstract]
Schedule of Prepaid Expense and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Prepaid insurance $ 432,170 $ 9,808 Other 343,415 205,171 Total $ 775,585 $ 214,979
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Accrued legal $ 1,900,000 $ 24,729 Accrued personnel costs 899,796 120,856 Accrued excise taxes 202,341 — Accrued advisory fee 100,000 — Other 262,080 224,066 Total $ 3,364,217 $ 369,651

Accrued Expenses - (Tables)

Accrued Expenses - (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued expenses consisted	Accrued expenses consisted of the following as of December 31: 2023 2022 Accrued vacation $ 55,683 $ 91,125 Accrued wages 65,173 80,904 Accrued legal 24,729 79,691 Accrued interest 50,037 — Other 174,029 116,646 Total $ 369,651 $ 368,366

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Maturities of Long-Term Debt	Future principal payments on the long-term debt as of September 30, 2024 are as follows: Year ending December 31: 2024 (remaining) $ 32,718 2025 10,441,377 2026 9,197 Total payments 10,483,292 Less: Unamortized debt issuance costs (6,127,060) Less: Current maturities of long-term debt (887,321) Long-term debt $ 3,468,911	Future principal payments on the long-term debt as of December 31, 2023 are as follows: Year ending December 31: 2024 $ 4,261,221 2025 86,784 2026 9,196 Total Payments 4,357,201 Less: Unamortized debt issuance costs (61,857) Less: Current maturities of long-term debt (4,199,362) Long-term debt $ 95,982

Leases (Tables)

Leases (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Schedule of ROU Assets and Lease Liabilities	The following table reflects the Company’s ROU assets and lease liabilities as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 Assets: Operating lease ROU assets, net $ 1,020,947 $ 1,267,121 Liabilities: Operating lease liabilities, current $ 394,208 $ 361,305 Operating lease liabilities 762,904 1,062,633 $ 1,157,112 $ 1,423,938	The following table reflects the Company’s ROU assets and lease liabilities as of December 31: 2023 2022 Assets: Operating lease ROU assets, net $ 1,267,121 $ 1,572,323 Liabilities: Operating lease liabilities, current $ 361,305 $ 313,448 Operating lease liabilities 1,062,633 1,423,938 $ 1,423,938 $ 1,737,386
Schedule of Supplemental Cash Flow Information Related to Operating Leases	The following table presents supplemental cash flow information related to the Company’s operating leases for the three and nine months ended: Three Months Ended Nine Months Ended September 30, 2024 2023 2024 2023 Operating cash flows from operating leases $ 116,994 $ 110,278 $ 345,302 $ 330,833	The following table presents supplemental cash flow information related to the Company’s operating leases for the years ended December 31: 2023 2022 Operating cash flows from operating leases $ 441,111 $ 428,263
Lessee, Operating Lease, Liability, to be Paid, Maturity	As of September 30, 2024, the maturity of operating lease liabilities was as follows: Year ending December 31: 2024 (remaining) $ 116,994 2025 476,164 2026 490,449 2027 206,864 Total payments 1,290,471 Less: Interest (133,359) Present value of obligations $ 1,157,112	As of December 31, 2023, the maturity of operating lease liabilities was as follows: Year ending December 31: 2024 $ 462,295 2025 476,164 2026 490,449 2027 206,864 Total payments 1,635,772 Less: Interest (211,834) Present value of obligations $ 1,423,938

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Schedule of Stock by Class	Common stock reserved for future issuance as of September 30, 2024 is as follows: Common stock warrants 23,889,364 Potential shares from Pre-Paid Advance 10,126,981 Merger earnout consideration shares 9,000,000 Options outstanding under the 2024 Incentive Plan 2,072,000 Options available under the 2024 Incentive Plan 286,093 Potential shares from Cable Car Loan 750,000 Potential shares from convertible notes 250,224 46,374,662	Common stock reserved for future issuance as of December 31, 2023 is as follows: Common stock warrants 1,231,484 Options outstanding 3,646,922 Options available under the Plan 3,353,078 Potential shares from convertible notes 2,073,554 Subscription agreements 3,833,912 14,138,960
Schedule of Warrant Activity		The following table represents the warrant activity as follows: Number of Warrants Outstanding, January 1, 2022 624,508 Granted 280,962 Outstanding, December 31, 2022 905,470 Granted 326,104 Outstanding, December 31, 2023 1,231,574
Schedule of Stockholders' Equity Note, Warrants or Rights	The following table represents the QT Imaging warrant activity as follows for the nine months ended September 30, 2024: Number of Outstanding, January 1, 2024 422,064 Exercised (16,320) Terminated pursuant to business combination agreement (405,744) Outstanding, September 30, 2024 —	As of December 31, 2023, outstanding warrants to purchase shares of common stock by exercise price are as follows: Exercise Price Exercisable For Expiration Date(s) Number of $ 10.00 Common Stock March 2025 516,391 $ 8.50 Common Stock August 2030 150,000 $ 4.25 Common Stock July 2027 to September 2028 10,329 $ 4.00 Common Stock November 2027 to March 2029 494,525 $ 2.50 Common Stock November 1, 2028 60,329 1,231,574
Schedule of Fair Value of Warrants to Purchase Common Stock Issued Using the Black-Scholes Option Pricing Model		The determination of the fair value of warrants to purchase common stock issued during the years ended December 31, 2023 and 2022 is computed using the Black-Scholes option pricing model with the following weighted-average assumptions: 2023 2022 Expected warrant term (years) 5.0 5.6 Expected volatility 60.2 % 62.3 % Risk-free rate of return 4.0 % 3.6 % Expected annual dividend yield — —

Stock Incentive Plan (Tables)

Stock Incentive Plan (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Payment Arrangement, Option, Activity	The following table summarizes information regarding activity in the QT Imaging Plan and the 2024 Incentive Plan during the nine months ended September 30, 2024: Number of Weighted- Weighted-Average Outstanding, January 1, 2024 1,249,809 $ 24.80 6.9 Granted under the 2024 Incentive Plan 2,072,000 $ 0.74 Cancelled (12,128) $ 22.40 Terminated pursuant to Business Combination Agreement (1,237,681) $ 24.83 Outstanding, September 30, 2024 2,072,000 $ 0.74 9.8 Exercisable as of September 30, 2024 — $ — — Vested and expected to vest as of September 30, 2024 2,072,000 $ 0.74 9.8
Schedule of Total Number of Shares Available for Grant Under the Plan		The following table represents the total number of shares available for grant under the Plan: Available for Grant Balance as of December 31, 2021 3,578,276 Granted (541,208) Cancelled 22,396 Balance as of December 31, 2022 3,059,464 Cancelled 293,615 Balance as of December 31, 2023 3,353,079
Schedule of Activity in the Plan		The following table summarizes information regarding activity in the Plan during the years ended December 31, 2023 and 2022: Number of Options Weighted-Average Exercise Price Weighted- Average Remaining Contractual Life (years) Outstanding, December 31, 2021 3,421,724 $ 8.77 9.2 Granted 541,208 6.50 Cancelled (22,396) 8.50 Outstanding, December 31, 2022 3,940,536 8.46 8.4 Cancelled (293,615) 7.90 Outstanding, December 31, 2023 3,646,921 $ 8.50 6.9 Vested and exercisable and expected to vest, December 31, 2023 3,433,227 $ 8.54 6.7 Vested and exercisable, December 31, 2023 3,371,096 $ 8.57 6.8
Schedule of the Options Outstanding and Exercisable		The options outstanding and exercisable as of December 31, 2023 were as follows: Exercise Prices Number Outstanding Weighted-Average Remaining Contractual Life (years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $ 6.50 453,323 8.4 $ 6.50 341,559 $ 6.50 8.50 2,585,671 6.6 8.50 2,421,609 8.50 10.00 607,927 7.0 10.00 607,928 10.00 3,646,921 6.9 $ 8.50 3,371,096 $ 8.57
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions	The determination of the fair value of options granted during the three and nine months ended September 30, 2024 is computed using the Black-Scholes option pricing model with the following weighted-average assumptions: Stock price per share $ 0.74 Expected option term (years) 5.7 Expected volatility 67.9 % Risk-free rate of return 4.3 % Expected annual dividend yield — %	The determination of the fair value of options granted during the year ended December 31, 2022 is computed using the Black-Scholes option pricing model with the following weighted-average assumptions: 2022 Expected option term (years) 7.4 Expected volatility 69.1 % Risk-free rate of return 2.5 % Expected annual dividend yield —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	The following table shows stock-based compensation expense by functional area in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine months ended September 30, 2024 2023 2024 2023 Research and development $ 22,248 $ 26,313 $ 36,198 $ 78,941 Selling, general and administrative 104,955 169,162 129,989 533,789 $ 127,203 $ 195,475 $ 166,187 $ 612,730	The following table shows stock-based compensation expense by functional area in the consolidated statements of operations and comprehensive loss for the years ended December 31: 2023 2022 Research and development $ 105,255 $ 142,118 Selling, general and administrative 604,139 648,637 $ 709,394 $ 790,755

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description: Level September 30, 2024 December 31, 2023 Assets: Certificate of deposit 2 $ 20,000 $ 20,000 Liabilities: Warrant liability 2 $ 9,783 $ — Earnout liability 3 $ 700,000 $ — Derivative liability 3 $ 320,900 $ —
Fair Value Measurement Inputs and Valuation Techniques	Significant assumptions used in the valuation of the fair value of the earnout liability as of issuance on March 4, 2024 and as of September 30, 2024 were as follows: March 4, 2024 September 30, 2024 Fair value of common stock $ 3.53 $ 0.71 Volatility of revenue 26.0 % 23.0 % Discount rate applicable to revenue 7.0 % 7.0 % Risk-free rate 4.5 % 3.7 % Risk premium 2.5 % 3.3 % Cost of debt 15.5 % 15.5 % Credit risk spread 11.0 % 11.9 % Equity volatility 130.0 % 115.0 % Significant assumptions used in the valuation of the fair value of the derivative liability as of issuance on March 4, 2024 and as of September 30, 2024 were as follows: March 4, 2024 September 30, 2024 Fair value of common stock $ 3.53 $ 0.71 Term in years 1.25 1.23 Volatility 130.0 % 115.0 % Risk-free rate 4.9 % 3.9 % Debt discount 30.0 % 30.0 %
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation	The activity for the fair value of the warrant liability during the three and nine months ended September 30, 2024 was as follows: Warrant Liability Beginning balance, January 1, 2024 $ — Net liabilities assumed from GigCapital5 8,894 Change in fair value 23,123 Ending balance, March 31, 2024 32,017 Increase due to warrant modification 200,513 Change in fair value (213,942) Ending balance, June 30, 2024 18,588 Change in fair value (8,805) Ending balance, September 30, 2024 $ 9,783 The activity for the fair value of the earnout liability for the three and nine months ended September 30, 2024 was as follows: Earnout Liability Beginning balance, January 1, 2024 $ — Change in fair value 1,060,000 Ending balance, March 31, 2024 1,060,000 Change in fair value (310,000) Ending balance, June 30, 2024 750,000 Change in fair value (50,000) Ending balance, September 30, 2024 $ 700,000 The activity for the fair value of the derivative liability during the three and nine months ended September 30, 2024 was as follows: Derivative Liability Beginning balance, January 1, 2024 $ — Fair value at issuance 5,120,900 Change in fair value (2,983,100) Ending balance, March 31, 2024 2,137,800 Change in fair value (1,729,700) Ending balance, June 30, 2024 408,100 Change in fair value (87,200) Ending balance, September 30, 2024 $ 320,900
GIGCAPITAL5, INC
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis		The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2023 and 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description: Level December 31, 2023 December 31, 2022 Assets: Marketable securities held in Trust Account 1 $ — $ 41,561,656 Liabilities: Warrant liability 2 $ 7,950 $ 31,800 Note payable to related party at fair value 3 $ 1,506,389 $ 257,492
Schedule of Estimated Fair Value of Working Capital Note		The estimated fair value of the Working Capital Note was based on the following ranges of significant inputs at issuance for advances made under the Working Capital Note during the year ended December 31, 2023 and as of December 31, 2023 and 2022 for all advances made under the Working Capital Note: Assumptions At Issuance As of As of Expected term 0.7 - 0.8 0.7 0.9 Volatility 65 % 65.0 % 65.0 % Risk free rate 4.5% - 5.5% 5.1 % 4.7 % Discount rate 9.7% - 25.8% 11.3 % 24.4% - 29.4% Probability of conversion 25.0% - 55.0% 25.0 % 65.0 %
Schedule of Change in Fair Value of Warrant Liability and Working Capital Note		The following table presents information about the change in fair value of the Company’s Level 3 Working Capital Note during the years ended December 31, 2023 and 2022: Year Ended Year Ended Fair value - beginning of period $ 257,492 $ — Additions 1,240,000 260,000 Change in fair value 8,897 (2,508) Fair value - end of period $ 1,506,389 $ 257,492

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Line Items]
Schedule of Income before Income Tax, Domestic and Foreign	Loss before income tax expense consisted of the following for the years ended December 31: 2023 2022 United States $ (6,097,351) $ (6,254,468) International — — Total loss before income tax expense $ (6,097,351) $ (6,254,468)
Schedule of Components of Income Tax Expense (Benefit)	Income tax expense consisted of the following for the years ended December 31: 2023 2022 Current: Federal $ — $ — State 1,600 1,600 Foreign — — Total current tax expense 1,600 1,600 Deferred: Federal — — State — — Foreign — — Total deferred tax expense — — Total income tax expense $ 1,600 $ 1,600
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense differed from the amount computed by applying the federal statutory income tax rate to pretax loss as a result of the following for the years ended December 31: 2023 2022 Federal tax at statutory rate $ (1,280,444) $ (1,313,438) State taxes (22,915) (542,562) Change in valuation allowance 1,080,617 1,846,087 Other 224,342 11,513 Total income tax expense $ 1,600 $ 1,600
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are related to the following as of December 31: 2023 2022 Deferred tax assets: Net operating losses $ 3,070,085 $ 2,280,097 Stock-based compensation 856,902 784,932 Operating lease liabilities 386,588 516,031 Section 174 expenses, net 487,860 476,842 Accruals and reserves 489,382 227,221 Intangible assets 118,691 214,100 Property and equipment 90,104 44,128 Gross deferred tax assets 5,499,612 4,543,351 Valuation allowance (5,155,597) (4,074,980) Net deferred tax assets 344,015 468,371 Deferred tax liabilities: Operating lease right-of-use assets (344,015) (468,371) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is a follows as of December 31: 2023 2022 Balance as the beginning of the year $ 49,255 $ — Increases related to prior year tax positions — 47,882 Increases related to current year tax positions — 1,373 Balance as the end of the year $ 49,255 $ 49,255
GIGCAPITAL5, INC
Income Taxes [Line Items]
Schedule of Income before Income Tax, Domestic and Foreign	The sources of loss before provision for income taxes are as follows for the year ended December 31, 2023 and 2022: Year Ended Year Ended Domestic $ (3,605,472) $ (2,287,692) Foreign — — Total $ (3,605,472) $ (2,287,692)
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes was comprised of the following for the year ended December 31, 2023 and 2022: Year Ended Year Ended Current: Federal $ 285,990 $ 342,216 State and local 133,129 144,399 Foreign — — Total current 419,119 486,615 Deferred: Federal — — State and local — — Foreign — — Total deferred — — Total provision for income taxes $ 419,119 $ 486,615
Schedule of Effective Income Tax Rate Reconciliation	Reconciliation of the federal statutory income tax rate to the effective income tax rate is as follows: Year Ended Year Ended Statutory income tax benefit $ (757,149) $ (480,415) State income taxes, net of federal (236,036) (184,760) Warrant and note payable revaluation 47,377 (75,812) Valuation allowance on start-up costs 1,364,927 1,227,602 Provision for income taxes $ 419,119 $ 486,615
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities as of December 31, 2023 and 2022 were as follows: December 31, December 31, Deferred tax assets: Start-up costs $ 2,895,226 $ 1,530,299 Valuation allowance (2,895,226) (1,530,299) Net deferred tax assets (liabilities) $ — $ —

Description of Organization a_2

Description of Organization and Business Operations - Additional Information (Details) - USD ($)											1 Months Ended		3 Months Ended		9 Months Ended		11 Months Ended	12 Months Ended			14 Months Ended
	Mar. 04, 2024	Feb. 15, 2024	Jan. 04, 2024	Dec. 28, 2023	Sep. 28, 2023	Mar. 20, 2023	Nov. 30, 2022	Sep. 27, 2022	Sep. 28, 2021	Sep. 23, 2021	Dec. 31, 2023	Nov. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Feb. 20, 2024	Feb. 07, 2024	Dec. 13, 2023	Oct. 27, 2023	Aug. 28, 2023	Jul. 25, 2023	Jun. 26, 2023	Apr. 27, 2023	Mar. 28, 2023	Feb. 28, 2023	Feb. 27, 2023	Jan. 25, 2023	Dec. 27, 2022	Nov. 28, 2022	Oct. 26, 2022	Sep. 26, 2022	Sep. 23, 2022
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of common stock and warrants, net of issuance costs															$ 0	$ 1,017,850
Accumulated deficit											$ (17,770,145)		$ (32,122,605)		(32,122,605)				$ (17,770,145)	$ (11,671,194)	$ (17,770,145)
Net loss													$ (3,619,494)	$ (1,375,939)	(9,166,958)	(4,588,900)			(6,098,951)	(6,256,068)
Net cash used in operating activities															$ (8,806,402)	$ (1,965,772)			$ (2,651,143)	$ (3,861,735)
Description of trigger event based on common stock																			when the daily volume-weighted average price is less than $2.00 per share for five consecutive trading days.
Discription of having sufficient fund																			12 months
Common stock, par or stated value per share (in dollars per share)	$ 0.0001										$ 0.0001		$ 0.0001		$ 0.0001				$ 0.0001	$ 0.001	$ 0.0001
Sale of units description							In November 2022, the Company initiated an offering to sell to a select group of accredited investors only, on a private placement basis, 1,000,000 units for a purchase price of $4.00 per unit (the “Units”), each Unit consisting of one share of common stock and one warrant to purchase one share of common stock with an exercise price of $4.00 (the “2022 Offering”).
Sale of units in private placement (in shares)																					490,000
Monthly extension of amendment description																			The Company’s initial public offering prospectus and Amended and Restated Certificate of Incorporation provided that the Company initially had until September 28, 2022 (the date which was 12 months after the consummation of the Offering) to complete the Business Combination (the “Combination Period”). On September 23, 2022, the Company held a special meeting of its stockholders and the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation that extends the date by which the Company must consummate a Business Combination transaction from September 28, 2022 up to March 28, 2023 in one-month extensions (the “Extension”).
Description of proposals																			At the March special meeting, the stockholders approved two proposals: (A) to amend the Company’s Amended and Restated Certificate of Incorporation, giving the Company the right to extend the date by which it has to consummate a Business Combination up to six (6) times for an additional one (1) month each time, from March 28, 2023 to September 28, 2023 provided that the Sponsor (or its designees) must deposit into the Trust Account for each one-month extension funds equal to $100,000 (the “Second Extension”); (B) to amend the Company’s investment management trust agreement, dated as of September 23, 2021, by and between the Company and Continental Stock Transfer & Trust Company, allowing the Company to extend the Combination Period up to six (6) times for an additional one (1) month each time from March 28, 2023 to August 28, 2023 by depositing into the Trust Account for each one-month extension, the sum of $100,000.
Yorkville
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of units in private placement (in shares)	1,000,000
Funicular Funds
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from notes payable											$ 1,500,000
GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Date of incorporation																			Jan. 19, 2021
Percentage of shares sold during offering											4.30%								4.30%		4.30%
Issuance of common stock (in shares)									23,000,000
Proceeds from sale of common stock and warrants, net of issuance costs									$ 225,400,000	$ 30,000,000
Accumulated deficit											$ (17,104,720)								$ (17,104,720)	$ (13,080,129)	$ (17,104,720)
Net loss																			(4,024,591)	(2,774,307)
Net cash used in operating activities																			$ (1,944,104)	$ (1,261,550)
Description of trigger event based on common stock																			when the daily volume-weighted average price is less than $2.00 per share for five consecutive trading days
Discription of having sufficient fund																		12 months
Common stock, par or stated value per share (in dollars per share)										$ 0.0001	$ 0.0001								$ 0.0001	$ 0.0001	$ 0.0001
Number of public share per unit										1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)									$ 11.50	$ 11.50							$ 11.50
Sale of stock, price per share (in dollars per share)									$ 10
Transaction costs, net									$ 13,193,740										$ 25,000
Transaction costs																			$ 0	$ 85,000
Deferred underwriting fees									9,200,000
Offering costs									843,740
Reimbursement of offering expenses									$ 1,450,000
Number of public shares to be redeemed (in shares)					904,023						995,049								995,049		995,049
Amount withdrawn from trust account					$ 9,828,000														$ 10,449,625
Debt instrument, face amount																																					$ 960,000
Issued and outstanding common stock own percentage																			75.60%
US Government treasury bills maturity description																			U.S. government treasury bills with a maturity of one hundred and eighty-five (185) days or less
Public shares redemption percentage																			100%
Monthly extension fee payable																										$ 100,000					$ 160,000
GIGCAPITAL5, INC | Subsequent Event
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of restricted investments			$ 26,201
Debt instrument, periodic payment, interest		$ 0
Temporary equity, shares outstanding (in shares)																						848,003
Percentage of public units sold in offering																						3.70%
Proceeds from trust account																						$ 9,356,221
GIGCAPITAL5, INC | Subsequent Event | Non-Convertible Loan Working Capital Amendment
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount																							$ 262,247
GIGCAPITAL5, INC | Charter Amendment Proposal
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Extension fund amount					100,000
GIGCAPITAL5, INC | Trust Amendment Proposal
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Extension fund amount					$ 100,000
GIGCAPITAL5, INC | Funicular Funds
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from notes payable											$ 1,500,000
GIGCAPITAL5, INC | Extension Note
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par or stated value per share (in dollars per share)																																						$ 0.0001
Number of public shares to be redeemed (in shares)																																						18,985,950
Amount withdrawn from trust account								$ 192,138,312
Debt instrument, face amount											1,560,000								$ 1,560,000		$ 1,560,000					$ 100,000				$ 100,000
GIGCAPITAL5, INC | Extension Note | Sponsor
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount																																					160,000
GIGCAPITAL5, INC | Working Capital Note
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount											$ 1,500,000								$ 1,500,000		$ 1,500,000			$ 53,640	$ 381,360		$ 65,000	$ 130,000	$ 65,000	$ 130,000		$ 350,000	$ 65,000
Conversion price (in dollars per share)											$ 10								$ 10		$ 10
GIGCAPITAL5, INC | Working Capital Note | Sponsor
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount																																	$ 65,000	$ 65,000	$ 65,000	$ 65,000	$ 65,000
GIGCAPITAL5, INC | First Non-Convertible Working Capital Note | Sponsor
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount																								$ 66,360
GIGCAPITAL5, INC | Second Non-Convertible Working Capital Note | Subsequent Event | Non-Convertible Loan Working Capital Amendment
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount																							262,247
GIGCAPITAL5, INC | Second Non-Convertible Working Capital Note | Sponsor | Subsequent Event | Non-Convertible Loan Working Capital Amendment
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount																							195,887
GIGCAPITAL5, INC | Third Non Convertible Working Capital Note | Subsequent Event | Non-Convertible Loan Working Capital Amendment
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount		297,247																					$ 297,247
GIGCAPITAL5, INC | Third Non Convertible Working Capital Note | Sponsor | Subsequent Event | Non-Convertible Loan Working Capital Amendment
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Debt instrument, face amount		$ 35,000
Founders | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of stock, price per share (in dollars per share)									$ 10
Sale of units in private placement (in shares)									795,000
Proceeds from sale of units, net of underwriting discounts paid									$ 7,950,000
Wells Fargo Securities LLC | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Deferred underwriting fee waiver amount						$ 6,440,000
Equity Purchase Agreement | Yorkville
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of common stock and warrants, net of issuance costs											$ 40,000,000
Business combination, pre-paid advance received											9,005,000
Equity Purchase Agreement | GIGCAPITAL5, INC | Yorkville
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of common stock and warrants, net of issuance costs											40,000,000
Business combination, pre-paid advance received											9,005,000
Stock Subscription Agreement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net impact of the Merger on the condensed consolidated statement of stockholders' deficit	$ 500,000										500,000
Stock Subscription Agreement | Yorkville
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of common stock and warrants, net of issuance costs	40,000,000
Business combination, pre-paid advance received	$ 9,025,000
Stock Subscription Agreement | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net impact of the Merger on the condensed consolidated statement of stockholders' deficit											$ 500,000
Warrants | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of units description																			Each Public Unit consists of one share of the Company’s common stock (a “Public Share”), $0.0001 par value, and one redeemable warrant (a “Public Warrant”).
Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock (in shares)																89,532			100,000
Common stock, par or stated value per share (in dollars per share)											$ 0.001								$ 0.001		$ 0.001
Common Stock | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Stock redeemed or called during period, shares (in shares)				2,385
Temporary equity, shares outstanding (in shares)											2,114,978								2,114,978	4,014,050	2,114,978
Common Stock | Founders | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of common stock and warrants, net of issuance costs																	$ 25,000
Maximum | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net interest to pay dissolution expenses																			$ 100,000
Maximum | Common Stock | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)											$ 9.20								$ 9.20		$ 9.20
Over-Allotment Option | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock (in shares)									3,000,000
Proceeds from sale of common stock and warrants, net of issuance costs									$ 230,000,000
Private Placement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of stock, price per share (in dollars per share)							$ 11.67					$ 11.67
Sale of units in private placement (in shares)												342,703	0	0	0	89,532			261,250	228,750	167,925
Private Placement | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from sale of common stock and warrants, net of issuance costs									6,900,000
Sale of units description																			Each Private Placement Unit consists of one share of the Company’s common stock, par value $0.0001 per share, and one redeemable warrant.
Private Placement | GIGCAPITAL5, INC | Working Capital Note
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of units in private placement (in shares)																			150,000
Private Placement | Founders | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of units description																			Each Private Placement Unit consists of one share of the Company’s common stock and one warrant (a “Private Placement Warrant”).
Sale of stock, price per share (in dollars per share)																	$ 10
Sale of units in private placement (in shares)																	795,000
Number of shares of common stock per unit (in shares)																	1
Private Placement | Warrants | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of shares of common stock per unit (in shares)											1								1		1
Private Placement | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock (in shares)																			261,250	228,750
Private Placement | Common Stock | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par or stated value per share (in dollars per share)											$ 0.0001								$ 0.0001		$ 0.0001
Number of shares of common stock per unit (in shares)											1								1		1
Underwriter Fees | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Transaction costs									4,600,000
Underwriting Agreement | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock (in shares)										20,000,000
Proceeds from sale of common stock and warrants, net of issuance costs									$ 232,300,000	$ 200,000,000
Underwriting Agreement | Over-Allotment Option | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Underwriters option period										45 days
Underwriting Agreement | Over-Allotment Option | Minimum | GIGCAPITAL5, INC
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock (in shares)										3,000,000

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Total Customer | Accounts Receivable, Net
Disaggregation of Revenue [Line Items]
Concentration risk, percentage			96%		100%
Total Customer | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	96%	93%	98%	97%
Customer A | Accounts Receivable, Net
Disaggregation of Revenue [Line Items]
Concentration risk, percentage			96%
Customer A | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	96%		65%
Customer B | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage			23%
Customer C | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage			10%
Customer D, related party | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage				18%
Customer E | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage				14%
Customer F | Accounts Receivable, Net
Disaggregation of Revenue [Line Items]
Concentration risk, percentage					100%
Customer G | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage		77%		54%
Customer H | Revenue
Disaggregation of Revenue [Line Items]
Concentration risk, percentage		16%		11%

The Company and Summary of Si_5

The Company and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 955,970	$ 24,657	$ 4,032,168	$ 35,404	$ 40,355	$ 708,244
Product
Disaggregation of Revenue [Line Items]
Revenue	917,238	6,634	3,882,039	12,881	17,832	701,092
Service
Disaggregation of Revenue [Line Items]
Revenue	$ 38,732	$ 18,023	$ 150,129	$ 22,523	$ 22,523	$ 7,152

The Company and Summary of Si_6

The Company and Summary of Significant Accounting Policies - Revenue from External Customers by Geographic Areas (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Revenue from External Customer [Line Items]
Revenue	$ 955,970	$ 24,657	$ 4,032,168	$ 35,404	$ 40,355	$ 708,244
United States
Revenue from External Customer [Line Items]
Revenue	942,265	20,759	4,000,590	31,506	35,165	7,200
International
Revenue from External Customer [Line Items]
Revenue	$ 13,705	$ 3,898	$ 31,578	$ 3,898	$ 5,190	$ 701,044

The Company and Summary of Si_7

The Company and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	46,088,569	2,266,568	10,785,872	5,560,876
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	23,889,364	401,389	1,231,484	905,470
Options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	2,072,000	1,350,432	3,646,922	3,940,536
Potential shares from convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	250,224	254,328	2,073,554	714,870
Subscription agreements
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)			3,833,912	0
Potential shares from Pre-Paid Advance
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	10,126,981	0
Merger consideration earnout shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	9,000,000	0
Potential shares from Cable Car Loan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	750,000	0
Contingently issuable shares to GigCapital5 stockholders
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	260,419

The Company and Summary of Si_8

The Company and Summary of Significant Accounting Policies - Summary of Net Loss Per Common Share Basic and Diluted (Details) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2024		Sep. 30, 2023		Sep. 30, 2024		Sep. 30, 2023		Dec. 31, 2023	Dec. 31, 2022
Numerator
Net loss and comprehensive loss attributable to QT Imaging Holdings, Inc.	$ (3,619,494)		$ (1,375,939)		$ (9,166,958)		$ (4,588,900)		$ (6,097,351)	$ (6,254,468)
Less: deemed dividend related to the modification of equity classified warrants	0		0		(5,185,502)		0
Net loss and comprehensive loss attributable to common stockholders	(3,619,494)		(1,375,939)		(14,352,460)		(4,588,900)
Net loss	$ (3,619,494)		$ (1,375,939)		$ (9,166,958)		$ (4,588,900)		$ (6,098,951)	$ (6,256,068)
Denominator
Weighted average common shares outstanding, basic (in shares)	21,441,416	[1]	9,541,643	[1]	18,712,468	[1]	9,533,185	[1]	27,815,913	27,364,975
Weighted average common shares outstanding, diluted (in shares)	21,441,416	[1]	9,541,643	[1]	18,712,468	[1]	9,533,185	[1]	27,815,913	27,364,975
Net loss per share common share, basic (in dollars per share)	$ (0.17)	[1]	$ (0.14)	[1]	$ (0.77)	[1]	$ (0.48)	[1]	$ (0.22)	$ (0.23)
Net loss per share common share, diluted (in dollars per share)	$ (0.17)	[1]	$ (0.14)	[1]	$ (0.77)	[1]	$ (0.48)	[1]	$ (0.22)	$ (0.23)
Common Stock Subject to Possible Redemption
Denominator
Weighted average common shares outstanding, basic (in shares)									3,020,634	17,954,419
Net loss per share common share, basic (in dollars per share)									$ 0.37	$ 0.06
Non-Redeemable Common Stock
Denominator
Weighted average common shares outstanding, basic (in shares)									6,540,000	6,540,000
Net loss per share common share, basic (in dollars per share)									$ (0.78)	$ (0.60)
GIGCAPITAL5, INC
Numerator
Net loss and comprehensive loss attributable to QT Imaging Holdings, Inc.									$ (3,605,472)	$ (2,287,692)
Net loss and comprehensive loss attributable to common stockholders									(5,132,332)	(3,918,090)
Net loss									(4,024,591)	(2,774,307)
Net income attributable to common stock subject to possible redemption									$ 1,107,741	$ 1,143,783
Denominator
Weighted average common shares outstanding, basic (in shares)									6,540,000	6,540,000
Weighted average common shares outstanding, diluted (in shares)									6,540,000	6,540,000
Net loss per share common share, basic (in dollars per share)									$ (0.78)	$ (0.60)
Net loss per share common share, diluted (in dollars per share)									$ (0.78)	$ (0.60)
GIGCAPITAL5, INC | Common Stock Subject to Possible Redemption
Numerator
Interest earned on marketable securities held in Trust Account, net of taxes									$ 1,107,741	$ 1,143,783
Net income attributable to common stock subject to possible redemption									$ 1,107,741	$ 1,143,783
Denominator
Weighted average common shares outstanding, basic (in shares)									3,020,634	17,954,419
Weighted average common shares outstanding, diluted (in shares)									3,020,634	17,954,419
Net loss per share common share, basic (in dollars per share)									$ 0.37	$ 0.06
Net loss per share common share, diluted (in dollars per share)									$ 0.37	$ 0.06
GIGCAPITAL5, INC | Non-Redeemable Common Stock
Numerator
Net loss									$ (4,024,591)	$ (2,774,307)
Net income attributable to common stock subject to possible redemption									(1,107,741)	(1,143,783)
Net loss attributable to non-redeemable common stock									$ (5,132,332)	$ (3,918,090)
Denominator
Weighted average common shares outstanding, diluted (in shares)									6,540,000	6,540,000
Net loss per share common share, diluted (in dollars per share)									$ (0.78)	$ (0.60)
[1] Amounts for the three and nine months ended September 30, 2023 and before that date differ from those in prior year condensed consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).

The Company and Summary of Si_9

The Company and Summary of Significant Accounting Policies - Narrative (Details)										1 Months Ended			3 Months Ended		9 Months Ended		10 Months Ended	12 Months Ended		14 Months Ended
	Feb. 15, 2025 USD ($)	Jan. 15, 2025 USD ($)	Nov. 04, 2024 USD ($)	Sep. 11, 2024 USD ($) $ / shares	Mar. 04, 2024 USD ($) trading_day $ / shares shares	Dec. 13, 2023 USD ($) shares	Nov. 15, 2023 USD ($) shares	Nov. 10, 2023 USD ($) $ / shares shares	Mar. 20, 2023 USD ($)	Dec. 31, 2023 USD ($) shares	Sep. 30, 2023 USD ($)	Nov. 30, 2022 $ / shares shares	Sep. 30, 2024 USD ($) note $ / shares shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($) component note $ / shares shares	Sep. 30, 2023 USD ($) shares	Nov. 15, 2025 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2023 USD ($) shares	Nov. 12, 2024 USD ($)	Oct. 31, 2024 $ / shares	Dec. 19, 2023 USD ($) shares	Nov. 30, 2023 USD ($)	Dec. 31, 2021 USD ($)
Property, Plant and Equipment [Line Items]
Restricted cash and cash equivalents										$ 20,000								$ 20,000	$ 20,000	$ 20,000
Other assets, fair value disclosure										20,000								20,000	20,000	20,000
Contract with customer asset net current										0								0	0	0
Product warranty obligation, term													12 months		12 months
Research and development													$ 925,214	$ 311,829	$ 2,492,842	$ 1,083,373		1,485,636	2,386,086
Accumulated deficit										17,770,145			32,122,605		32,122,605			17,770,145	11,671,194	$ 17,770,145
Net cash used in operating activities															8,806,402	1,965,772		2,651,143	3,861,735
Net loss													$ 3,619,494	1,375,939	9,166,958	4,588,900		$ 6,098,951	6,256,068
Sale of stock, number of shares issued in transaction (in shares) | shares																				490,000
Proceeds from sale of common stock and warrants, net of issuance costs															$ 0	1,017,850
Description of trigger event based on common stock																		when the daily volume-weighted average price is less than $2.00 per share for five consecutive trading days.
Discription of having sufficient fund																		12 months
Factor to be considered for receiving shares in the new company											0.15
Business combination, exchange ratio					34.27%
Triggered event, daily volume-weighted average price per share (in dollars per share) | $ / shares					$ 0.8768
Number of consecutive trading days | trading_day					5
Payment term range, cash in advance, duration													30 days		30 days
Number of clinics | note													2		6
Number of components | component															600
Number of dependent components | component															5
Restricted cash equivalents										20,000			$ 20,000		$ 20,000			$ 20,000		$ 20,000
Allowance for credit loss										0			0		0			0		0
Finance lease, right-of-use asset, after accumulated amortization										0			0		0			0		0
Asset impairment charges													0	0	0	0
Contract with customer, liability										347,619			19,841		19,841			347,619	0	347,619
Contract with customer, asset										0			0		0			0		0
Income tax examination, penalties and interest accrued											$ 0		$ 0	$ 0	$ 0	$ 0
Unrecognized tax benefits										49,255								49,255	49,255	49,255					$ 0
Share price (in dollars per share) | $ / shares													$ 0.74		$ 0.74
Long-term debt													$ 10,483,292		$ 10,483,292
Contract with customer, liability, revenue recognized													11,905		27,778
GIGCAPITAL5, INC
Property, Plant and Equipment [Line Items]
Cash equivalents										$ 0								0	$ 0	$ 0
Offering costs charged to stockholders' deficit upon completion of offering																		$ 13,193,740
Issued and outstanding subject to possible redemption | shares										2,114,978								2,114,978	4,014,050	2,114,978
Unrecognized tax benefits										$ 0								$ 0	$ 0	$ 0
Amount accrued for payment of interest and penalties										0								0	$ 0	0
Exit Strategy Partners, LLC
Property, Plant and Equipment [Line Items]
Stock issued during period, shares, issued for services (in shares) | shares						250,000
Consideration paid along the business combination						$ 125,000
Consideration payable on the first anniversary of business combination						100,000
Stock issued during period, value, issued for services						$ 225,000
Related Party
Property, Plant and Equipment [Line Items]
Contract with customer, liability										300,000			0		0			300,000		300,000
Related Party | Subsequent Event | Private Investment Public Entity Agreement
Property, Plant and Equipment [Line Items]
Common stock, value, subscriptions																					$ 2,560,000
Certificate of deposit | Fair Value, Inputs, Level 2
Property, Plant and Equipment [Line Items]
Certificate of deposit										20,000			$ 20,000		$ 20,000			$ 20,000		$ 20,000
Customer One | Revenue Benchmark | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration risk, percentage																		49%	98%
Customer One | Accounts Receivable, Net | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration risk, percentage																		100%
Stock Subscription Agreement
Property, Plant and Equipment [Line Items]
Net impact of the Merger on the condensed consolidated statement of stockholders' deficit					$ 500,000					500,000
Yorkville
Property, Plant and Equipment [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares					1,000,000
Yorkville | Equity Purchase Agreement
Property, Plant and Equipment [Line Items]
Business combination, pre-paid advance received										9,005,000
Proceeds from sale of common stock and warrants, net of issuance costs										40,000,000
Yorkville | Stock Subscription Agreement
Property, Plant and Equipment [Line Items]
Business combination, pre-paid advance received					$ 9,025,000
Proceeds from sale of common stock and warrants, net of issuance costs					40,000,000
Funicular Funds
Property, Plant and Equipment [Line Items]
Proceeds from the Merger, net of transaction costs										$ 1,500,000
Funicular Funds, LP
Property, Plant and Equipment [Line Items]
Proceeds from the Merger, net of transaction costs					$ 1,500,000
Private Placement
Property, Plant and Equipment [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares												342,703	0	0	0	89,532		261,250	228,750	167,925
Sale of stock, price per share (in dollars per share) | $ / shares												$ 11.67
Bridge Loan
Property, Plant and Equipment [Line Items]
Debt instrument face value								$ 1,000,000																$ 200,000
Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares										1,369,255								1,369,255		1,369,255
Share price (in dollars per share) | $ / shares					$ 2
Long-term debt										$ 774,337			$ 0		$ 0			$ 774,337		$ 774,337
Yorkville Pre-paid Advance | Yorkville
Property, Plant and Equipment [Line Items]
Pre-paid advance agreement					$ 10,000,000
Debt instrument, convertible, triggered periodic payment				$ 1,521,581
Debt instrument, convertible, triggered principal amount				$ 1,145,407	$ 1,500,000
Share price (in dollars per share) | $ / shares				$ 0.8768
Yorkville Pre-paid Advance | Yorkville | Subsequent Event
Property, Plant and Equipment [Line Items]
Share price (in dollars per share) | $ / shares																						$ 0.50
Conversion of stock, amount converted			$ 254,593
Long-term debt			$ 8,600,000
Yorkville Pre-paid Advance | Yorkville | Forecast
Property, Plant and Equipment [Line Items]
Debt instrument, convertible, triggered periodic payment	$ 500,000	$ 500,000															$ 500,000
Securities Purchase Agreement | Bridge Loan
Property, Plant and Equipment [Line Items]
Debt instrument face value								$ 1,000,000
Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares								500,000
Percentage cash option value at the date maturity								120%
Securities Purchase Agreement | Bridge Loan | Meteora Capital Partners LP
Property, Plant and Equipment [Line Items]
Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares								50,000
Merger earnout consideration shares | GIGCAPITAL5, INC
Property, Plant and Equipment [Line Items]
Debt instrument face value																							$ 500,000
Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares								1,200,000															200,000
Additional common stock shares issuable and convertible into shares of the company upon consummation of business combination | shares								50,000
Proceeds from sale of common stock and warrants, net of issuance costs								$ 3,000,000
Fourth Amendment | Private Placement | US Capital Global QT Imaging LLC
Property, Plant and Equipment [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares								25,000
Sale of stock, price per share (in dollars per share) | $ / shares								$ 2.50
Fourth Amendment | Bridge Loan | Private Placement | US Capital Global QT Imaging LLC
Property, Plant and Equipment [Line Items]
Debt instrument face value								$ 200,000
Sale of stock, number of shares issued in transaction (in shares) | shares								35,329
Sale of stock, price per share (in dollars per share) | $ / shares								$ 2.50
Commission payable on warrant								$ 20,000
Equity Purchase Agreement | YA II PN Ltd
Property, Plant and Equipment [Line Items]
Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares							1,000,000
Common stock shares subscribed but unissued value							$ 50,000,000
Debt instrument term							36 months
Additional debt instrument							$ 10,000,000
Patents
Property, Plant and Equipment [Line Items]
Useful Life										12 years	12 years		12 years	12 years	12 years	12 years		12 years	12 years	12 years
Wells Fargo Securities LLC | GIGCAPITAL5, INC
Property, Plant and Equipment [Line Items]
Deferred underwriting fee waiver amount									$ 6,440,000
Mr Weightman | GIGCAPITAL5, INC
Property, Plant and Equipment [Line Items]
Issuance of shares subject to forfeiture | shares																		5,000

Inventory - Schedule of Inven_2

Inventory - Schedule of Inventory, Current (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 2,600,114	$ 2,529,364	$ 2,567,311
Work in process	74,540	1,627,802	1,683,341
Finished Goods	506,900	261,031	528,254
Inventory	$ 3,181,554	$ 4,418,197	$ 4,778,906

Business Combination and Rela_2

Business Combination and Related Agreement - Additional Information (Details) - USD ($)	Dec. 08, 2022	Sep. 30, 2024	Mar. 04, 2024	Dec. 31, 2023	Dec. 31, 2022	Sep. 23, 2021
Business Acquisition [Line Items]
Common stock, par or stated value per share (in dollars per share)		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.001
GIGCAPITAL5, INC
Business Acquisition [Line Items]
Common stock, par or stated value per share (in dollars per share)				$ 0.0001	$ 0.0001	$ 0.0001
GIGCAPITAL5, INC | PIPE Subscription Agreements | Maximum
Business Acquisition [Line Items]
Aggregate gross proceed under agreements	$ 26,000,000
GIGCAPITAL5, INC | Business Combination Agreement
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Dec. 08, 2022
Business acquisition, share price (in dollars per share)	$ 0.001
Common stock, par or stated value per share (in dollars per share)	$ 0.0001

Business Combination - Narrativ

Business Combination - Narrative (Details)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

14 Months Ended

15 Months Ended

Sep. 30, 2026 milestone $ / shares shares

Sep. 30, 2025 placement shares

Sep. 30, 2024 USD ($) placement shares

Mar. 04, 2024 USD ($) shares

Dec. 13, 2023 USD ($) shares

Sep. 21, 2023 shares

Feb. 29, 2024 USD ($) agreement $ / shares shares

Sep. 30, 2024 USD ($) placement

Sep. 30, 2024 USD ($) placement

Sep. 30, 2026 USD ($) milestone $ / shares shares

Sep. 30, 2025 USD ($) placement shares

Dec. 31, 2023 USD ($) shares

Sep. 30, 2024 USD ($) placement shares

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

490,000

Debt amount

$ 4,357,201

Less: GigCapital5 transaction costs paid from Trust

$ 1,073,667

Number of additional subscription agreement | agreement

2

Earnout liability

$ 700,000

$ 700,000

$ 700,000

$ 0

$ 700,000

Merger Earnout Consideration Shares

Schedule Of Reverse Recapitalization [Line Items]

Contingent consideration, liability, shares (in shares) | shares

9,000,000

2024 Earnout Shares

Schedule Of Reverse Recapitalization [Line Items]

Contingent consideration, liability, shares (in shares) | shares

2,500,000

3,000,000

Contingent consideration, liability, additional shares (in shares) | shares

500,000

Number of placements | placement

8

8

8

8

Contingent consideration, liability, achieved revenue

$ 4,400,000

2025 Earnout Shares | Forecast

Schedule Of Reverse Recapitalization [Line Items]

Contingent consideration, liability, shares (in shares) | shares

2,500,000

3,000,000

Contingent consideration, liability, additional shares (in shares) | shares

500,000

Number of placements | placement

4

4

Contingent consideration, liability, achieved revenue

$ 17,100,000

2026 Earnout Shares | Forecast

Schedule Of Reverse Recapitalization [Line Items]

Contingent consideration, liability, shares (in shares) | shares

2,500,000

3,000,000

Contingent consideration, liability, additional shares (in shares) | shares

500,000

Contingent consideration, liability, achieved revenue

$ 30,000,000

Contingent consideration, liability, earnout period, stock price trigger (in dollars per share) | $ / shares

$ 15

$ 15

Number of milestones achieved | milestone

1

1

Contingent consideration, liability, earnout period, threshold trading days

20 days

Contingent consideration, liability, earnout period, threshold trading day period

30 days

Subscription Agreement And Business Combination Agreement

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

200,000

Consideration received on transaction

$ 500,000

Stock Subscription Agreements

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

150,000

General and Administrative Expense | Subscription Agreement And Business Combination Agreement

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

$ 0

$ 206,000

General and Administrative Expense | Stock Subscription Agreements

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

0

529,500

Yorkville Pre-paid Advance

Schedule Of Reverse Recapitalization [Line Items]

Pre-paid advance agreement, term

15 months

Debt instrument, interest rate, stated percentage

6%

Interest increase upon default

18%

Issuance of common stock (in shares) | shares

1,000,000

Potential shares from Cable Car Loan

Schedule Of Reverse Recapitalization [Line Items]

Debt instrument, interest rate, stated percentage

0%

Debt amount

$ 1,500,000

Debt, term

13 months

Issuance of common stock (in shares) | shares

180,000

Yorkville

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

1,000,000

Yorkville | Yorkville Pre-paid Advance

Schedule Of Reverse Recapitalization [Line Items]

Pre-paid advance agreement

$ 10,000,000

William Blair & Co., L.L.C.

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

740,000

Assumed liabilities settled

2,410,000

William Blair & Co., L.L.C. | General and Administrative Expense

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

0

202,200

Mizuho Securities USA, LLC

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

100,000

Assumed liabilities settled

250,000

Number of non-redemption agreement | agreement

1

Consideration received on transaction

$ 250,000

Mizuho Securities USA, LLC | General and Administrative Expense

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

0

103,000

Donnelley Financial Solutions, LLC

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

200,000

Consideration received on transaction

$ 500,000

IB Capital LLC

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

240,000

Consideration received on transaction

$ 600,000

Donnelley Financial Solutions, LLC and IB Capital LLC

Schedule Of Reverse Recapitalization [Line Items]

Assumed liabilities settled

1,100,000

Donnelley Financial Solutions, LLC and IB Capital LLC | General and Administrative Expense

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

0

453,200

LionBay Ventures

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

10,000

Business acquisition, number of common stock purchased (in shares) | shares

17,000

Business acquisition, strike price per share (in dollars per share) | $ / shares

$ 8.50

LionBay Ventures | General and Administrative Expense

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

0

35,300

Exit Strategy Partners, LLC

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

250,000

Payment for professional fees

125,000

$ 225,000

Accrued professional fees

$ 100,000

Exit Strategy Partners, LLC | General and Administrative Expense

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

0

1,107,500

Non-Redeeming Shareholders | September 2023 Non-Redemption

Schedule Of Reverse Recapitalization [Line Items]

Sale of stock, number of shares issued in transaction (in shares) | shares

427,477

Non-Redeeming Shareholders | General and Administrative Expense | September 2023 Non-Redemption

Schedule Of Reverse Recapitalization [Line Items]

Less: GigCapital5 transaction costs paid from Trust

$ 0

$ 1,508,994

Business Combination - Schedule

Business Combination - Schedule of Business Acquisitions, by Acquisition (Details) - USD ($)		9 Months Ended
	Mar. 04, 2024	Sep. 30, 2024	Sep. 30, 2023
Reverse Recapitalization [Abstract]
Cash in GigCapital5 Trust Account, net of redemptions	$ 13,952,525
Plus: cash in GigCapital5 operating bank account	4,829
Less: Payments made pursuant to non-redemption agreements	(10,791,550)
Less: GigCapital5 transaction costs paid from Trust	(1,073,667)
Less: Repayment of GigCapital5 related party notes	(853,607)
Proceeds from the Merger, net of transaction costs	1,238,530	$ 1,238,530	$ 0
Assumed net liabilities from GigCapital5, excluding net cash proceeds	(10,507,695)
Net impact of the Merger on the condensed consolidated statement of stockholders' deficit	$ (9,269,165)

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Sep. 30, 2024	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,213,649	$ 4,192,831	$ 4,938,768
Less: accumulated depreciation	(4,722,729)	(4,070,679)	(4,441,021)
Property and equipment, net	$ 490,920	$ 122,152	497,747
Scanners
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Property, plant and equipment, gross	$ 3,309,957	$ 2,254,548	3,047,841
Computer and lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,359,491	$ 1,384,307	1,346,726
Computer and lab equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years	3 years
Computer and lab equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years	5 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plants and equipment useful life	Various
Property, plant and equipment, gross	$ 421,266	$ 421,266	421,266
Software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years	3 years
Property, plant and equipment, gross	$ 40,599	$ 50,374	40,599
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years	7 years
Property, plant and equipment, gross	$ 82,336	$ 82,336	$ 82,336

Property and Equipment, Net - N

Property and Equipment, Net - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 19,508	$ 76,351	$ 114,144	$ 216,272	$ 294,813	$ 465,869

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets (Details) - Patents - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years	12 years	12 years
Gross Carrying Value	$ 2,230,570	$ 2,230,570	$ 2,230,570	$ 2,230,570
Accumulated Amortization	2,230,570	2,140,431	2,140,431	1,954,550
Net Carrying Value	$ 0	$ 90,139	$ 90,139	$ 276,020
Useful Life Remaining	0 years	6 months	6 months	1 year 6 months

Intangible Assets, Net - Narrat

Intangible Assets, Net - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 0	$ 46,470	$ 90,139	$ 139,410	$ 185,881	$ 185,881

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 90,139

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Offsetting [Abstract]
Prepaid insurance	$ 432,170	$ 9,808
Other	343,415	205,171
Prepaid expenses and other current assets	$ 775,585	$ 214,979	$ 98,876

Balance Sheet Details - Sched_2

Balance Sheet Details - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Offsetting [Abstract]
Accrued legal	$ 1,900,000	$ 24,729
Accrued personnel costs	899,796	120,856
Accrued excise taxes	202,341	0
Accrued advisory fee	100,000	0
Other	262,080	224,066
Accrued expenses and other current liabilities	$ 3,364,217	$ 369,651	$ 368,366

Offering - Additional Informati

Offering - Additional Information (Details) - USD ($)			12 Months Ended
	Nov. 30, 2022	Sep. 28, 2021	Dec. 31, 2023	Dec. 31, 2021	Sep. 23, 2021
Class of Stock [Line Items]
Sale of units description	In November 2022, the Company initiated an offering to sell to a select group of accredited investors only, on a private placement basis, 1,000,000 units for a purchase price of $4.00 per unit (the “Units”), each Unit consisting of one share of common stock and one warrant to purchase one share of common stock with an exercise price of $4.00 (the “2022 Offering”).
GIGCAPITAL5, INC
Class of Stock [Line Items]
Issuance of common stock (in shares)		23,000,000
Sale of stock, price per share (in dollars per share)		$ 10
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 11.50		$ 11.50	$ 11.50
Minimum price per share required for redemption of warrants (in dollars per share)			$ 18
GIGCAPITAL5, INC | IPO
Class of Stock [Line Items]
Issuance of common stock (in shares)		23,000,000
Sale of stock, price per share (in dollars per share)		$ 10
GIGCAPITAL5, INC | Warrants
Class of Stock [Line Items]
Sale of units description			Each Public Unit consists of one share of the Company’s common stock (a “Public Share”), $0.0001 par value, and one redeemable warrant (a “Public Warrant”).
Period after business combination when warrants become exercisable			30 days
Warrants exercisable expiration period after completion of business combination			5 years
Period after offering when warrants become exercisable			12 months
Period allotted to complete the business combination			30 months
Net cash settlement value of warrants			$ 0
Redemption price per warrant			$ 0.01
Minimum period of prior written notice of redemption of warrants			30 days
Minimum price per share required for redemption of warrants (in dollars per share)			$ 18
GIGCAPITAL5, INC | Warrants | IPO
Class of Stock [Line Items]
Number of shares of common stock per unit (in shares)		1

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued expenses consisted (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued vacation	$ 55,683	$ 91,125
Accrued wages	65,173	80,904
Accrued legal	24,729	79,691
Accrued interest	50,037	0
Other	174,029	116,646
Total	$ 369,651	$ 368,366

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details)										3 Months Ended	9 Months Ended		10 Months Ended	12 Months Ended		14 Months Ended
	Feb. 15, 2025 USD ($)	Jan. 15, 2025 USD ($)	Sep. 11, 2024 USD ($) trading_day $ / shares	Mar. 04, 2024 USD ($) trading_day $ / shares shares	Nov. 15, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 14, 2021 USD ($)	Feb. 24, 2021 USD ($)	May 05, 2020 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2024 USD ($) trading_day $ / shares	Sep. 30, 2023 USD ($)	Nov. 15, 2025 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	Sep. 26, 2024	Nov. 30, 2023 USD ($)	Nov. 10, 2023 USD ($) $ / shares	Jun. 07, 2021
Short-Term Debt [Line Items]
Proceeds from issuance of long-term debt											$ 10,525,000	$ 0		$ 800,000	$ 348,760
Long term debt, gross														4,357,201		$ 4,357,201
Long-term debt, current maturities														4,199,362		4,199,362
Long term debt, excluding current maturities														$ 95,982		$ 95,982
Debt instrument, interest rate during period						12%
Debt instrument, maturity date														Jul. 06, 2024
Shares issued (in shares) | shares														1,231,574		1,231,574
Gain (loss) on extinguishment of debt														$ (376,086)	0
Unamortized debt issuance expense										$ 6,127,060	6,127,060			61,857		$ 61,857
Long-term debt										$ 10,483,292	$ 10,483,292
Amortization of debt issuance costs														66,367	39,923
Share price (in dollars per share) | $ / shares										$ 0.74	$ 0.74
Debt instrument, convertible, threshold trading days | trading_day											3
Sale of stock, number of shares issued in transaction (in shares) | shares																490,000
Debt instrument, convertible, threshold consecutive trading days | trading_day											5
Yorkville
Short-Term Debt [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares				1,000,000
Bridge Loan
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage																		0%
Debt instrument, face amount																		$ 200,000	$ 1,000,000
Interest expense for loan										$ 0	$ 25,663
Unamortized debt issuance expense														$ 25,663		$ 25,663
Debt instrument face amount with no interest rate																			$ 200,000
Percentage of cash option value of debt instrument at the date maturity																			120%
Cash option value of debt instrument at the date maturity																			$ 240,000
Conversion price (in dollars per share) | $ / shares																			$ 2
Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares														1,369,255		1,369,255
Long-term debt										0	0			$ 774,337		$ 774,337
Debt instrument, unamortized discount (premium) and debt issuance costs, net														25,663		$ 25,663
Amortization of debt issuance costs														$ 21,592
Share price (in dollars per share) | $ / shares				$ 2
Yorkville Pre-paid Advance
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage				6%
Interest expense for loan										1,244,332	2,431,398
Outstanding amount										2,980,159	2,980,159
Derivative liability										5,874,434	5,874,434
Interest payable										24,744	24,744
Unamortized discount										$ 5,120,900	$ 5,120,900
Yorkville Pre-paid Advance | Forecast | Omnibus Agreement | Yorkville
Short-Term Debt [Line Items]
Sale of stock, percentage of ownership after transaction													100%
Sale of stock, number of shares issued in transaction (in shares) | shares													4,000
Yorkville Pre-paid Advance | Yorkville
Short-Term Debt [Line Items]
Share price (in dollars per share) | $ / shares			$ 0.8768
Debt instrument, convertible, triggered measuring period				6 months
Debt instrument, convertible, triggered periodic payment			$ 1,521,581
Debt instrument, convertible, triggered percentage			50%	50%
Debt instrument, convertible, triggered principal amount			$ 1,145,407	$ 1,500,000
Debt instrument, convertible, triggered periodic payment interest			318,904
Debt instrument, convertible, triggered periodic payment, early premium			$ 57,270
Debt instrument, convertible, triggered periodic payment, premium, percentage			5%	5%						5%	5%
Debt instrument, convertible, triggered, extended measuring period																	6 months
Yorkville Pre-paid Advance | Yorkville | Forecast
Short-Term Debt [Line Items]
Debt instrument, convertible, triggered periodic payment	$ 500,000	$ 500,000											$ 500,000
Debt instrument, convertible, periodic payment, premium, percentage		5%
Yorkville Pre-paid Advance | Yorkville | Trigger Scenario One
Short-Term Debt [Line Items]
Debt instrument, convertible, threshold trading days | trading_day				5
Debt instrument, convertible, threshold consecutive trading days | trading_day				7
Yorkville Pre-paid Advance | Yorkville | Trigger Scenario Two
Short-Term Debt [Line Items]
Debt instrument, convertible, triggered percentage				50%
Debt instrument, convertible, threshold consecutive trading days | trading_day				5
Debt instrument, convertible, daily volume-weighted average price, floor price, percentage				110%
Yorkville Pre-paid Advance | Yorkville | Trigger Scenario Three
Short-Term Debt [Line Items]
Debt instrument, convertible, triggered percentage				50%
Debt instrument, convertible, threshold trading day for price triggered | trading_day				1
Yorkville Pre-paid Advance | Yorkville | Trigger Scenario Four
Short-Term Debt [Line Items]
Debt instrument, convertible, threshold trading days | trading_day			5
Debt instrument, convertible, triggered measuring period			6 months
Convertible Note
Short-Term Debt [Line Items]
Shares issued (in shares) | shares														60,329		60,329
Proceeds from convertible debt														$ 15,000,000
Debt instrument conversion price per share percentage														90%		90%
Debt instrument, increase, accrued interest														$ 635,854
Gain (loss) on extinguishment of debt														$ 376,086
Commission paid for debt instrument | $ / shares														$ 20,000		$ 20,000
Debt issuance costs, net														$ 32,828		$ 32,828
Fair value of common stock covered by warrants or rights														156,505		156,505
US Capital Note
Short-Term Debt [Line Items]
Debt instrument, increase, accrued interest														50,037
Debt instrument interest expenses														340,758	326,255
Unamortized debt issuance expense														$ 36,194	$ 68,737	$ 36,194
Common Stock
Short-Term Debt [Line Items]
Shares issued (in shares) | shares														14,854		14,854
Exercise price range three
Short-Term Debt [Line Items]
Shares issued (in shares) | shares														10,329		10,329
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 4.25		$ 4.25
Exercise price range three | Common Stock
Short-Term Debt [Line Items]
Shares issued (in shares) | shares														10,329		10,329
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 4.25		$ 4.25
Exercise Price Range Four
Short-Term Debt [Line Items]
Shares issued (in shares) | shares														494,525		494,525
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 4		$ 4
Exercise Price Range Four | Common Stock
Short-Term Debt [Line Items]
Shares issued (in shares) | shares														4,525		4,525
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 4		$ 4
Convertible Promissory Note Agreement | US Capital Global QT Imaging LLC
Short-Term Debt [Line Items]
Payment as advance of debt instrument						$ 10,000,000
Fourth Amendment | US Capital Global QT Imaging LLC | Convertible Note
Short-Term Debt [Line Items]
Debt instrument outstanding | shares														2,495,000		2,495,000
Fourth Amendment | US Capital Global QT Imaging LLC | US Capital Note
Short-Term Debt [Line Items]
Debt instrument outstanding | shares														3,294,659	2,426,263	3,294,659
Paycheck Protection Program Loan
Short-Term Debt [Line Items]
Percentage of the loan and related interest was forgivable																				100%
Interest expense for loan														$ 3,004	$ 4,305
Paycheck Protection Program Loan 1
Short-Term Debt [Line Items]
Proceeds from issuance of long-term debt									$ 1,158,266
Long term debt, gross														285,115		$ 285,115
Debt instrument, periodic payment														$ 6,400
Debt instrument, interest rate, stated percentage														1%		1%
Debt instrument, date of first required payment														Aug. 05, 2021
Debt instrument, face amount														$ 107,979	183,273	$ 107,979
Long-term debt, current maturities														76,058	75,294	76,058
Long term debt, excluding current maturities														31,921	107,979	31,921
Paycheck Protection Program Loan 1 | Principal amount of PPP Loan
Short-Term Debt [Line Items]
Debt forgiveness amount							$ 873,151
Paycheck Protection Program Loan 1 | Interest amount of PPP Loan
Short-Term Debt [Line Items]
Debt forgiveness amount							$ 9,823
Paycheck Protection Program Loan 2
Short-Term Debt [Line Items]
Proceeds from issuance of long-term debt								$ 1,158,265
Long term debt, gross														228,019		$ 228,019
Debt instrument, periodic payment														$ 4,605
Debt instrument, interest rate, stated percentage														1%		1%
Debt instrument, date of first required payment														Dec. 27, 2021
Debt instrument, face amount														$ 118,369	172,132	$ 118,369
Long-term debt, current maturities														54,308	53,763	54,308
Long term debt, excluding current maturities														$ 64,061	$ 118,369	$ 64,061
Paycheck Protection Program Loan 2 | Principal amount of PPP Loan
Short-Term Debt [Line Items]
Debt forgiveness amount					$ 930,246
Paycheck Protection Program Loan 2 | Interest amount of PPP Loan
Short-Term Debt [Line Items]
Debt forgiveness amount					$ 6,822

Long-Term Debt - Schedule of Ma

Long-Term Debt - Schedule of Maturities of Long-Term Debt (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Long-term debt, maturity, remainder of fiscal year	$ 32,718
Long-term debt, maturity, year one	10,441,377	$ 4,261,221
Long-term debt, maturity, year two	9,197	86,784
Long-term debt, maturity, year three		9,196
Total Payments		4,357,201
Less: Unamortized debt issuance costs	$ (6,127,060)	(61,857)
Less: Current maturities of long-term debt		(4,199,362)
Long-term debt		$ 95,982

Long-Term Debt - Paycheck Prote

Long-Term Debt - Paycheck Protection Program Loan (Details) - USD ($)				3 Months Ended		9 Months Ended
	Nov. 15, 2021	Aug. 05, 2021	Jun. 14, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Feb. 24, 2021	May 05, 2020
Debt Instrument [Line Items]
Debt amount								$ 4,357,201
Long-term debt, current								4,199,362
Long-term debt								95,982
PPP Loan 1
Debt Instrument [Line Items]
Debt amount		$ 285,115		$ 51,008		$ 51,008		107,979		$ 1,158,266
Debt forgiveness amount			$ 873,151
Debt forgiveness amount, interest portion			$ 9,823
Debt instrument, periodic payment		$ 6,400
Debt instrument, interest rate, stated percentage		1%
Long-term debt, current								76,058
Long-term debt								31,921
Interest expense				384	$ 384	1,397	$ 1,397
PPP Loan 2
Debt Instrument [Line Items]
Debt amount	$ 228,019			77,691		77,691		118,369	$ 1,158,265
Debt forgiveness amount	930,246
Debt forgiveness amount, interest portion	6,822
Debt instrument, periodic payment	$ 4,605
Debt instrument, interest rate, stated percentage	1%
Long-term debt, current				54,725		54,725		54,308
Long-term debt				22,966		22,966		$ 64,061
Interest expense				$ 716	$ 716	$ 2,377	$ 2,377

Long-Term Debt - Convertible No

Long-Term Debt - Convertible Notes Payable (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 04, 2024	Nov. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Debt Instrument [Line Items]
Shares issued (in shares)							1,231,574
Debt amount							$ 4,357,201
Loss on extinguishment of debt							376,086	$ 0
Unamortized debt issuance expense			$ 6,127,060		$ 6,127,060		$ 61,857
Class of warrant or right, outstanding (in shares)							1,231,574	905,470	624,508
Long-term debt, net			10,483,292		10,483,292
Convertible Note Warrants
Debt Instrument [Line Items]
Shares issued (in shares)	5,594
Note and US Capital Note | Convertible Debt
Debt Instrument [Line Items]
Interest payable							$ 50,037
Unamortized debt issuance expense							36,194
Long-term debt, net							$ 3,294,659
Interest expense			$ 0	$ 86,238	$ 88,692	$ 256,253
The Note
Debt Instrument [Line Items]
Debt, term										6 months
Minimum proceeds, conversion threshold										$ 15,000,000
Conversion price rate										90%
Debt fee amount		$ 20,000
Unamortized debt issuance expense		32,828
Conversion of stock, shares converted (in shares)	359,266
The Note | Convertible Note Warrants
Debt Instrument [Line Items]
Shares issued (in shares)							5,091
Class of warrant or right, outstanding (in shares)	16,320
Warrants outstanding value		156,505
The Note | $12.40 Exercise Price
Debt Instrument [Line Items]
Shares issued (in shares)							3,540
Class of warrant or right, exercise price of warrants or rights (in dollars per share)							$ 12.40
The Note | $11.67 Exercise Price
Debt Instrument [Line Items]
Shares issued (in shares)							1,551
Class of warrant or right, exercise price of warrants or rights (in dollars per share)							$ 11.67
The Note | Convertible Debt
Debt Instrument [Line Items]
Debt instrument, face amount										$ 10,000,000
Debt instrument, interest rate, stated percentage										12%
Debt amount	$ 3,233,388	2,495,000
Interest payable		635,854
Loss on extinguishment of debt		$ 376,086
US Capital Note
Debt Instrument [Line Items]
Conversion of stock, shares converted (in shares)	100,000
US Capital Note | Convertible Debt
Debt Instrument [Line Items]
Long-term debt, net	$ 200,000

Long-Term Debt - Bridge Loan (D

Long-Term Debt - Bridge Loan (Details)		3 Months Ended	9 Months Ended
	Mar. 04, 2024 USD ($) lender $ / shares	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Nov. 30, 2023 USD ($) investor	Nov. 10, 2023 USD ($)
Debt Instrument [Line Items]
Number of investors | investor					5
Stock price per share (in dollars per share) | $ / shares		$ 0.74	$ 0.74
Long-term debt, net		$ 10,483,292	$ 10,483,292
Unamortized debt issuance expense		6,127,060	6,127,060	$ 61,857
Aggregate Bridge Loans
Debt Instrument [Line Items]
Debt instrument, face amount					$ 1,000,000
Aggregate amount of cash value option portion	$ 960,000
Interest expense		0	160,000
Bridge Loan
Debt Instrument [Line Items]
Debt instrument, face amount					$ 200,000	$ 1,000,000
Debt instrument, interest rate, stated percentage					0%
Maturity cash value option rate					120%
Maturity cash value option					$ 240,000
Stock price per share (in dollars per share) | $ / shares	$ 2
Lenders who opted for the cash value option | lender	4
Total number of lenders | lender	5
Long-term debt, net		0	0	774,337
Unamortized debt issuance expense				$ 25,663
Interest expense		$ 0	$ 25,663

Long-Term Debt - Yorkville Pre-

Long-Term Debt - Yorkville Pre-paid Advance (Details) - Yorkville Pre-paid Advance - USD ($)		3 Months Ended	9 Months Ended
	Mar. 04, 2024	Sep. 30, 2024	Sep. 30, 2024
Debt Instrument [Line Items]
Pre-paid advance agreement, term	15 months
Debt instrument, interest rate, stated percentage	6%
Interest increase upon default	18%
Issuance of common stock (in shares)	1,000,000
Debt fee amount	$ 975,000
Commitment fee	$ 375,000
Original issue discount	6%
Structuring fee		$ 0	$ 20,000
Derivative liability		5,874,434	5,874,434
Unamortized discount		5,120,900	5,120,900
Outstanding amount		2,980,159	2,980,159
Interest payable		24,744	24,744
Interest expense		$ 1,244,332	$ 2,431,398
Yorkville
Debt Instrument [Line Items]
Pre-paid advance agreement	$ 10,000,000

Long-Term Debt - Cable Car Loan

Long-Term Debt - Cable Car Loan (Details) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 04, 2024	Feb. 29, 2024	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Debt amount					$ 4,357,201
Long-term debt			$ 10,483,292	$ 10,483,292
Unamortized debt issuance expense			6,127,060	6,127,060	$ 61,857
Potential shares from Cable Car Loan
Debt Instrument [Line Items]
Debt amount	$ 1,500,000
Conversion price (in dollars per share)	$ 2
Debt, term	13 months
Debt instrument, interest rate, stated percentage	0%
Issuance of common stock (in shares)	180,000
Proceeds from issuance of debt		$ 1,500,000
Debt fee amount		$ 40,740
Long-term debt			1,247,374	1,247,374
Interest expense			108,706	234,445
Unamortized debt issuance expense			$ 252,626	$ 252,626

Leases - Schedule of ROU Assets

Leases - Schedule of ROU Assets and Lease Liabilities (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets:
Operating lease right-of-use assets, net	$ 1,020,947	$ 1,267,121	$ 1,572,323
Liabilities:
Operating lease liabilities, current	394,208	361,305	313,448
Operating lease liabilities	762,904	1,062,633	1,423,938
Lease, liability	$ 1,157,112	$ 1,423,938	$ 1,737,386

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 116,994	$ 110,278	$ 345,302	$ 330,833	$ 441,111	$ 428,263

Leases - Schedule of Maturity o

Leases - Schedule of Maturity of Operating Lease Liabilities (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Lessee, operating lease, liability, to be paid, remainder of fiscal year	$ 116,994
Lessee, operating lease, liability, to be paid, year one	476,164	$ 462,295
Lessee, operating lease, liability, to be paid, year two	490,449	476,164
Lessee, operating lease, liability, to be paid, year three	206,864	490,449
Lessee, operating lease, liability, to be paid, year four		206,864
Total payments	1,290,471	1,635,772
Less: Interest	(133,359)	(211,834)
Operating lease liabilities	$ 1,157,112	$ 1,423,938	$ 1,737,386

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Lessor, Lease, Description [Line Items]
Non-cash operating lease expense	$ 113,748	$ 113,536	$ 341,031	$ 340,354	$ 453,889	$ 452,894
Operating lease, weighted average remaining lease term	2 years 8 months 12 days	3 years 8 months 12 days	2 years 8 months 12 days	3 years 8 months 12 days	3 years 4 months 24 days
Operating lease, weighted average discount rate, percent	8%	8%	8%	8%	8%
Less than 12 months
Lessor, Lease, Description [Line Items]
Non-cash operating lease expense	$ 5,532	$ 5,319	$ 16,383	$ 15,705	$ 21,024	$ 20,029

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)					12 Months Ended
	Dec. 31, 2023		Nov. 15, 2023	Mar. 20, 2023	Dec. 31, 2023		Sep. 30, 2024	[1]	Dec. 31, 2022
Other Commitments [Line Items]
Common stock subscribed but not issued value	$ 958	[1]			$ 958	[1]	$ 2,144		$ 27,580
GIGCAPITAL5, INC
Other Commitments [Line Items]
Underwriting discount per public unit paid in cash					$ 0.20
Deferred underwriting commissions per public unit					$ 0.40
Aggregate deferred underwriting commissions	$ 9,200,000				$ 9,200,000
GIGCAPITAL5, INC | Wells Fargo Securities LLC
Other Commitments [Line Items]
Deferred underwriting fee waiver amount				$ 6,440,000
GIGCAPITAL5, INC | Over-Allotment Option
Other Commitments [Line Items]
Underwriters option period					45 days
Option to purchase additional public units to cover over-allotments					3,000,000
Over-allotment option, exercise date					Sep. 28, 2021
Definitive Stock Subscription Agreement | GIGCAPITAL5, INC
Other Commitments [Line Items]
Common stock shares of the company issuable that will represent the total shareholding of the investee in the combined company (in shares)	1,400,000				1,400,000
Estimated gross proceeds from stock issuance	$ 3,500,000
November Two Thousand And Twenty Three Stock Subscription Agreements | November Two Thousand And Twenty Three Non Redemption Agreement | GIGCAPITAL5, INC | GIG Five Capital
Other Commitments [Line Items]
Common stock shares subscribed but not issued of the combined company (in shares)	1,200,000				1,200,000
Number of shares non redeemable per investor (in shares)	400,000				400,000
Per share amount to be deduced from redemption price (in dollars per share)	$ 2.50				$ 2.50
Standby Equity Purchase Agreement | Prepaid Advance In The Form Of Promissory Note | GIGCAPITAL5, INC | QTI Holdings
Other Commitments [Line Items]
Debt instrument face value			$ 10,000,000
Standby Equity Purchase Agreement | Yorkville | GIGCAPITAL5, INC | QTI Holdings
Other Commitments [Line Items]
Common stock subscribed but not issued value			$ 50,000,000
Period post business combination during which the stock may be issued			36 months
Number of shares issuable in the aggregate represent the aggregate shares post business combination (in shares)			1,000,000
[1] Amounts as of December 31, 2023 differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Details)				1 Months Ended	3 Months Ended					9 Months Ended			11 Months Ended	12 Months Ended		14 Months Ended
	Nov. 10, 2023 $ / shares shares	Nov. 30, 2022 $ / shares shares	Sep. 23, 2021 $ / shares shares	Nov. 30, 2022 $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares		Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares		Dec. 31, 2021 $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	May 13, 2024 $ / shares	May 12, 2024 $ / shares	Mar. 04, 2024 vote $ / shares shares	Feb. 20, 2024 shares	Jun. 30, 2023 shares	[1]	Sep. 28, 2021 $ / shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares)					500,000,000					500,000,000				100,000,000	100,000,000	100,000,000
Common stock, par or stated value per share (in dollars per share) | $ / shares					$ 0.0001					$ 0.0001				$ 0.0001	$ 0.001	$ 0.0001			$ 0.0001
Preferred stock, par or stated value per share (in dollars per share) | $ / shares					$ 0.0001					$ 0.0001				0.0001	$ 0.001	$ 0.0001
Common stock, dividends, per share, declared (in dollars per share) | $ / shares														$ 0
Sale of stock, number of shares issued in transaction (in shares)																490,000
Sale of units description		In November 2022, the Company initiated an offering to sell to a select group of accredited investors only, on a private placement basis, 1,000,000 units for a purchase price of $4.00 per unit (the “Units”), each Unit consisting of one share of common stock and one warrant to purchase one share of common stock with an exercise price of $4.00 (the “2022 Offering”).
Proceeds from issuance of units | $																$ 1,932,850
Change in fair value of warrant liability | $					$ (8,805)	$ (213,942)	$ 23,123	$ 0		$ (199,624)	$ 0			$ 0	$ 108,100
Fair value of warrants issued with debt | $														$ 0	$ 5,066
Number of entitled vote | vote																			1
Common stock, shares issued (in shares)					21,441,416					21,441,416				9,575,925	27,580,040	9,575,925
Common stock, shares, outstanding (in shares)					21,441,416					21,441,416				9,575,925	27,580,040	9,575,925			21,437,216
Common stock, capital shares reserved for future issuance (in shares)					46,374,662					46,374,662				14,138,960		14,138,960
Preferred stock, shares authorized (in shares)					10,000,000					10,000,000				10,000,000	10,000,000	10,000,000
Preferred stock, shares issued (in shares)					0					0				0	0	0
Preferred stock, shares outstanding (in shares)					0					0				0	0	0
Class of warrant or right, outstanding (in shares)													624,508	1,231,574	905,470	1,231,574
Class of warrant or right, modification, liability | $										$ 200,513
US Capital Global QT Imaging LLC | Fourth Amendment
Class of Stock [Line Items]
Change in fair value of warrant liability | $														$ 156,505
Warrants
Class of Stock [Line Items]
Sale of stock, price per share (in dollars per share) | $ / shares														$ 4		$ 4
Change in fair value of warrant liability | $														$ 462,413	$ 404,888
Adjustment of warrants granted for services | $														0	108,100
Fair value of warrants issued with debt | $														$ 15,317	$ 5,066
Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares)														100,000,000		100,000,000
Common stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.001		$ 0.001
Common stock, shares issued (in shares)														27,941,290	27,580,040	27,941,290
Common stock, shares, outstanding (in shares)					21,441,416	21,441,416		9,541,643	[1]	21,441,416	9,541,643	[1]	27,351,290	27,941,290	27,580,040	27,941,290					9,541,643
Common Stock | Working Capital Note
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)														2,073,554		2,073,554
Preferred Stock
Class of Stock [Line Items]
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.001		$ 0.001
Preferred stock, shares authorized (in shares)														10,000,000		10,000,000
Preferred stock, shares issued (in shares)														0	0	0
Preferred stock, shares outstanding (in shares)														0	0	0
QT Imaging Private Placement Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right (in shares)		1		1
PubCo Warrants
Class of Stock [Line Items]
Shares issued, price per share (in dollars per share) | $ / shares					$ 9.20					$ 9.20
Total equity proceeds, percentage					65%					65%
Class of warrant or right, threshold trading days					20 days					20 days
Class of warrant or right, greater than the market value, percentage					115%					115%
Class of warrant or right, threshold trading day period					30 days					30 days
Expiration term										5 years
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 11.50					$ 11.50							$ 2.30	$ 11.50
Class of warrant or right, outstanding (in shares)					23,889,364					23,889,364
PubCo Warrants | Minimum
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 0.01					$ 0.01
PubCo Warrants | Maximum
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 18					$ 18							$ 3.60	$ 18
QT Imaging Warrants
Class of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, non-option equity instruments, issued (in shares)					0			0		0	0
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares																			$ 11.67
Class of warrant or right, outstanding (in shares)					0					0				422,064		422,064
Warrants and rights outstanding, fair value | $								$ 0			$ 462,413
QT Imaging Remaining Warrants
Class of Stock [Line Items]
Warrants and rights outstanding, fair value | $											$ 15,317
Private Placement
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)				342,703	0			0		0	89,532			261,250	228,750	167,925
Sale of stock, price per share (in dollars per share) | $ / shares		$ 11.67		$ 11.67
Proceeds from issuance of units | $														$ 1,026,550	$ 906,300
Consideration received on transaction | $								$ 0			$ 1,026,550					$ 1,932,850
Private Placement | US Capital Global QT Imaging LLC | Fourth Amendment
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	25,000
Sale of stock, price per share (in dollars per share) | $ / shares	$ 2.50
Private Placement | QT Imaging Private Placement Warrants
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares		$ 11.67		$ 11.67
GIGCAPITAL5, INC
Class of Stock [Line Items]
Common stock, shares authorized (in shares)														100,000,000	100,000,000	100,000,000
Common stock, par or stated value per share (in dollars per share) | $ / shares			$ 0.0001											$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001	$ 0.0001	$ 0.0001
Sale of stock, price per share (in dollars per share) | $ / shares																							$ 10
Common stock, shares issued (in shares)														6,545,000	6,545,000	6,545,000
Common stock, shares, outstanding (in shares)														6,545,000	6,545,000	6,545,000
Redeemable common stock, shares (in shares)							0							2,114,978	4,014,050	2,114,978
Preferred stock, shares authorized (in shares)														1,000,000	1,000,000	1,000,000
Preferred stock, shares issued (in shares)														0	0	0
Preferred stock, shares outstanding (in shares)														0	0	0
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares			$ 11.50										$ 11.50										$ 11.50
Minimum price per share required for redemption of warrants (in dollars per share) | $ / shares														$ 18		$ 18
GIGCAPITAL5, INC | Insider Shares Grant Agreements
Class of Stock [Line Items]
Effective date of grant award agreement														Sep. 23, 2021
GIGCAPITAL5, INC | Mr Weightman | Insider Shares Grant Agreements
Class of Stock [Line Items]
Number of shares subject to forfeiture (in shares)														5,000
Common stock issued in consideration for future service (in shares)			5,000										5,000	5,000
Effective date of grant award agreement													Sep. 23, 2021
Description of fair value of common stock shares vest recognition														If an initial Business Combination occurs and the 5,000 shares have not been previously forfeited, the fair value of the common stock on the date the shares vest will be recognized as stock-based compensation in the Company’s statements of operations and comprehensive loss when the completion of the Business Combination becomes probable.
GIGCAPITAL5, INC | Interest Solutions (ICR) | Insider Shares Grant Agreements
Class of Stock [Line Items]
Common stock issued in consideration for future service (in shares)														10,000
Number of shares not subject to forfeiture (in shares)														10,000
Number of shares, grant date fair value expensed upon issuance (in shares)														10,000
GIGCAPITAL5, INC | Non-Employee Consultants | Restricted Stock | Insider Shares Grant Agreements
Class of Stock [Line Items]
Number of shares subject to forfeiture (in shares)														15,000
GIGCAPITAL5, INC | Warrants
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 11.50		11.50
Percentage of warrants exercise price														115%
Period after business combination when warrants become exercisable														30 days
Period after offering when warrants become exercisable														12 months
Warrants exercisable expiration period after completion of business combination														5 years
Period allotted to complete the business combination														30 months
Net cash settlement value of warrants | $														$ 0
Redemption price per warrant | $ / shares														$ 0.01		$ 0.01
Minimum period of prior written notice of redemption of warrants														30 days
Class of warrant or right, outstanding (in shares)														23,795,000	23,795,000	23,795,000
GIGCAPITAL5, INC | Warrants | Minimum
Class of Stock [Line Items]
Percentage of aggregate gross proceeds of equity issuances														65%
GIGCAPITAL5, INC | Warrants | Maximum
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 9.20		$ 9.20
GIGCAPITAL5, INC | Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares)														100,000,000		100,000,000
Common stock, voting rights per share														Holders of the Company’s common stock are entitled to one vote for each share of common stock
Common stock, shares issued (in shares)														6,545,000	6,545,000	6,545,000
Common stock, shares, outstanding (in shares)													6,545,000	6,545,000	6,545,000	6,545,000
Redeemable common stock, shares (in shares)														2,114,978	4,014,050	2,114,978
Temporary equity, shares outstanding (in shares)														2,114,978	4,014,050	2,114,978
Common stock, capital shares reserved for future issuance (in shares)														23,945,000		23,945,000
GIGCAPITAL5, INC | Common Stock | Maximum
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares														$ 9.20		$ 9.20
GIGCAPITAL5, INC | Common Stock | Working Capital Note
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)														150,000		150,000
GIGCAPITAL5, INC | Common Stock | Warrants
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)														23,795,000		23,795,000
GIGCAPITAL5, INC | Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)														1,000,000		1,000,000
Preferred stock, shares issued (in shares)														0	0	0
Preferred stock, shares outstanding (in shares)														0	0	0
GIGCAPITAL5, INC | Subsequent Event
Class of Stock [Line Items]
Temporary equity, shares outstanding (in shares)																				848,003
GIGCAPITAL5, INC | Private Placement
Class of Stock [Line Items]
Sale of units description														Each Private Placement Unit consists of one share of the Company’s common stock, par value $0.0001 per share, and one redeemable warrant.
GIGCAPITAL5, INC | Private Placement | Working Capital Note
Class of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares)														150,000
GIGCAPITAL5, INC | Private Placement | Common Stock
Class of Stock [Line Items]
Common stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001
[1] Amounts as of December 31, 2023 and before that date differ from those in prior year consolidated financial statements as they were retrospectively adjusted as a result of the accounting or the Business Combination (as defined in the Notes to Condensed Consolidated Financial Statements).

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	46,374,662	14,138,960
Common stock warrants
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	23,889,364
Potential shares from Pre-Paid Advance
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	10,126,981
Merger earnout consideration shares
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	9,000,000
Potential shares from Cable Car Loan
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	750,000
Potential shares from convertible notes
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	250,224
Options outstanding under the 2024 Incentive Plan
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	2,072,000
Options available under the 2024 Incentive Plan
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	286,093
Common Stock | Common stock warrants
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		1,231,484
Common Stock | Options outstanding
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		3,646,922
Common Stock | Options available under the Plan
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		3,353,078
Common Stock | Potential shares from convertible notes
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		2,073,554
Common Stock | Subscription agreements
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		3,833,912

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Warrant Activity (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	1,231,574	905,470	624,508
Granted (in shares)		326,104	280,962
Ending balance (in shares)		1,231,574	905,470
QT Imaging Warrants
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	422,064
Exercised (in shares)	(16,320)
Terminated pursuant to business combination agreement (in shares)	(405,744)
Ending balance (in shares)	0	422,064

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Outstanding Warrants to Purchase Shares of Common Stock by Exercise Price (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Shares Outstanding Under Warrants (in shares)	1,231,574
Exercise price range one
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 10
Expiration Date(s)	Mar. 31, 2025
Number of Shares Outstanding Under Warrants (in shares)	516,391
Exercise price range two
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 8.50
Expiration Date(s)	Aug. 31, 2030
Number of Shares Outstanding Under Warrants (in shares)	150,000
Exercise price range three
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 4.25
Number of Shares Outstanding Under Warrants (in shares)	10,329
Exercise price range three | Minimum
Class of Warrant or Right [Line Items]
Expiration Date(s)	Jul. 31, 2027
Exercise price range three | Maximum
Class of Warrant or Right [Line Items]
Expiration Date(s)	Sep. 30, 2028
Exercise Price Range Four
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 4
Number of Shares Outstanding Under Warrants (in shares)	494,525
Exercise Price Range Four | Minimum
Class of Warrant or Right [Line Items]
Expiration Date(s)	Nov. 30, 2027
Exercise Price Range Four | Maximum
Class of Warrant or Right [Line Items]
Expiration Date(s)	Mar. 31, 2029
Exercise Price Range Five
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 2.50
Expiration Date(s)	Nov. 01, 2028
Number of Shares Outstanding Under Warrants (in shares)	60,329

Stockholders' Deficit - Stockho

Stockholders' Deficit - Stockholders' Deficit - Schedule of Outstanding Warrants to Purchase Shares of Common Stock by Exercise Price (Details)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected warrant term (years)	5 years 8 months 12 days	5 years 8 months 12 days
Expected volatility	67.90%	67.90%
Risk-free rate of return	4.30%	4.30%
Expected annual dividend yield	0%	0%
Warrants
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected warrant term (years)			5 years	5 years 7 months 6 days
Expected volatility			60.20%	62.30%
Risk-free rate of return			4%	3.60%
Expected annual dividend yield			0%	0%

Stock Incentive Plan - Addition

Stock Incentive Plan - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 04, 2024	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Feb. 15, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation by share based award number of shares authorized (in shares)		7,000,000	7,000,000
Expiration period		10 years
Percentage of total voting power								10%
Share based compensation arrangement by share award non vested options forfeited in period shares (in shares)								293,615	22,396
Grants in period, weighted average grant date fair value (in dollars per share)									$ 2.27
Share based compensation options cost not yet recognized								$ 329,925
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition						2 years 3 months 18 days
Common stock, capital shares reserved for future issuance (in shares)				46,374,662		46,374,662		14,138,960
Granted under the 2024 Incentive Plan (in shares)					0		0		541,208
Share-based payment arrangement, nonvested award, cost not yet recognized, amount				$ 846,533		$ 846,533
Inventories
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, capitalized, amount								$ 0	$ 0
2024 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period			10 years
Grants in period, weighted average grant date fair value (in dollars per share)				$ 0.47		$ 0.47
Common stock, capital shares reserved for future issuance (in shares)										2,358,093
Percentage of outstanding stock maximum	5%
Stock ownership percent			10%
Exercise price of common stock, percent			110%
Exercise price of common stock, term			5 years
Number outstanding (in shares)				2,072,000		2,072,000
Granted under the 2024 Incentive Plan (in shares)				2,072,000		2,072,000
QT Imaging Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period			10 years
Share-based payment arrangement, capitalized, amount				$ 0	$ 0	$ 0	$ 0
Common stock, capital shares reserved for future issuance (in shares)		7,000,000	7,000,000
Stock ownership percent			10%
Exercise price of common stock, percent			110%
Exercise price of common stock, term			5 years
Award requisite service period			4 years
Options terminated (in shares)	1,237,681					1,237,681
Subsequent Event | Business Combination Agreement
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement by share award non vested options forfeited in period shares (in shares)	3,646,921
Incentive stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation by share based award purchase price of stock percent		110%
Options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition								1 year 3 months 18 days
Options outstanding | 2024 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period			10 years
Options outstanding | QT Imaging Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period			10 years

Stock Incentive Plan - Summary

Stock Incentive Plan - Summary of QT Imaging Plan (Details) - $ / shares		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 04, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Options
Grants (in shares)			0		0		541,208
Vested and expected to vest (in shares)						3,371,096
Weighted- Average Exercise Price
Beginning balance, outstanding, weighted-average exercise price (in dollars per share)				$ 8.50	$ 8.46	$ 8.46	$ 8.77
Granted under the 2024 Incentive Plan, weighted-average exercise price (in dollars per share)							6.50
Terminated pursuant to Business Combination Agreement, weighted-average exercise price (in dollars per share)						7.90	8.50
Ending balance, outstanding, weighted-average exercise price (in dollars per share)						8.50	$ 8.46	$ 8.77
Vested and expected to vest, weighted-average exercise price (in dollars per share)						$ 8.57
Weighted-Average Remaining Contractual Life (years)
Outstanding, weighted-average remaining contractual term (in years)						6 years 10 months 24 days	8 years 4 months 24 days	9 years 2 months 12 days
Vest and expected to vest, weighted-average remaining contractual term (in years)						6 years 9 months 18 days
QT Imaging Incentive Plan
Number of Options
Terminated pursuant to Business Combination Agreement (in shares)	(1,237,681)			(1,237,681)
Weighted- Average Exercise Price
Terminated pursuant to Business Combination Agreement, weighted-average exercise price (in dollars per share)				$ 24.83
QT Imaging Incentive Plan And 2024 Equity Incentive Plan
Number of Options
Beginning balance, outstanding (in shares)				1,249,809
Cancelled (in shares)				(12,128)
Ending balance, outstanding (in shares)		2,072,000		2,072,000		1,249,809
Exercisable (in shares)		0		0
Vested and expected to vest (in shares)		2,072,000		2,072,000
Weighted- Average Exercise Price
Beginning balance, outstanding, weighted-average exercise price (in dollars per share)				$ 24.80
Cancelled, weighted-average exercise price (in dollars per share)				22.40
Ending balance, outstanding, weighted-average exercise price (in dollars per share)		$ 0.74		0.74		$ 24.80
Exercisable, weighted-average exercise price (in dollars per share)		0		0
Vested and expected to vest, weighted-average exercise price (in dollars per share)		$ 0.74		$ 0.74
Weighted-Average Remaining Contractual Life (years)
Outstanding, weighted-average remaining contractual term (in years)				9 years 9 months 18 days		6 years 10 months 24 days
Vest and expected to vest, weighted-average remaining contractual term (in years)				9 years 9 months 18 days
2024 Equity Incentive Plan
Number of Options
Grants (in shares)		2,072,000		2,072,000
Ending balance, outstanding (in shares)		2,072,000		2,072,000
Weighted- Average Exercise Price
Granted under the 2024 Incentive Plan, weighted-average exercise price (in dollars per share)				$ 0.74

Stock Incentive Plan - Schedule

Stock Incentive Plan - Schedule of Total Number of Shares Available for Grant Under the Plan (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Beginning balance (in shares)	3,059,464	3,578,276
Granted (in shares)		(541,208)
Cancelled (in shares)	293,615	22,396
Ending balance (in shares)	3,353,079	3,059,464

Stock Incentive Plan - Share-Ba

Stock Incentive Plan - Share-Based Payment Arrangement, Activity (Details) - $ / shares		3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 04, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding (in shares)			3,646,921	3,940,536	3,940,536	3,421,724
Grants (in shares)		0		0		541,208
Number of options cancelled (in shares)					(293,615)	(22,396)
Number of options outstanding (in shares)					3,646,921	3,940,536	3,421,724
Number of options vested and exercisable and expected to vest (in shares)					3,433,227
Vested and expected to vest (in shares)					3,371,096
Beginning balance, outstanding, weighted-average exercise price (in dollars per share)			$ 8.50	$ 8.46	$ 8.46	$ 8.77
Granted under the 2024 Incentive Plan, weighted-average exercise price (in dollars per share)						6.50
Weighted - average exercise price cancelled (in dollars per share)					7.90	8.50
Ending balance, outstanding, weighted-average exercise price (in dollars per share)					8.50	$ 8.46	$ 8.77
Weighted - average exercise price outstanding vested and exercisable and expected to vest (in dollars per share)					8.54
Vested and expected to vest, weighted-average exercise price (in dollars per share)					$ 8.57
Weighted-average remaining contractual life (years)					6 years 10 months 24 days	8 years 4 months 24 days	9 years 2 months 12 days
Weighted - average remaining contractual life (years) vested and exercisable and expected to vest					6 years 8 months 12 days
Vest and expected to vest, weighted-average remaining contractual term (in years)					6 years 9 months 18 days
Weighted- Average Exercise Price
Beginning balance, outstanding, weighted-average exercise price (in dollars per share)			8.50	$ 8.46	$ 8.46	$ 8.77
Terminated pursuant to Business Combination Agreement, weighted-average exercise price (in dollars per share)					7.90	8.50
Ending balance, outstanding, weighted-average exercise price (in dollars per share)					$ 8.50	$ 8.46	$ 8.77
Weighted-Average Remaining Contractual Life (years)
Outstanding, weighted-average remaining contractual term (in years)					6 years 10 months 24 days	8 years 4 months 24 days	9 years 2 months 12 days
QT Imaging Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted - average exercise price cancelled (in dollars per share)			$ 24.83
Number of Options
Terminated pursuant to Business Combination Agreement (in shares)	(1,237,681)		(1,237,681)
Weighted- Average Exercise Price
Terminated pursuant to Business Combination Agreement, weighted-average exercise price (in dollars per share)			$ 24.83

Stock Incentive Plan - Schedu_2

Stock Incentive Plan - Schedule of the Options Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure In Tabular Form Of Stock Options Outstanding And Excercisable [Line Items]
Weighted-average exercise price (in dollars per share)	$ 8.50	$ 8.46	$ 8.77
Number Outstanding (in shares)	3,646,921	3,940,536	3,421,724
Outstanding, weighted-average remaining contractual term (in years)	6 years 10 months 24 days	8 years 4 months 24 days	9 years 2 months 12 days
Number Exercisable (in shares)	3,371,096
Exercise price range one
Disclosure In Tabular Form Of Stock Options Outstanding And Excercisable [Line Items]
Weighted-average exercise price (in dollars per share)	$ 6.50
Number Outstanding (in shares)	453,323
Outstanding, weighted-average remaining contractual term (in years)	8 years 4 months 24 days
Number Exercisable (in shares)	341,559
Exercise price range two
Disclosure In Tabular Form Of Stock Options Outstanding And Excercisable [Line Items]
Weighted-average exercise price (in dollars per share)	$ 8.50
Number Outstanding (in shares)	2,585,671
Outstanding, weighted-average remaining contractual term (in years)	6 years 7 months 6 days
Number Exercisable (in shares)	2,421,609
Exercise price range three
Disclosure In Tabular Form Of Stock Options Outstanding And Excercisable [Line Items]
Weighted-average exercise price (in dollars per share)	$ 10
Number Outstanding (in shares)	607,927
Outstanding, weighted-average remaining contractual term (in years)	7 years
Number Exercisable (in shares)	607,928

Stock Incentive Plan - Schedu_3

Stock Incentive Plan - Schedule of the Fair Value of Options Granted (Details)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected option term (years)	5 years 8 months 12 days	5 years 8 months 12 days
Expected volatility	67.90%	67.90%
Risk-free rate of return	4.30%	4.30%
Expected annual dividend yield	0%	0%
Options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected option term (years)			7 years 4 months 24 days
Expected volatility			69.10%
Risk-free rate of return			2.50%
Expected annual dividend yield			0%

Stock Incentive Plan - Share-_2

Stock Incentive Plan - Share-Based Payment Arrangement, Expensed and Capitalized, Amount (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation	$ 127,203	$ 195,475	$ 166,187	$ 612,730	$ 709,394	$ 790,755
Research and development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation	22,248	26,313	36,198	78,941	105,255	142,118
Selling, general and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation	$ 104,955	$ 169,162	$ 129,989	$ 533,789	$ 604,139	$ 648,637

National Institutes of Health_2

National Institutes of Health Subaward (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 18, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Aug. 18, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Grants receivable		$ 10,349		$ 10,349		$ 161,638		$ 1,078,347
Grants receivable, annual payment timing, duration								5 years
Grant receivable, written notice termination, period								30 days
Total costs incurred, grants costs				385,280
Costs incurred, grants costs		3,359	$ 151,996	36,226	$ 250,713
Research and development
Accounts, Notes, Loans and Financing Receivable [Line Items]
Grant income		3,359
Costs incurred, grants costs			128,769	20,430	215,616
Selling, general and administrative
Accounts, Notes, Loans and Financing Receivable [Line Items]
Grant income		$ 0
Costs incurred, grants costs			$ 23,227	15,796	$ 35,097
Year One Allocation
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total costs incurred, grants costs				351,994
Year Two Allocation
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total costs incurred, grants costs				$ 194,566
For Developing Ultra Sound Scanner To Detect Cancer
Accounts, Notes, Loans and Financing Receivable [Line Items]
Grants received during the period	$ 1,078,347
Government assistance transaction duration	5 years
Aggregate costs incurred as per allocation						349,054
Aggregate costs one year allocation						351,994
Aggregate costs two year allocation						194,566
Aggregate costs incurred and recognized						318,276	$ 30,778
For Developing Ultra Sound Scanner To Detect Cancer | Prepaid Expenses and Other Current Assets
Accounts, Notes, Loans and Financing Receivable [Line Items]
Government assistance cumulative amount current						161,638	30,778
For Developing Ultra Sound Scanner To Detect Cancer | Research and development
Accounts, Notes, Loans and Financing Receivable [Line Items]
Government assistance amount						277,037	22,503
For Developing Ultra Sound Scanner To Detect Cancer | Selling, general and administrative
Accounts, Notes, Loans and Financing Receivable [Line Items]
Government assistance amount						$ 41,239	$ 8,275

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Liabilities:
Warrant liability	$ 9,783	$ 18,588	$ 32,017	$ 0
Note payable to related party	$ 0			705,000	$ 0
GIGCAPITAL5, INC
Assets:
Marketable securities held in Trust Account				23,302,116	41,561,656
Liabilities:
Note payable to related party				1,506,389	257,492
GIGCAPITAL5, INC | Level 1
Assets:
Marketable securities held in Trust Account				0	41,561,656
GIGCAPITAL5, INC | Fair Value, Inputs, Level 2
Liabilities:
Warrant liability				7,950	31,800
GIGCAPITAL5, INC | Fair Value, Inputs, Level 3
Liabilities:
Note payable to related party				$ 1,506,389	$ 257,492

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Estimated Fair Value of Working Capital Note (Details) - GIGCAPITAL5, INC - Fair Value, Inputs, Level 3	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Expected term	8 months 12 days	10 months 24 days
Volatility	65%	65%
Risk free rate	5.10%	4.70%
Discount rate	11.30%
Probability of conversion	25%	65%
Minimum
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Discount rate		24.40%
Maximum
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Discount rate		29.40%
Issuance
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Volatility	65%
Issuance | Minimum
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Expected term	8 months 12 days
Risk free rate	4.50%
Discount rate	9.70%
Probability of conversion	25%
Issuance | Maximum
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Expected term	9 months 18 days
Risk free rate	5.50%
Discount rate	25.80%
Probability of conversion	55%

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Fair Value of Working Capital Note (Details) - GIGCAPITAL5, INC - Working Capital Note - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 257,492	$ 0
Additions	1,240,000	260,000
Change in fair value	8,897	(2,508)
Ending balance	$ 1,506,389	$ 257,492

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Earnout liability	$ 700,000	$ 0
Fair Value, Inputs, Level 2
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Warrant liability	9,783	0
Fair Value, Inputs, Level 3
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Earnout liability	700,000	0
Derivative liability	320,900	0
Certificate of deposit | Fair Value, Inputs, Level 2
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Certificate of deposit	$ 20,000	$ 20,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 28, 2021	Sep. 23, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Class of warrant or right, outstanding (in shares)		1,231,574	905,470	624,508
Monthly payment discount, triggered principal amount	$ 1,500,000
Monthly payment discount, triggered percentage	50%
Variable price conversion right, conversion price percentage	95%
GIGCAPITAL5, INC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 11.50	$ 11.50	$ 11.50
Interest receivable on cash and marketable securities held in the Trust Account		$ 0	$ 133,211
Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Class of warrant or right, outstanding (in shares)	889,364
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.011

Fair Value Measurements - Warra

Fair Value Measurements - Warrant liability (Details) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Warrant Liability [Roll Forward]
Beginning balance	$ 18,588	$ 32,017	$ 0		$ 0
Net liabilities assumed from GigCapital5			8,894
Change in fair value	(8,805)	(213,942)	23,123	$ 0	(199,624)	$ 0	$ 0	$ 108,100
Increase due to warrant modification		200,513
Ending balance	$ 9,783	$ 18,588	$ 32,017		$ 9,783		$ 0

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value, Concentration of Risk (Details)	Sep. 30, 2024 $ / shares	Mar. 04, 2024 $ / shares
Fair value of common stock
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.71	3.53
Derivative liability, measurement input	0.71	3.53
Term in years
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Derivative liability, measurement input	1.23	1.25
Volatility of revenue
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.230	0.260
Derivative liability, measurement input	1.150	1.300
Discount rate applicable to revenue
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.070	0.070
Risk-free rate
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.037	0.045
Derivative liability, measurement input	0.039	0.049
Risk premium
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.033	0.025
Cost of debt
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.155	0.155
Credit risk spread
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	0.119	0.110
Equity volatility
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Reverse recapitalization, contingent consideration, liability, measurement input	1.150	1.300
Debt discount
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Derivative liability, measurement input	0.300	0.300

Fair Value Measurements - Earno

Fair Value Measurements - Earnout and Derivative Rollforward (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Earnout Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 750,000	$ 1,060,000	$ 0
Change in fair value	(50,000)	(310,000)	1,060,000
Ending balance	700,000	750,000	1,060,000
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	408,100	2,137,800	0
Fair value at issuance			5,120,900
Change in fair value	(87,200)	(1,729,700)	(2,983,100)
Ending balance	$ 320,900	$ 408,100	$ 2,137,800

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Tax Examination [Line Items]
United States					$ (6,097,351)	$ (6,254,468)
International					0	0
Loss before income tax expense	$ (3,619,494)	$ (1,375,939)	$ (9,166,958)	$ (4,588,900)	(6,097,351)	(6,254,468)
GIGCAPITAL5, INC
Income Tax Examination [Line Items]
United States					(3,605,472)	(2,287,692)
International					0	0
Loss before income tax expense					$ (3,605,472)	$ (2,287,692)

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 0	$ 0
State	1,600	1,600
Foreign	0	0
Total current tax expense	1,600	1,600
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax expense	0	0
Income tax expense	1,600	1,600
GIGCAPITAL5, INC
Current:
Federal	285,990	342,216
State	133,129	144,399
Foreign	0	0
Total current tax expense	419,119	486,615
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax expense	0	0
Income tax expense	$ 419,119	$ 486,615

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of the Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Examination [Line Items]
Federal tax at statutory rate	$ (1,280,444)	$ (1,313,438)
State taxes	(22,915)	(542,562)
Change in valuation allowance	1,080,617	1,846,087
Other	224,342	11,513
Income tax expense	1,600	1,600
GIGCAPITAL5, INC
Income Tax Examination [Line Items]
Federal tax at statutory rate	(757,149)	(480,415)
State taxes	(236,036)	(184,760)
Warrant and note payable revaluation	47,377	(75,812)
Change in valuation allowance	1,364,927	1,227,602
Income tax expense	$ 419,119	$ 486,615

Income Taxes - Schedule of Tax

Income Taxes - Schedule of Tax Effects of Temporary Differences that Gave Rise to Significant Portions of the Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating losses	$ 3,070,085	$ 2,280,097
Stock-based compensation	856,902	784,932
Operating lease liabilities	386,588	516,031
Section 174 expenses, net	487,860	476,842
Accruals and reserves	489,382	227,221
Intangible assets	118,691	214,100
Property and equipment	90,104	44,128
Gross deferred tax assets	5,499,612	4,543,351
Valuation allowance	(5,155,597)	(4,074,980)
Net deferred tax assets	344,015	468,371
Deferred tax liabilities:
Operating lease right-of-use assets	(344,015)	(468,371)
GIGCAPITAL5, INC
Deferred tax assets:
Start-up costs	2,895,226	1,530,299
Valuation allowance	$ (2,895,226)	$ (1,530,299)

Income Taxes - Schedule Of The

Income Taxes - Schedule Of The Beginning And Ending Amount Of Gross Unrecognized Tax Benefits (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as the beginning of the year	$ 49,255	$ 0
Increases related to prior year tax positions	0	47,882
Increases related to current year tax positions	0	1,373
Balance as the end of the year	$ 49,255	$ 49,255

Income Taxes - Schedule Of Th_2

Income Taxes - Schedule Of The Beginning And Ending Amount Of Gross Unrecognized Tax Benefits Narrative (Detail)	Dec. 31, 2023 USD ($)
Maximum
Income Tax Examination [Line Items]
Signifiacnt change in unrecognized tax benefits is reasonably possible amount of unrecorded benefit	$ 49,255
Minimum
Income Tax Examination [Line Items]
Signifiacnt change in unrecognized tax benefits is reasonably possible amount of unrecorded benefit	$ 0

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Valuation allowance						$ 5,155,597	$ 4,074,980
Increase in valuation allowance						1,080,617	1,846,087
Unrecognized tax benefits						49,255	49,255	$ 0
Effective income tax rate reconciliation, percent	0%	0%	0%	0%
Forecast
Income Tax Contingency [Line Items]
Effective income tax rate reconciliation, percent					0%
Domestic Tax Jurisdiction | 2040
Income Tax Contingency [Line Items]
Net operating lease carry forwards						10,700,000
State and Local Jurisdiction | Indefinitely
Income Tax Contingency [Line Items]
Net operating lease carry forwards							12,448,000
GIGCAPITAL5, INC
Income Tax Contingency [Line Items]
Valuation allowance						2,895,226	1,530,299
Increase in valuation allowance						1,364,927	1,227,602
Unrecognized tax benefits						0	0
Amount accrued for payment of interest and penalties						0	$ 0
Increase in unrecognized tax benefits is reasonably possible						0
Decrease in unrecognized tax benefits is reasonably possible						$ 0

Related Party Transactions (Det

Related Party Transactions (Details)							1 Months Ended						3 Months Ended		9 Months Ended		11 Months Ended	12 Months Ended		14 Months Ended
	Apr. 17, 2024 USD ($)	Mar. 04, 2024 USD ($) $ / shares	Feb. 15, 2024 USD ($)	Nov. 30, 2022 $ / shares	Sep. 28, 2021 USD ($) $ / shares shares	Sep. 23, 2021 USD ($) $ / shares shares	Jun. 30, 2024 USD ($)	Nov. 30, 2023 USD ($) shares	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Nov. 30, 2022 $ / shares shares	Jul. 31, 2020 USD ($) note stockholder $ / shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) shares $ / shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Apr. 05, 2024	Feb. 07, 2024 USD ($)	Dec. 13, 2023 USD ($)	Oct. 27, 2023 USD ($)	Oct. 26, 2023 USD ($)	Sep. 15, 2023 USD ($)	Sep. 12, 2023 USD ($)	Aug. 29, 2023 USD ($)	Aug. 28, 2023 USD ($)	Aug. 15, 2023 USD ($)	Jul. 25, 2023 USD ($)	Jun. 26, 2023 USD ($)	Jun. 12, 2023 USD ($)	May 03, 2023 USD ($) restatement	Apr. 27, 2023 USD ($)	Mar. 28, 2023 USD ($)	Feb. 27, 2023 USD ($)	Jan. 25, 2023 USD ($)	Dec. 27, 2022 USD ($)	Nov. 28, 2022 USD ($)	Oct. 26, 2022 USD ($)	Sep. 26, 2022 USD ($)	Sep. 23, 2022 $ / shares	Mar. 31, 2022	Dec. 31, 2020	Jul. 01, 2020 USD ($)
Related Party Transaction [Line Items]
Accrued liabilities current													$ 3,364,217		$ 3,364,217			$ 369,651	$ 368,366	$ 369,651
Conversion of long-term debt into common stock															$ 3,433,388	$ 0
Induced conversion of debt expenses																		168,356	$ 0
Issuance of common stock																1,026,550		$ 402,000
Common stock, shares, issued (in shares) | shares													21,441,416		21,441,416			9,575,925	27,580,040	9,575,925
Number of restatement | restatement																																		6
Contract with customer, liability													$ 19,841		$ 19,841			$ 347,619	$ 0	$ 347,619
Proceeds from issuance of unit															$ 0	1,017,850
Share price (in dollars per share) | $ / shares													$ 0.74		$ 0.74
Sale of units in private placement (in shares) | shares																				490,000
Sale of units description				In November 2022, the Company initiated an offering to sell to a select group of accredited investors only, on a private placement basis, 1,000,000 units for a purchase price of $4.00 per unit (the “Units”), each Unit consisting of one share of common stock and one warrant to purchase one share of common stock with an exercise price of $4.00 (the “2022 Offering”).
Common stock, par or stated value per share (in dollars per share) | $ / shares		$ 0.0001											$ 0.0001		$ 0.0001			$ 0.0001	$ 0.001	$ 0.0001
Note payable to related party													$ 0		$ 0			$ 705,000	$ 0	$ 705,000
Deferred revenue															$ 327,778	$ (300,000)
Private Placement
Related Party Transaction [Line Items]
Issuance of common stock																		$ 1,026,550	$ 906,300
Sale of units in private placement (in shares) | shares											342,703		0	0	0	89,532		261,250	228,750	167,925
Sale of stock, price per share (in dollars per share) | $ / shares				$ 11.67							$ 11.67
Common Stock
Related Party Transaction [Line Items]
Issuance of common stock																$ 9		$ 100
Common stock, shares, issued (in shares) | shares																		27,941,290	27,580,040	27,941,290
Common stock, par or stated value per share (in dollars per share) | $ / shares																		$ 0.001		$ 0.001
Common Stock | Private Placement
Related Party Transaction [Line Items]
Issuance of common stock																		$ 261	$ 229
Investor
Related Party Transaction [Line Items]
Debt instrument, interest rate, stated percentage																			8%																										5%
Minimum proceeds from equity financing																			$ 5,000,000
Long term debt date of maturity																		Jul. 01, 2025		Jul. 01, 2025
Debt instrument number of shares issuable upon conversion | shares																		704,299
Conversion of long-term debt into common stock								$ 200,000
Debt instrument accrued interest component converted into equity								$ 33,644
Debt conversion converted amount shares issued (in shares) | shares								100,000
Induced conversion of debt expenses																		$ 168,356
Convertible notes non current																		3,143,725	3,343,725	$ 3,143,725
Interest payable current																		377,772	230,627	377,772
Interest expenses on long term debt																		180,789	$ 137,709
Debt instrument, face amount																																														$ 3,500,000
Debt instrument conversion price per share | $ / shares																			$ 5
Investor | Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount																		705,000		705,000					$ 55,000	$ 50,000	$ 75,000	$ 100,000		$ 75,000			$ 100,000	$ 250,000
Three Hundred And Three Development Corporation
Related Party Transaction [Line Items]
Contracts with customer liability advances received during the period									$ 100,000	$ 200,000
Related Party
Related Party Transaction [Line Items]
Contract with customer, liability													$ 0		$ 0			300,000		300,000
GIGCAPITAL5, INC
Related Party Transaction [Line Items]
Accrued liabilities current																		$ 893,830	$ 103,344	$ 893,830
Common stock, shares, issued (in shares) | shares																		6,545,000	6,545,000	6,545,000
Proceeds from issuance of unit					$ 225,400,000	$ 30,000,000
Sale of stock, price per share (in dollars per share) | $ / shares					$ 10
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 11.50	$ 11.50											$ 11.50
Minimum price per share required for redemption of warrants (in dollars per share) | $ / shares																		$ 18		$ 18
Holding period of shares for completion of initial business combination																		6 months
Period after completion of business combination to allow transfer of shares																		30 days
Warrants transfer restrictions period following consummation of business combination																		1 year
Debt instrument, face amount																																										$ 960,000
Common stock, par or stated value per share (in dollars per share) | $ / shares						$ 0.0001												$ 0.0001	$ 0.0001	$ 0.0001
Note payable to related party																		$ 1,506,389	$ 257,492	$ 1,506,389
Fair value, option, aggregate differences																		1,560,000		1,560,000
Debt discount on note payable to related party																		245,253	$ 54,034
GIGCAPITAL5, INC | Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount																		$ 1,500,000		$ 1,500,000			$ 53,640	$ 381,360							$ 65,000	$ 130,000			$ 65,000	$ 130,000	$ 350,000	$ 65,000
Debt instrument conversion price per share | $ / shares																		$ 10		$ 10
Note payable to related party																		$ 1,506,389		$ 1,506,389
Fair value, option, aggregate differences																		8,897		8,897
GIGCAPITAL5, INC | Extension Note
Related Party Transaction [Line Items]
Debt instrument, face amount																		$ 1,560,000		1,560,000									$ 100,000							100,000
Common stock, par or stated value per share (in dollars per share) | $ / shares																																											$ 0.0001
Debt instrument average market discount rate																		18.22%
Debt discount on reduction to carrying principle amount																		$ 299,287
Debt discount on note payable to related party																		1,564,673
Interest expense																		219,686
Unamortized debt discount																		$ 61,687		$ 61,687
GIGCAPITAL5, INC | Maximum
Related Party Transaction [Line Items]
Period after initial business combination to allow transfer of shares																		90 days
GIGCAPITAL5, INC | Private Placement
Related Party Transaction [Line Items]
Proceeds from issuance of unit					$ 6,900,000
Sale of units description																		Each Private Placement Unit consists of one share of the Company’s common stock, par value $0.0001 per share, and one redeemable warrant.
GIGCAPITAL5, INC | Private Placement | Working Capital Note
Related Party Transaction [Line Items]
Sale of units in private placement (in shares) | shares																		150,000
GIGCAPITAL5, INC | Insider Shares Grant Agreements
Related Party Transaction [Line Items]
Effective date of grant award agreement																		Sep. 23, 2021
GIGCAPITAL5, INC | Common Stock
Related Party Transaction [Line Items]
Common stock, shares, issued (in shares) | shares																		6,545,000	6,545,000	6,545,000
Stock price threshold that allows transfer of shares (in dollars per share) | $ / shares																		$ 11.50
GIGCAPITAL5, INC | Common Stock | Maximum
Related Party Transaction [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares																		$ 9.20		$ 9.20
GIGCAPITAL5, INC | Common Stock | Private Placement
Related Party Transaction [Line Items]
Number of shares of common stock per unit (in shares) | shares																		1		1
Common stock, par or stated value per share (in dollars per share) | $ / shares																		$ 0.0001		$ 0.0001
GIGCAPITAL5, INC | Warrants
Related Party Transaction [Line Items]
Sale of units description																		Each Public Unit consists of one share of the Company’s common stock (a “Public Share”), $0.0001 par value, and one redeemable warrant (a “Public Warrant”).
Period after business combination when warrants become exercisable																		30 days
Period after offering when warrants become exercisable																		12 months
Warrants exercisable expiration period after completion of business combination																		5 years
Net cash settlement value of warrants																		$ 0
Redemption price per warrant | $ / shares																		$ 0.01		0.01
Minimum period of prior written notice of redemption of warrants																		30 days
Minimum price per share required for redemption of warrants (in dollars per share) | $ / shares																		$ 18		$ 18
GIGCAPITAL5, INC | Warrants | Private Placement
Related Party Transaction [Line Items]
Number of shares of common stock per unit (in shares) | shares																		1		1
GIGCAPITAL5, INC | Founders
Related Party Transaction [Line Items]
Forfeiture of shares (in shares) | shares						4,312,500
Sale of units in private placement (in shares) | shares					795,000
Sale of stock, price per share (in dollars per share) | $ / shares					$ 10
GIGCAPITAL5, INC | Founders | Private Placement
Related Party Transaction [Line Items]
Sale of units in private placement (in shares) | shares																	795,000
Sale of stock, price per share (in dollars per share) | $ / shares																	$ 10
Number of shares of common stock per unit (in shares) | shares																	1
Sale of units description																		Each Private Placement Unit consists of one share of the Company’s common stock and one warrant (a “Private Placement Warrant”).
GIGCAPITAL5, INC | Founders | Common Stock
Related Party Transaction [Line Items]
Sale of common stock, shares (in shares) | shares																	5,735,000
Proceeds from issuance of unit																	$ 25,000
Share price (in dollars per share) | $ / shares																	$ 0.0043592
GIGCAPITAL5, INC | Founders | Warrants | Private Placement
Related Party Transaction [Line Items]
Period after business combination when warrants become exercisable																		30 days
Period after offering when warrants become exercisable																		12 months
Warrants exercisable expiration period after completion of business combination																		5 years
Sale of units description																		(or such lesser period depending upon the number of one-month extensions which occur)
Net cash settlement value of warrants																		$ 0
Redemption price per warrant | $ / shares																		$ 0.01		$ 0.01
Minimum period of prior written notice of redemption of warrants																		30 days
Minimum price per share required for redemption of warrants (in dollars per share) | $ / shares																		$ 18		$ 18
GIGCAPITAL5, INC | Mr Weightman
Related Party Transaction [Line Items]
Forfeiture of shares (in shares) | shares																	5,000
Monthly payment for services						$ 2,500
GIGCAPITAL5, INC | Mr Weightman | Maximum
Related Party Transaction [Line Items]
Monthly payment for services						$ 15,000
GIGCAPITAL5, INC | Mr Weightman | Insider Shares Grant Agreements
Related Party Transaction [Line Items]
Effective date of grant award agreement																	Sep. 23, 2021
Common stock issued in consideration for future service (in shares) | shares						5,000											5,000	5,000
GIGCAPITAL5, INC | GigManagement, LLC
Related Party Transaction [Line Items]
Accrued liabilities current																		$ 780,000		$ 780,000
Related party transaction, amounts of transaction																		30,000
GIGCAPITAL5, INC | Sponsor | First Non-Convertible Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount																							66,360
GIGCAPITAL5, INC | Sponsor | Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount																							$ 53,640	$ 381,360							$ 65,000	$ 130,000			$ 65,000	$ 130,000	350,000		$ 65,000	$ 65,000	$ 65,000	65,000
GIGCAPITAL5, INC | Sponsor | Extension Note
Related Party Transaction [Line Items]
Debt instrument, face amount																																					$ 160,000				$ 160,000	$ 160,000
Advisory Fees To Directors For Board Committee Services And Analytical Services | GIGCAPITAL5, INC | Director
Related Party Transaction [Line Items]
Accrued liabilities current																		696,000		696,000
Management Services Agreement | John Han C Clock
Related Party Transaction [Line Items]
Other operating income																		48,000	$ 48,000
Accounts payable current																		0	0	0
Business Associate Agreement | John Han C Clock
Related Party Transaction [Line Items]
Non trade receivables current																		0	0	0
Business Associate Agreement | Selling, general and administrative | John Han C Clock
Related Party Transaction [Line Items]
Related party transactions purchases from related party																		8,100	$ 7,200
2020 Notes | Related Party
Related Party Transaction [Line Items]
Debt instrument, interest rate, stated percentage												5%																																8%
Number of convertible notes issued | note												3
Number of stockholders | stockholder												3
Shares issued, price per share (in dollars per share) | $ / shares												$ 14.59
Issuance of common stock												$ 5,000,000
Common stock, shares, issued (in shares) | shares													250,224		250,224
Interest receivable													$ 507,029		$ 507,029			377,772		377,772
Interest expense													43,400	$ 45,921	129,257	136,265
Debt instrument, face amount												$ 3,500,000	3,143,725		3,143,725			$ 3,143,725		$ 3,143,725
Working Capital Loan and Extension Note | Related Party | Working Capital Loans
Related Party Transaction [Line Items]
Debt instrument, additional principal amount																									$ 55,000	$ 50,000	$ 75,000	$ 100,000		$ 75,000			$ 100,000
Debt instrument, face amount													705,000		705,000																			$ 250,000
Working Capital Loan and Extension Note | Related Party | Extension Note
Related Party Transaction [Line Items]
Notes assumed		$ 1,560,000
Management Services and Business Associate Agreement | Related Party
Related Party Transaction [Line Items]
Management fee expense													0	12,000	12,000	36,000
Foundation | Related Party
Related Party Transaction [Line Items]
Contract with customer, liability									$ 100,000	$ 200,000				$ 100,000		$ 100,000
Deferred revenue							$ 300,000								300,000
Services Agreement | Related Party
Related Party Transaction [Line Items]
Services agreement, service term																					1 year
Services agreement, incurred amount													19,350		29,871
Space and Equipment Sublease Agreement | Related Party
Related Party Transaction [Line Items]
Sublease periodic payments	$ 5,666
Sublease payments, due date, period after beginning of month	10 days
Sublease term	1 year
Sublease renewal term	1 year
Proceeds from rents received													$ 16,998		$ 33,996
Subsequent Event | GIGCAPITAL5, INC
Related Party Transaction [Line Items]
Debt instrument, periodic payment, interest			$ 0
Subsequent Event | Non-Convertible Loan Working Capital Amendment | GIGCAPITAL5, INC
Related Party Transaction [Line Items]
Debt instrument, face amount																						$ 262,247
Subsequent Event | Non-Convertible Loan Working Capital Amendment | GIGCAPITAL5, INC | Second Non-Convertible Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount																						262,247
Subsequent Event | Non-Convertible Loan Working Capital Amendment | GIGCAPITAL5, INC | Third Non Convertible Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount			297,247																			297,247
Subsequent Event | Non-Convertible Loan Working Capital Amendment | GIGCAPITAL5, INC | Sponsor | Second Non-Convertible Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount																						$ 195,887
Subsequent Event | Non-Convertible Loan Working Capital Amendment | GIGCAPITAL5, INC | Sponsor | Third Non Convertible Working Capital Note
Related Party Transaction [Line Items]
Debt instrument, face amount			$ 35,000

Subsequent Events (Details)

Subsequent Events (Details)

1 Months Ended

9 Months Ended

10 Months Ended

12 Months Ended

Feb. 15, 2025 USD ($)

Jan. 15, 2025 USD ($)

Nov. 04, 2024 USD ($) $ / shares shares

Sep. 11, 2024 USD ($) $ / shares

Mar. 04, 2024 USD ($) $ / shares shares

Mar. 01, 2024 USD ($) shares

Feb. 29, 2024 USD ($) $ / shares shares

Feb. 28, 2024 shares

Feb. 26, 2024 shares

Sep. 28, 2021 $ / shares shares

Feb. 29, 2024 USD ($) $ / shares shares

Sep. 30, 2024 USD ($) $ / shares

Sep. 30, 2023 USD ($)

Nov. 15, 2025 USD ($)

Dec. 31, 2023 USD ($) shares

Dec. 31, 2022 shares

Nov. 12, 2024 USD ($)

Oct. 31, 2024 $ / shares

Feb. 23, 2024 USD ($) shares

Feb. 22, 2024 USD ($) shares

Feb. 21, 2024 USD ($) shares

Feb. 20, 2024 USD ($) shares

Feb. 15, 2024 USD ($)

Feb. 07, 2024 USD ($)

Feb. 01, 2024 USD ($) $ / shares

Sep. 26, 2022 USD ($)

Dec. 31, 2021 $ / shares

Sep. 23, 2021 $ / shares

Subsequent Event [Line Items]

Common stock value subscribed but not issued in the combined company

$ 500,000

Conversion of long-term debt into common stock

$ 3,433,388

$ 0

Stock issued during the period value new issues

$ 1,026,550

$ 402,000

Share based compensation arrangement by share award non vested options forfeited in period shares (in shares) | shares

293,615

22,396

Shares issued (in shares) | shares

1,231,574

Share price (in dollars per share) | $ / shares

$ 0.74

Long-term debt

$ 10,483,292

Yorkville Pre-paid Advance

Subsequent Event [Line Items]

Debt instrument stated interest rate percentage

6%

Stock issued during the period shares new issues (in shares) | shares

1,000,000

Yorkville Pre-paid Advance | Yorkville

Subsequent Event [Line Items]

Share price (in dollars per share) | $ / shares

$ 0.8768

Debt instrument, convertible, triggered periodic payment

$ 1,521,581

Subsequent Event | Yorkville Pre-paid Advance | Yorkville

Subsequent Event [Line Items]

Conversion price (in dollars per share) | $ / shares

$ 0.6629

Share price (in dollars per share) | $ / shares

$ 0.50

Long-term debt

$ 8,600,000

Conversion of stock, amount converted

$ 254,593

Subsequent Event | Yorkville Pre-paid Advance | Yorkville | Common Stock

Subsequent Event [Line Items]

Conversion of stock, shares issued (in shares) | shares

384,059

Subscription Agreement With William Blair And Co LLC | Subsequent Event

Subsequent Event [Line Items]

Common stock shares issued and convertible into shares of the company upon consummation of business combination (in shares) | shares

740,000

Non Redemption Agreement Two Thousand And Twenty Three Mizhuo Securities USA LLC | Subsequent Event

Subsequent Event [Line Items]

Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares

100,000

100,000

Common stock shares subscribed but unissued value

$ 250,000

$ 250,000

Additional Subscription Agreement With Donnelly Financial Solutions | Subsequent Event

Subsequent Event [Line Items]

Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares

200,000

200,000

Common stock shares subscribed but unissued value

$ 500,000

$ 500,000

Additional Subscription Agreement With IB Capital LLC | Subsequent Event

Subsequent Event [Line Items]

Common stock shares issuable and convertible into shares of the company upon consummation of business combination (in shares) | shares

240,000

240,000

Common stock shares subscribed but unissued value

$ 600,000

$ 600,000

Cable Car Note Purchase Agreement | Subsequent Event

Subsequent Event [Line Items]

Debt instrument term

13 months

Common stock shares issued and convertible into shares of the company upon consummation of business combination (in shares) | shares

180,000

Debt instrument, face amount

$ 1,500,000

Conversion price (in dollars per share) | $ / shares

$ 2

Settlement And Termination Agreement With Lion Bay Ventures | Subsequent Event

Subsequent Event [Line Items]

Share-based compensation arrangement by share-based payment award, options, expirations in period (in shares) | shares

17,000

Share based compensation by share based award options expirations in period weighted average exercise period (in dollars per share) | $ / shares

$ 8.50

Stock issued during the period shares new issues (in shares) | shares

10,000

Subscription And Business Combination Agreement | Subsequent Event

Subsequent Event [Line Items]

Stock issued during the period shares new issues (in shares) | shares

583,596

Stock issued during the period value new issues

$ 500,000

Stock shares issued during the period converted into common stock of the company (in shares) | shares

200,000

Business Combination Agreement | Subsequent Event

Subsequent Event [Line Items]

Class of warrants or rights exercise price of warrants or rights cancelled (in dollars per share) | $ / shares

$ 4

Share based compensation arrangement by share award non vested options forfeited in period shares (in shares) | shares

3,646,921

Yorkville Note Agreement | Subsequent Event

Subsequent Event [Line Items]

Debt instrument stated interest rate percentage

6%

Debt instrument term

15 months

Debt instrument default interest rate percentage

18%

Proceeds from convertible debt

$ 9,005,000

Stock issued during the period shares conversion of convertible securities (in shares) | shares

1,000,000

US Capital Note Balance | Subsequent Event

Subsequent Event [Line Items]

Debt conversion converted amount shares issued (in shares) | shares

291,798

Debt instrument accrued interest component converted into equity

$ 3,233,388

Debt instrument principal component converted into equity

$ 200,000

Debt instrument converted number of shares issued for accrued interest (in shares) | shares

1,048,330

Shares issued (in shares) | shares

60,329

Class of warrants or rights number of shares issued exercise of warrants (in shares) | shares

16,320

Non Redemption Agreement September Two Thousand And Twenty Three | Subsequent Event

Subsequent Event [Line Items]

Stock issued during the period shares new issues (in shares) | shares

427,477

Bridge Loan Agreement | Subsequent Event

Subsequent Event [Line Items]

Aggregate cash payment option excercised

$ 960,000

Cash payment option excercised by each lender

$ 240,000

Forecast | Yorkville Pre-paid Advance | Yorkville

Subsequent Event [Line Items]

Debt instrument, convertible, triggered periodic payment

$ 500,000

$ 500,000

$ 500,000

Related Party | Subsequent Event | Private Investment Public Entity Agreement

Subsequent Event [Line Items]

Shares issued, price per share (in dollars per share) | $ / shares

$ 0.584

Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares

$ 0.672

Shares issued, purchase price

$ 1,560,000

Class of warrant or right, shares subscribed but unissued (in shares) | shares

4,383,558

Common stock, value, subscriptions

$ 2,560,000

Common stock, shares subscribed but unissued (in shares) | shares

4,383,558

GIGCAPITAL5, INC

Subsequent Event [Line Items]

Common stock shares issued such that these shares represent ownership by investee in the current company (in shares) | shares

740,000

Stock issued during the period shares new issues (in shares) | shares

23,000,000

Debt instrument, face amount

$ 960,000

Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares

$ 11.50

$ 11.50

$ 11.50

GIGCAPITAL5, INC | Subsequent Event

Subsequent Event [Line Items]

Temporary equity, shares outstanding (in shares) | shares

848,003

Percent of shares part of public offering

3.7

Proceeds from trust account

$ 9,356,221

GIGCAPITAL5, INC | Subsequent Event | Third Non Convertible Extension Note

Subsequent Event [Line Items]

Debt instrument, face amount

$ 297,247

GIGCAPITAL5, INC | Subsequent Event | Third Non Convertible Extension Note | Sponsor

Subsequent Event [Line Items]

Debt instrument, face amount

$ 35,000

GIGCAPITAL5, INC | Subsequent Event | Yorville Note | Yorkville

Subsequent Event [Line Items]

Debt instrument stated interest rate percentage

6%

Common stock shares issued such that these shares represent ownership by investee in the current company (in shares) | shares

1,000,000

Debt instrument term

15 months

Proceeds from debt net of issuance costs

$ 9,000,000

Debt instrument default interest rate percentage

18%

Debt instrument, face amount

$ 10,000,000

GIGCAPITAL5, INC | Non-Convertible Loan Working Capital Amendment | Subsequent Event

Subsequent Event [Line Items]

Debt instrument, face amount

$ 262,247

GIGCAPITAL5, INC | Non-Convertible Loan Working Capital Amendment | Subsequent Event | Second Non-Convertible Working Capital Note

Subsequent Event [Line Items]

Debt instrument, face amount

262,247

GIGCAPITAL5, INC | Non-Convertible Loan Working Capital Amendment | Subsequent Event | Second Non-Convertible Working Capital Note | Sponsor

Subsequent Event [Line Items]

Debt instrument, face amount

$ 195,887

GIGCAPITAL5, INC | Gig Acquisition Five | Subsequent Event | Eleventh Amended And Restated Working Capital Note

Subsequent Event [Line Items]

Conversion of long-term debt into common stock

$ 943,640

Debt conversion converted amount shares issued (in shares) | shares

94,364

Debt instrument converted warrants issued | shares

94,364

Repayment of convertible debt

$ 556,360

Debt instrument, face amount

$ 1,500,000

Conversion price (in dollars per share) | $ / shares

$ 10

GIGCAPITAL5, INC | QTI Holdings | Funicular Funds, LP | Subsequent Event | Note Purchase Agreement

Subsequent Event [Line Items]

Debt instrument stated interest rate percentage

0%

0%

Common stock shares issued such that these shares represent ownership by investee in the current company (in shares) | shares

180,000

Debt instrument term

13 months

Debt instrument, face amount

$ 1,500,000

$ 1,500,000

Conversion price (in dollars per share) | $ / shares

$ 2

$ 2

Services Share Issuance Agreement | GIGCAPITAL5, INC | QTI Holdings | Subsequent Event | Mizuho Securities USA, LLC

Subsequent Event [Line Items]

Common stock value subscribed but not issued in the combined company

$ 250,000

Common stock shares subscribed but not issued in the combined company (in shares) | shares

100,000

Insider Shares Grant Agreements | GIGCAPITAL5, INC | Restricted Stock | Non-Employee Consultants | Subsequent Event

Subsequent Event [Line Items]

Share based compensation by share based award equity instruments other than options forfeited during the period (in shares) | shares

5,000

Subscription agreements | GIGCAPITAL5, INC | IB Capital LLC | Subsequent Event | QTI Holdings

Subsequent Event [Line Items]

Common stock value subscribed but not issued in the combined company

$ 600,000

Common stock shares subscribed but not issued in the combined company (in shares) | shares

240,000

Subscription agreements | GIGCAPITAL5, INC | QTI Holdings | Subsequent Event | Donnelly Financial Solutions

Subsequent Event [Line Items]

Common stock shares subscribed but not issued in the combined company (in shares) | shares

200,000